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Portal and systemic haemodynamic response to
acute and chronic administration of low and high
dose isosorbide-5-mononitrate in patients with
cirrhosis.
The effect ofN-acetylcysteine on systemic and
portal haemodynamics and oxygen delivery and
consumption in patients with cirrhosis.
The effect ofN-acetylcysteine on forearm blood
flow in patients with cirrhosis.
The pharmacokinetics ofN-acetylcysteine in patients
with cirrhosis.










Study of the haemodynamic response to drugs is important in evaluation of their
ability to achieve reduction of oesophageal variceal bleeding and to optimise
their haemodynamic action in patients with liver disease. My studies have
concentrated on the evaluation of two drugs, N-acetylcysteine and
isosorbide-5-mononitrate (a drug reported to have a problem of tolerance).
The portal and systemic haemodynamic response to low and high dose
isosorbide-5-mononitrate (Is-5-Mn) was studied. 10 mg or 40 mg of oral Is-5-Mn
was given acutely and chronically (bd for 4 weeks) allowing a 16 hour nitrate
free interval to 25 patients with cirrhosis. Both doses of nitrate reduced the
hepatic venous pressure gradient acutely and chronically, without evidence of
tolerance, by a reduction in the wedged hepatic venous pressure. The effect on
mean azygos blood flow was dependent on the initial azygos blood flow, not on
the dose of nitrate used; if low then vasodilation was seen in response to
Is-5-Mn and vice-versa. As the effect of Is-5-Mn on cardiac output, systemic
resistance and its pharmacokinetics in the presence of chronic liver disease has
been previously reported this was not studied further.
Intravenous N-acetylcysteine (NAC) was given to 11 patients with cirrhosis.
There was no effect on mean heart rate or blood pressure despite a significant
fall in systemic and pulmonary vascular resistance. Cardiac index increased but
estimated liver blood flow and hepatic venous pressure gradients did not change
significantly. Administration of NAC increased oxygen delivery but not
arteriovenous oxygen extraction ratio or mean tissue oxygen consumption.
Therefore NAC administration does not appear to confer haemodynamic
benefit on patients with cirrhosis.
Studies using forearm blood plethysmography confirmed that intra-arterial
administration of NAC causes local vasodilation in patients with cirrhosis and in
normal controls.
Pharmacokinetic studies during intravenous NAC administration revealed that
the area under the curve and therefore the half-life and clearance of the drug
were significantly impaired in the presence of chronic liver disease. This
contrasts with previous reports in acute liver damage due to paracetamol.
Mechanisms of nitrate and NAC action and tolerance are described.
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"If oesophago-gastric varices did not form and bleed portal hypertension would
be ofvirtually no clinical significance"
(Dame Sheila Sherlock 1993)
Unfortunately, they do form and bleed and this presents one of the major
clinical problems in hepatology. Cirrhosis, the commonest cause of portal
hypertension, is a leading cause of death in the Western world being the ninth




Cirrhosis is defined as widespread fibrosis and nodule formation within the
liver. It follows hepatocellular necrosis due to a variety of insults and reflects
the fact that the liver's response to necrosis is limited. The distribution of the
fibrous septa tends to vary according to the causative agent; in
haemochromatosis there is portal zone or Zone 1 fibrosis, whereas in alcoholic
cirrhosis, the fibrosis is predominantly in Zone 3 (Figure 1).
The fibrosis disrupts hepatic architecture, impeding exchange of oxygen and
nutrients through the basement membranes between liver cells and the blood,
and causing portal hypertension (Shibayama et al, 1989). Fibrous tissue is not
just a structural support for damaged hepatocytes but may modulate hepatocyte
patterns of function (Biagini and Ballardini, 1989).
Cirrhosis is usually believed to be irreversible, but fibrosis has been shown to
regress in treated haemochromatosis and Wilson's disease and the concept of
reversibility is therefore an exciting therapeutic goal.
Three anatomical categories of cirrhosis are recognised: micronodular,
macronodular and mixed, although this distinction is rather arbitrary. Thick
septae divide small regenerating nodules in micronodular cirrhosis and
macronodular cirrhosis is characterised by septa and nodules of various sizes.
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portal triad » = direction of blood flow
Figure 1
The zones of the liver
Zone 1 occurs around the portal triad which
contains the portal vein, hepatic artery and bile
duct.
Zone 3 is near the circulatory periphery: this zone





There are many causes of liver cirrhosis, some ofwhich are shown in Table 1.
The commonest cause world-wide is hepatitis B infection but in the United
Kingdom is excessive alcohol consumption.
Aetiological distinction is important both for prognosis and treatment.
Hepatitis B and C are not discussed here as patients known to have viral
hepatitis or cirrhosis were excluded from this study because of the potential
infection risk to staff.
Alcohol
Matthew Baillie in 1793 is credited with being the first person to report an
association between alcohol consumption and cirrhosis.
In 1956, the French mathematician Ledermann hypothesised that per capita
alcohol consumption was a good indicator of the proportion of heavy drinkers in
a given population, and that alcohol-related problems including cirrhosis
increased with per capita consumption (Ledermann, 1956).
Numerous epidemiological studies have since confirmed a strong association
between per capita alcohol consumption and the morbidity and mortality from
cirrhosis. Cirrhosis mortality abruptly decreased in Europe after the First and
Second World Wars, when rationing of alcohol was in force, and during the
prohibition era (1919-32) in the United States.
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Table 1
Aetiology of cirrhosis (world-wide)
Alcohol
Cholestasis (intra- and extra-hepatic)
Cryptogenic (of unknown aetiology = 10-15% cirrhosis in United Kingdom)





Immunological (chronic active hepatitis)
Metabolic:
Alpha-1-antitrypsin deficiency
Copper overload (Wilson's disease)
Diabetes mellitus
Galactosaemia




Toxins and drugs e.g. methotrexate, amiodarone
Viral hepatitis (B, C and D)
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Unfortunately world-wide alcohol consumption is increasing and countries such
as Japan are now discovering that alcoholic cirrhosis, once a rarity, has become
a significant cause ofmorbidity and mortality (Ohnishi and Okuda, 1986).
Cirrhosis is the most severe form of alcoholic liver injury and characteristically
is of the micronodular type (Leevy, 1968; Saunders et al, 1985; Sherlock and
Dooley, 1993). The first stage of hepatic damage by alcohol appears to be
formation of a fatty liver. Thereafter alcoholic hepatitis and perivenular fibrosis
are thought to develop into cirrhosis. Whether an individual has to pass
through all these stages in the development of cirrhosis is controversial.
Not everyone who abuses alcohol develops liver damage; it is estimated that at
least 80% of heavy drinkers show some features of fatty liver, 10-35% develop
alcoholic hepatitis and approximately 10% will develop cirrhosis (Grant et al,
1988).
A retrospective study in men showed that 50% of men with an average intake of
alcohol of greater than 160 g (approximately 16 units) per day for 20 years
developed cirrhosis (Lelbach, 1975). Fifty-two per cent of a predominantly
male group of patients, drinking in excess of 80 g of alcohol per day, developed
cirrhosis over a 20-year period (Saunders, 1985). Later studies have suggested
risk levels as low as 40 g alcohol per day for men (Pequinot et al 1974; Pequinot
et al, 1978; Batey et al, 1992).
The duration of alcohol abuse appears important. Neither cirrhosis nor
alcoholic hepatitis were seen in patients who consumed an average of 160 g of
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ethanol per day for less than five years, whereas 50% of patients consuming
these levels of alcohol for an average of 21 years developed cirrhosis (Lelbach
et al, 1975).
Liver injury appears not to be related to the type of beverage; only to its alcohol
content. Regular drinking appears more dangerous than intermittent drinking,
since presumably in the latter the liver has greater chance to recover from the
toxic effects of ethanol. In a UK study of problem drinkers the risk of cirrhosis
was 12 times greater in those drinking 6-7 days per week than those who drank
on 1-3 days per week, after controlling for cumulative alcohol consumption.
Over 90% of cirrhotic patients had a pattern of unremitting daily drinking,
whereas those who showed minor abnormalities mostly had an intermittent
pattern of consumption (Saunders et al, 1985).
Sex-related differences in alcoholic liver disease were first reported by Spain
(1945) and there is now a large body of evidence indicating that women are
more susceptible than men to alcohol-related liver disease. They tend to
develop cirrhosis at a younger age, at lower levels of alcohol consumption
(exceeding 20 g per day, compared with over 40 g per day for men) and after a
shorter periods of alcohol abuse (by approximately 6 years) (Wilkinson et al,
1969; Morgan and Sherlock, 1977; Saunders et al, 1981; Bhattacharayya and
Rake, 1983; Norton et al, 1987).
Alcoholism is increasing among women as the social stigma surrounding
drinking declines and the access to alcohol becomes easier. However, they are
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less likely to be suspected of alcohol abuse; they present at a more advanced
stage of disease, and are more likely to relapse after treatment (Morgan and
Sherlock, 1977). They are also more likely to progress from alcoholic hepatitis
to cirrhosis even if they stop drinking (Pares et al, 1986). The increased
vulnerability ofwomen to alcohol-induced liver injury has been attributed to
significantly higher blood alcohol concentrations and area under the
concentration-time curve that are attained compared with men after
consumption of the same amount of alcohol. Women often weigh less than men
and have therefore a lower volume of distribution for alcohol.
Different rates of alcohol elimination between individuals (and consequently
risk of toxic effects of alcohol) may be related to genetic polymorphism of two
enzyme systems, MEOS (microsomal ethanol oxidising system) and ADH
(alcohol dehydrogenase), which metabolise alcohol. Genetic polymorphism for
ADH has been found at two gene loci and differences have been shown to alter
rates of ethanol oxidation and acetaldehyde generation (Bosron and Li, 1986).
Acetaldehyde, the principle metabolite of alcohol, is metabolically extremely
reactive and hepatotoxic (Sherlock, 1993). Alcoholics have higher than normal
blood acetaldehyde levels after alcohol (Peters and Ward, 1988). This might be
secondary to enzyme induction or a primary genetic abnormality.
In addition an increased prevalence of histocompatibility antigens HLA-B8,
HLA-B13 and HLA-B40 has been reported in patients with alcoholic cirrhosis
compared with non-alcoholic controls. The presence of HLA-B8 has been
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linked to more rapid progression of liver injury and development of cirrhosis in
both men and women (Saunders et al, 1982) but it is unclear whether this
reflects an association with excessive alcohol consumption or an increased
susceptibility to alcoholic liver disease.
It has been postulated that concurrent infection with viral hepatitis B and/or
hepatitis C increases susceptibility to alcohol induced liver damage and worsens
the prognosis.
Patients with alcoholic cirrhosis have a high prevalence of serum antibodies to
hepatitis B virus (Mills et al, 1981) and an association between hepatitis B
surface antigen positivity and a tendency to severe alcoholic liver disease has
led to the suggestion that alcohol and hepatitis B infection may act
synergistically to produce liver damage (Chung et al, 1989; Villa et al, 1982).
However, another study showed no such correlation (Mendenhall et al, 1991),
so the association is controversial.
In contrast, a significant correlation has been demonstrated between antibodies
to hepatitis C virus and alcoholic liver disease. Hepatitis C antibodies are more
prevalent in patients with severe alcoholic liver disease (Pares et al, 1990).
These findings are particularly relevant to Japan where there is a high
prevalence of both hepatitis B and hepatitis C, and where the incidence of
alcoholic liver disease is rapidly increasing in association with increasing per
capita consumption of alcohol (Ohnishi and Okuda, 1986).
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Much also depends on nutrition; alcohol given to rats does not produce liver
damage unless accompanied by a diet deficient in essential nutrients
particularly choline. In rhesus monkeys the liver damage induced by alcohol
could be prevented by increasing dietary protein and choline (Rogers et al,
1979). Certainly patients with decompensated liver disease, given a third of
their calories as alcohol together with a nutritious diet, improve steadily
(Reynolds et al, 1965), whereas liver function does not improve with alcohol
abstinence if dietary protein remains low (Phillips et al, 1952). It seems likely
that both alcohol and nutrition play a part in alcohol hepatotoxicity, alcohol
being the more important.
Primary biliary cirrhosis
Primary biliary cirrhosis was first described in 1851 by Addison and Gull and is
a disease of unknown cause in which intra-hepatic bile ducts are progressively
destroyed. Ahrens et al gave the name primary biliary cirrhosis (PBC) to the
condition in 1950. It is associated with a marked immunological disturbance
which has been related to the degree of bile duct destruction (Fox et al, 1969;
Gershwin and Mackay, 1991), the final event being an attack by cytotoxic
T-cells. The trigger for the immune cascade may be viral, bacterial or defective
immune regulation.
Circulating antibodies against mitochondria are found in virtually 100% of
patients with PBC (Walker et al, 1965; Munoz et al, 1981). They are not organ
specific but are directed at the inner mitochondrial membrane at the pyruvate
dehydrogenase complex. Currently, the presence of anti-mitochondrial
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antibodies is detected by indirect immunofluorescence on rat kidney substrate
but it is expected that a more specific and sensitive anti-M2 subtype of
antimitochondrial antibody test will be available soon for diagnostic purposes.
The prevalence of circulating antimitochondrial antibodies is increased in
relatives of patients (Feizi et al, 1972; Galbraith et al, 1974; Klein and Berg,
1990). PBC has been reported in sisters, twins, mothers and daughters and
other family clusters (Chohan, 1973; Tong et al, 1976).
It has been postulated that cross-reactivity of the antigens between bile ducts
and micro-organisms may account for the pathogenesis of PBC (Burroughs et
al, 1984).
90% of patients are female, usually between 40 and 59 years of age. The
disease starts insidiously with pruritis without jaundice, the latter appearing
within six months to two years. In 25% of patients both start together. Many
patients are now diagnosed asymptomatically by automated liver function tests
and they usually survive at least 10 years and for some life-expectancy is no
different from the general population (Beswick et al, 1985). In those with
symptomatic disease and jaundice the survival is about seven years (Sherlock,
1959) and serum bilirubin values are good indicators of prognosis (Shapiro et al,
1979; Epstein et al, 1985).
Treatment for PBC includes general measures such as control of itch.
Ursodeoxycholic acid improves liver function but does not increase survival
(Heuman et al, 1991). PBC is sometimes the commonest and often the second
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most frequent indication for hepatic transplantation in adults. There does
however appear to be a risk of recurrence of the disease in the transplanted
liver.
A host of associations with PBC are reported including rheumatoid arthritis,
dermatomyositis, mixed connective tissue disease, CREST syndrome and
systemic lupus erythematosis.
Secondary biliary cirrhosis
One patient in our study had secondary biliary cirrhosis as a result of bile duct
surgery. He had no history of alcohol consumption.
PROGNOSIS OF CIRRHOSIS
Liver cirrhosis results in two major complications; hepato-cellular failure and
portal hypertension. Treatment and prognosis depend on both these factors,
the latter being the more important. The introduction of liver transplantation
has emphasised the need for accurate prognosis so that surgery, if indicated,
may be performed at the right time. Of the systems designed to assess
prognosis, two have been widely used - Child's grading and Pughs modification
of Child's grading. In 1964 Child and Turcotte introduced a system of grading
to assess the risk of surgery in patients with liver disease: It was based on five
variables - serum concentrations of bilirubin and albumin, the absence or extent
of ascites and of neurological disorder, and the nutritional status (Table 2). The
main problem with this grading system is that the findings in an individual
patient may be a mixture of those in columns A, B and C.
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(Child & Turcotte, 1964)
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Pugh and his colleagues (1973) therefore modified Child's grading by adding
prolongation of the prothrombin time to the list of variables and giving a score
to each observation and summing of the scores in order to obtain an overall
result (Table 3). This modified score remains a very useful method of assessing
prognosis in cirrhosis (Infante-Rivard et al, 1987). The one-year survival in
good-risk (Child A and B) patients is about 70% and in poor-risk (Child C)
patients about 30%.
Cox's regression model using proportional hazards has been applied to primary
biliary cirrhosis and a prognostic index formulated (Christensen et al, 1986).
Poor prognosis is associated with a low prothrombin index, marked ascites,
gastrointestinal bleeding, advanced age, high daily intake of alcohol, high serum
bilirubin and alkaline phosphatase, low albumin values and poor nutrition.
Study of a very large number of Italian patients with cirrhosis showed that
decompensation (i.e. onset of jaundice and ascites) developed at a rate of 10%
per year. Only 20% of decompensated patients survived six years. Significant
mediators of death were advanced age, male sex, encephalopathy, variceal
haemorrhage, varices, prothrombin time, hepatitis B surface antigen positivity
and hepatocellular carcinoma (D'Amico, 1986).
Alcoholics, if they continue drinking, tend to have the worst prognosis as
hepatocellular disease is greater. If they abstain however, their prognosis is
better than that of patients with "cryptogenic" cirrhosis, ie cirrhosis of unknown
aetiology. Prognosis is also better if hepatic decompensation has followed a
15
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Child's-Pugh Grade A = 5 or 6 points
Child's-Pugh Grade B = 7 to 9 points
Child's Pugh Grade C = 10 to 15 points
Minimum score = 5 points; Maximum = 15 points
(Pugh et al, 1973)
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correctable factor, such as gastrointestinal haemorrhage, rather than being
spontaneous. Patients who fail to improve within one month of starting hospital
treatment, have a poor outlook and persistent hypotension (BP systolic <100
mmHg) is also an adverse prognostic factor.
THE PORTAL VENOUS SYSTEM
The portal system includes all veins that carry blood from the abdominal part of
the alimentary tract, the spleen, pancreas and gallbladder. The portal vein is
formed by the union of the superior mesenteric and splenic veins just
immediately anterior to the head of the pancreas at about the level of the
second lumbar vertebra. The portal vein enters the liver at the porta hepatis
before dividing into two main branches. It has no valves in its channels. Within
the liver it has a segmental distribution accompanying the hepatic artery.
The liver has a vast anastomotic vascular network, the large cross section of the
vessels producing a low resistance system. The hepatic vascular bed is
expandable, for example when a large increase in portal blood flow occurs
postprandially.
Portal blood flow in man is about 1.0-1.2 L/minute at rest and contributes 72%
of the total oxygen supply of the liver. Hepatic arterial pressure is
approximately 90 mmHg. The hepatic artery supplies the remainder with a flow
of approximately 350 mL/minute. Portal pressure is normally 6-8 mmHg and
hepatic vein pressure 2-4mmHg in man (Richardson and Withrington, 1981;
Hobsley, 1982; Sherlock and Dooley, 1993).
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Occlusion of the hepatic artery results in a fall in hepatic portal venous
resistance and increase in portal flowwhile conversely, reduction in the portal
inflow increases hepatic arterial blood flow termed reciprocity (Richardson and
Withrington, 1981). This intrinsic regulation of liver blood flow is postulated to
be due to either metabolic or myogenic mechanisms.
The metabolic hypothesis regards tissue oxygen supply as the regulated factor.
When tissue oxygen supply fails to meet demand, vasodilator metabolites are
released causing resistance causing vasodilation. Postulated mediators include
hydrogen ions (Cohn and Kountz, 1963; Gelman and Ernst, 1977), increased
plasma osmolality (Lautt et al 1977; Richardson andWithrington, 1980),
adenosine and all the phosphates of adenosine (ATP,ADP,AMP) (McCuskey,
1966; Su, 1978).
The myogenic hypothesis considers local intravascular pressure to be the
important regulated variable and it proposes that an increase in the transmural
pressure gradient across the arterioles stretches the vascular smooth muscle
cells which react by contracting and bring about an increase in vascular
resistance, thereby maintaining a constant blood flow in the face of increased
arterial pressure (Richardson and Withrington, 1981).
Whether autoregulation, in the sense of pressure-dependent control by blood
flow, occurs in the liver is controversial. Some studies have shown small
degrees of autoregulation in the hepatic arterial bed (Torrance, 1961; Hanson
and Johnson, 1966). Autoregulation appears to be more pronounced in fed
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than in fasted animals (Norris et al, 1979; Granger and Norris, 1980). There is
no such autoregulation in the portal vascular bed (Richardson and Withrington,
1981).
The control of the portal flow is not inherent to the liver but is due to altered
resistance of the vessels of the splanchnic organs that supply the portal system.
This concept that the portal inflow is controlled by the splanchnic arterioles and
not by the hepatic vessels is crucial to understanding the pathophysiology of
portal hypertension.
PORTAL HYPERTENSION
As early as 1748 it was noted that the portal vein, spleen and haemorrhoids
were related in an ill-defined syndrome (Stahl, 1748). Bleeding from
oesophageal varices was first reported in 1840 (Power) but its association with
cirrhosis was not appreciated until 1858 (Fauvel). Mclndoe first used the term
"portal hypertension" in 1928 and observed progressive dissociation of the portal
venous and hepatic arterial circulations resulting in diversion of portal blood
into collateral channels at an earlier stage than arterial blood (Mclndoe, 1928).
The hepatic cells thus came to be nourished almost entirely by the hepatic
artery.
The first measurements of portal pressure were made by Caughey in 1936, who
recorded an increase in splenic venous pressure in patients with Banti's
syndrome and thus established portal hypertension as a clinical entity
(Rousselot, 1936).
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HAEMODYNAMIC CHANGES IN CIRRHOSIS
Forwards and backwards (resistance) flow theories of portal hypertension
Portal hypertension is thought to result from an increased resistance to portal
venous blood flow through the liver ("backwards"/resistance mechanism)
and/or raised portal venous blood flow through the liver ("forward flow
mechanism").
Resistance factor
Although increased splanchnic flow is undoubtedly a factor in the development
of portal hypertension, increased intrahepatic resistance to blood flow is at least
as important and the site of this is the basis for the anatomical classification of
portal hypertension into presinusoidal, sinusoidal and post-sinusoidal types
(Groszmann et al, 1979; Groszmann, 1984). Progressive hepatic disease may
produce more complex flow patterns in which the presinusoidal, sinusoidal and
postsinusoidal patterns merge to produce a mixed type of lesion.
The precise cellular or subcellular location of the resistance in intrahepatic
portal hypertension is not well defined. In 1963, Schaffner and Popper used
electron microscopy to study biopsies from 63 patients and showed that the
space of Disse had increased collagen, sinusoidal lining cell proliferation and a
structure similar to a basement membrane. These findings supported the theory
of a sinusoidal location of resistance to intrahepatic blood flow. However
Viddins et al (1985) showed that in liver biopsies from patients with alcohol
induced cirrhosis there was a marked reduction in sinusoidal area when
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compared to normal biopsies. Furthermore, when the sinusoidal area was
diminished by greater than 80%, an inverse relationship with hepatocyte size
was noted and they concluded that hepatocyte expansion (i.e. ballooning) with
compression of the sinusoids was important in the aetiology of increased portal
pressure in severe alcoholic liver disease. Other studies have shown the
presence ofmyofibroblast-like cells surrounding the sinusoids and hepatic
venules.
Using isolated liver perfusion studies Bhatal and Grossman (1985) have
demonstrated that a reversible component of hepatic resistance in cirrhotic
livers and that vasodilators could reduce hepatic resistance i.e that it may be
amenable to pharmacological treatment.
Forward flow factor
Portal hypertension is associated with a hyperdynamic splanchnic circulation
characterised by low splanchnic arteriolar resistance and increased portal
venous inflow in experimental models of portal hypertension (Vorobioff et al,
1984) and in humans (Kotelanski et al, 1972) (Figure 2).
The increased blood flow is not limited to the splanchnic territory; high cardiac
output and low systemic vascular resistance characterises the circulation in
cirrhosis. These findings have been confirmed in the rat model and in cirrhotic
patients assessed by Doppler ultrasound and the systemic change occurs earlier
than the splanchnic one (Colombato et al, 1992), possibly because the increased











(by a myogenic reflex) the effect of circulating humoral vasodilators on the
splanchnic bed.
Evidence for both mechanisms in portal hypertension
Sikuler and Groszmann (1985) studied the evolution of portal hypertension in
rats with partial portal vein constriction, a model of portal hypertension that
mimics the haemodynamic changes seen in humans. Rapid changes occurred
including portal-systemic shunting, a decrease in splanchnic arteriolar
resistance and an increase in portal blood inflow. The latter contributes to
portal pressure and the maintenance of portal hypertension. Therefore,
although the initial pathological insult causes increased resistance, portal
hypertension is partially maintained by increased blood flow.
The mechanisms underlying the hyperdynamic circulation are under intense
investigation. Multiple theories have been proposed including arteriovenous
shunting and alterations in the sympathetic nervous system. Several vasoactive
substances have also been suggested as being responsible, including glucagon
(Kock et al, 1970; Benoit et al, 1984), bile acids (Ohkubo et al, 1984; Benoit et
al, 1989), prostaglandins or prostacyclin (Zipser et al, 1979; Bruix et al, 1985;
Blanchart et al, 1985; Sitzman et al, 1989), 5-hydroxytryptamine (Cummings et
al, 1986), gamma-aminobutyric acid (Minuk and MacConnell, 1988), and nitric
oxide (Vallance and Moncada, 1991). Glucagon and bile acids have been found
in high concentrations in blood from various models of portal hypertension and
in patients with chronic liver disease and are potent splanchnic vasodilators in
23
animals but neither consistently dilates other vascular beds (Korthuis et al,
1985; Genecin et al, 1990).
Prostaglandins El and E2 and prostacyclin have vasodilator effects. In humans
with cirrhosis, urinary prostaglandin E excretion is enhanced. In portal vein
ligated rats, portal vein prostaglandin activity is increased; however, no effect on
systemic or splanchnic haemodynamics was derived from the suppression of
prostaglandins by indomethacin (Blanchart et al, 1985).
Evidence for a hormonal agent is provided by several rat studies.
Cross-perfusion of intestinal vessels between normal rats and those with
induced portal hypertension revealed that the vasodilation of the intestinal
arteries was transferable (Benoit et al, 1984). Likewise, a study of
cross-perfusion between the hindquarters of non-cirrhotic rats (without livers)
and those with induced portal hypertension revealed increased blood flow and
decreased resistance in the non-cirrhotic partners (Korthuis et al, 1985).
When the liver was included in both circulations in such parabiosis experiments
however no evidence of a transferable humoral factor was found (Sikuler and
Groszmann, 1985), ie this may be due to dilution and subsequent ineffective
plasma concentrations of vasoactive substances or metabolism of the substance
by the normal liver suggesting that the substance(s) that mediate the
haemodynamic circulation depend on the existence of substantial functional or
anatomic portal-systemic shunting.
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More recently, the results of several studies suggest that nitric oxide, a powerful
endogenous vasodilator secreted by endothelial cells, may be involved in
inducing the vasodilatation seen in chronic liver disease (Pizcueta et al, 1992;
Sieber and Groszmann, 1992).
The role ofnitric oxide in portal hypertension and the development of the
hyperdynamic circulation of cirrhosis
Nitric oxide (NO), a vasodilator synthesised from L-arginine by vascular
endothelial cells (Palmer et al, 1988), accounts for the biological activity of
endothelium-derived relaxing factor (Palmer et al, 1987) which is said to play a
crucial role in blood pressure regulation (Rees et al, 1989). Released by
vascular endothelium, NO diffuses into vascular smooth muscle and results in
relaxation via the activation of cyclic GMP (Moncada and Higgs, 1993). Blood
flow and O2 tension are known to be potent stimuli for NO secretion (Miller et
al, 1986).
Vallance and Moncada (1991) first suggested that NO may have a role in the
hyperdynamic circulation of cirrhosis. Blockade of NO increases MABP and
systemic vascular resistance and decreases cardiac output in normal rats (Lee et
al, 1992; Pizcueta et al, 1992; Claria et al, 1992; Haylor et al, 1991). Inhibition
ofNO synthesis by N-omega-nitro-L-arginine (NNA) has been shown to restore
the vascular hyporesponsiveness to methoxamine in portal hypertensive rats
(Lee et al, 1992; Sieber and Groszmann, 1992; Sieber et al, 1993). In addition,
short-term administration of either N-omega-nitro-L-arginine or
NG-monomethyl-l-arginine (L-NMMA), another NO synthase inhibitor
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attenuates the hyperdynamic splanchnic and systemic circulation observed in
portal hypertensive rats (Lee et al, 1993 a and b; Pizcueta et al, 1992
respectively). Wu et al (1993) measured aortic, central and portal venous
pressures directly in portal hypertensive rabbits and found that L-NMMA
produced superior mesenteric artery vasoconstriction; indomethacin induced
further constriction implying that NO and prostaglandins probably act as
vasodilators by independent mechanisms. In vitro hyporesponsiveness to
angiotensin II in aortic rings of cirrhotic rats with ascites was reversed on
endothelium denudation or NO synthesis inhibition with
N-omega-nitro-L-arginine (Castro et al, 1993).
Although previous studies in experimental portal hypertension have suggested
that NO plays a role in the development of portal-systemic shunting, our work
with patients with cirrhosis showed that administration of L-NMMA to patients
with cirrhosis had no effect on azygos vein blood flow but did modify the
systemic circulation by reduction of heart rate and elevation of blood pressure
(Forrest et al, 1994). In addition, Calver et al (1994) demonstrated that nitric
oxide inhibition with L-NMMA did not reverse the vasodilation seen in a
forearm blood flow model of cirrhosis. The extent to which NO is responsible
for the haemodynamic changes that accompany cirrhosis thus remains
controversial.
The unstable nature of nitric oxide precludes its easy measurement; however it
is rapidly converted to serum nitrite and nitrate which can be measured. A
recent study has found that increased serum levels of nitrite and nitrate are
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found in patients with cirrhosis, particularly those with ascites and may be a
consequence of enhanced NO production in these patients (Guarner et al,
1993). However the finding could also be explained by dietary intake of proteins
or diminished renal excretion of nitrite/nitrate.
Role ofendothelins in cirrhosis
Endothelins are small peptides, mainly synthesised and released by endothelial
cells, that act on adjacent smooth muscle cells in a paracrine fashion. They
appear to be involved in the control of cardiovascular and renal function and
act as neuromodulators.
Endothelin-1 was first isolated in 1988 from the supernatants of endothelial
cells in culture (Yanagisawa et al, 1988). Two homologous forms have since
been identified; endothelin-2 and 3 (Inoue et al, 1989). Many factors are known
to influence the production of endothelins by cells including endotoxin,
adrenaline, angiotensin II and arginine-vasopressin (Yanagisawa M et al, 1988;
Emori et al, 1989; Sugiura et al, 1989). It is the most potent vasoconstrictor
known to date. When it was infused in vivo to animals or man an intense
sustained vasoconstriction followed an initial transient decrease in blood
pressure (resulting from stimulation of the endothelial vasodilators nitric oxide
and prostacyclin) (Miller et al, 1989; Vierhapper et al, 1990; deNucci et al,
1988). Endothelin-induced vasoconstriction appears to be due to a direct effect
on vascular smooth muscle cells and is reversed by nitric oxide; so there appears
to be a fine interplay between the nitric oxide and endothelins in the control of
vascular tone.
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Current information concerning the role of endothelins in cirrhosis is
conflicting. Six studies investigating the plasma concentration of endothelin in
cirrhosis have been published to date (Schrader et al, 1990; Moore et al, 1991;
Lerman et al, 1991; Veglio et al, 1992; Uchinhara et al, 1993 and Asbert et al,
1993). The studies show marked differences; only some show elevated plasma
levels of endothelins in patients with ascites. The discrepancies between these
studies are difficult to explain but neither the sodium intake or diuretics are
mentioned in many of them. In the study of Asbert et al (1993) control subjects
and cirrhotic patients were studied in conditions of identical sodium intake and
elevated plasma endothelin levels were found in cirrhotic patients with ascites
than controls.
This may be due to increased endothelial synthesis of endothelin in cirrhosis as
a compensatory mechanism to antagonize the effects of vasodilator factors of
endothelial origin eg nitric oxide or prostaglandins. Future studies using
specific antagonists of endothelin will it is hoped lead to a better understanding
of the pathophysiological role of endothelin on systemic and renal
haemodynamic and neurohumoural changes in cirrhosis.
The balance of forces in the hyperdynamic circulation of cirrhosis
Generalised vasodilation, probably mediated by a combination of the factors
already described, characterises the haemodynamics of portal hypertension.
What is not clear, however, is the event that leads from this vasodilation to the
state of high cardiac output and increased regional blood flow, since
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vasodilators given to controls produce only a transient increase in cardiac output
and regional blood flow, which usually does not persist.
It is suggested that for a hyperdynamic state to develop and persist requires not
only reduced cardiac afterload, but also an increased venous return. Genecin et
al (1990) and Albillos et al (1992) reported an expanded plasma volume after
initial vasodilation in rats with portal hypertension. They also found
amelioration of the hyperdynamic circulation after sodium restriction and
suggested that this "refill" of the circulation may be intrinsic to the development
of the hyperdynamic state and that blood volume expansion may be the link
between vasodilation and the hyperdynamic circulation.
In preascitic cirrhosis, the renin-angiotensin and sympathoadrenergic systems do
not differ from healthy controls either in the upright or supine position,
suggesting that the effective arterial blood volume was normal (Bernardi et al,
1992a). The haemodynamic pattern "appears to be a function of the distribution
of an expanded blood volume, trapped within the splanchnic area in the upright
posture and redistributed towards the central and systemic circulations in the
supine position" (Bernardi, 1993).
However, in advanced cirrhosis and ascites vasoconstrictor systems have been
shown to be activated in the upright posture and not suppressed within the
normal range by the supine-induced blood volume redistribution (Bernardi et
al, 1992b). Although haemodynamics are a function of blood volume
distribution, an activation of vasoconstrictor systems is also needed to
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counteract a putative but very likely trend to arteriolar vasodilation. Therefore
blood pressure homeostasis is achieved but at the price of renal sodium
retention (Bernardi et al, 1992c). Thus the fundamental assumption of the
peripheral vasodilation hypothesis is fulfilled, although it appears to mainly fit
with what occurs in the advanced stages of cirrhosis.
THE COLLATERAL SYSTEM
When the portal circulation is obstructed, whether within or outside the liver, a
collateral circulation develops to return portal blood into the systemic veins
(Figure 3). In the normal liver all of the portal venous blood flow can be
recovered from the hepatic veins but in cirrhosis only 10-15% is obtained; the
rest enters collateral vessels. Blood from the gastro-oesophageal collaterals,
retroperitoneal and venous systems of the abdomen ultimately reaches the
superior vena cava via the azygos or hemiazygos system (Figure 3 & Appendix
v)a small amount enters the inferior vena cava.
The presence of collaterals usually implies the existence of portal hypertension,
although occasionally portal pressure can be normal if the collateral circulation
is very extensive. The development of the collateral circulation reduces liver
blood flow and the liver therefore depends increasingly on blood from the
hepatic artery. It shrinks and its capacity to regenerate is impaired possibly due
to a lack of hepatotrophic factors, including insulin and glucagon.
The major source of blood flowing through oesophageal varices is the left
gastric vein, the posterior branch of which usually drains into the azygos system.
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Figure 3. The collateral circulation
When the portal circulation is obstructed, a collateral circulation
develops to return the portal blood into the systemic veins.
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The anterior branch of the gastric vein communicates with varices just below
the oesophageal junction and forms a bundle of thin parallel veins in the
junction area and continue as large tortuous vessels in the lower oesophagus.
There are four layers of veins in the oesophagus (Figure 4). Intra-epithelial
veins may represent the red spots seen on endoscopy (which predict variceal
rupture). The superficial venous plexus drains into larger, deep intrinsic veins.
Perforating veins connect the deeper veins with the adventitial plexus. Large
varices arise from the main trunks of the deep intrinsic veins and these
communicate with gastric varices.
The connection between portal and systemic circulation at the
gastro-oesophageal junction is extremely complex (Vianna et al, 1987). A
pallisade zone is seen between a gastric zone and the perforating zone. In the
pallisade zone flow is bidirectional and this area acts as a watershed between
portal and azygos systems. Turbulent flow in perforating veins between the
varices and the perioesophageal veins at the lower end of the stomach may
explain why rupture is frequent in this region (McCormack et al, 1983).
Recurrence of varices after endoscopic sclerotherapy may be related to the
communications between the various channels or perhaps to enlargement of
veins in the superficial venous plexus. Failure of sclerotherapy may also be due
















The layers of veins in the oesophagus.
(After Sherlock and Dooley, 1993)
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PORTAL GASTROPATHY
In portal hypertension gastric vascularity is abnormal showing increased
submucosal arteriovenous communications between the muscularis mucosa and
dilated pre-capillaries and veins - a vascular ectasia (Quintero et al, 1987). This
has been termed congestive gastropathy.
Such gastric mucosa may be at particular risk of bleeding and of damage, for
instance, by aspirin or non-steroidal anti-inflammatory drugs. Bleeding can
occur from gastric red spots (Quintero et al, 1987). These gastric changes may
be increased after successful oesophageal sclerotherapy. They are relieved only
by reducing the portal pressure.
CLINICAL FEATURES OF PORTAL HYPERTENSION
Haematemesis is the commonest presentation of portal hypertension although
melaena, without haematemesis, may occur both from bleeding varices and
portal hypertensive gastropathy.
Abdominal collateral veins
In intrahepatic portal hypertension, some blood from the left branch of the
portal vein may be deviated via para-umbilical veins to the umbilicus and
consequently to the caval system. The veins may be prominent over the anterior
abdomen while in extra-hepatic portal obstruction, dilated collateral veins may
appear in the flanks.
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The direction of flow of the blood in these vessels is downwards. A number of
prominent collateral veins radiating from the umbilicus is termed caput
medusae but this is rare; the blood flow is away from the umbilicus. The
presence of collateral vessels may also cause a venous hum
(Cruveiler-Baumgarten murmur) which can sometimes be heard in the region of
the xiphoid process or umbilicus with an associated thrill at the site of
maximum intensity. It is due to blood rushing through a large umbilical or
paraumbilical channel in the falciform ligament from the left branch of the
portal vein to the superior epigastric, internal mammary or inferior epigastric
veins. It is clinically significant in that it indicates a patent portal vein.
Splenomegaly
Splenomegaly is often associated with portal hypertension but its size bears
little relation to the degree of portal pressure. The degree of splenomegaly
tends to be larger in young patients and in those with macronodular cirrhosis
(Sherlock and Dooley, 1993). Secondary hypersplenism may be associated with
the splenomegaly of portal hypertension but is related to splenic size and
hyperplasia of the reticulo-endothelial system rather than portal pressure.
Anorectal varices
These are found in 44% of cirrhotic patients and may cause significant blood
loss (Hosking et al, 1989).
Oesophageal varices
Oesophageal varices show as protrusions into the lumen of the oesophagus on
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endoscopy. Their size is graded (North Italian Endoscopic Club, 1988) as
follows:
Grade 1 - the varices can be depressed by insufflation of air through the
endoscope.
Grade 2 - the varices cannot be depressed by the endoscope.
Grade 3 - the varices are confluent around the circumference of the
oesophagus.
The larger the varix the more likely it is to bleed. Colour is also important.
Varices usually appear white and opaque. Redness correlates with blood flow
through dilated sub-epithelial and communicating veins. Dilated sub-epithelial
veins may appear as raised cherry-red spots and red wale markings. These
colour changes predict variceal bleeding.
Bleeding is almost always localised to within the 5 cm above the cardia and this
is the area in which sclerotherapy and band ligation is directed (Johnston,
1981).
Congestive or portal hypertensive gastropathy
This is seen mostly in the fundus, but in about one third of patients extends
throughout the stomach. Sclerotherapy may increase gastropathy (D'Amico et
al, 1990).
Ascites
Ascites is defined as a detectable collection of free fluid within the peritoneal
space. Portal hypertension appears to be an important prerequisite for ascites
36
generation but ascites in cirrhosis always indicates liver cell failure in addition
to portal hypertension (Sherlock and Dooley, 1993).
THE PATHOGENESIS OF ASCITES
Patients with ascites retain salt and water because homeostatic mechanisms
become unbalanced (Arroyo et al, 1991). In the later stages of cirrhosis, there
may also be absolute as well as relative reductions in renal blood flow and
glomerular filtration rate due to vasoconstriction of the renal arteries. The
exact sequence of events by which the diseased liver promotes renal salt and
water retention and leads to renal failure however remains uncertain.
Hyperaldosteronism (which stimulates sodium reabsorption in the distal tubule
of the kidney) and increased sympathetic nervous activity (which enhances
sodium resorption in the proximal tubule, loop of Henle and distal tubule) both
appear to be important factors in the pathogenesis of sodium retention in
cirrhosis (Rosoff et al, 1975; Bichet et al, 1982a) and seem to outweigh the
effects of endogenous natriuretic hormones (Gines et al, 1988; La Villa et al,
1990).
The kidney is also less able to excrete free water because of reduced delivery of
filtrate to the ascending loop of Henle and hypersecretion of antidiuretic
hormone (Bichet et al, 1982b; Perez-Ayuso et al, 1984). Finally, an imbalance
between the activity of endogenous vasoconstrictor systems, for example the
renin-angiotensin-aldosterone and sympathetic nervous systems, and the renal
production of vasodilator substances, such as prostaglandins and renal
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kallikrein, may account for the development of renal vasoconstriction and renal
failure (Arroyo et al, 1986; Moore et al, 1990; Hayes et al, 1992b).
The degree of portal hypertension correlates well with the degree of stimulation
of neurohormonal systems involved in the pathogenesis of salt and water
retention and renal vasoconstriction (Bosch et al, 1980; Henriksen et al, 1984a).
Consequently, any hypothesis concerning the pathogenesis of ascites needs to
explain how portal hypertension might activate these systems.
Traditional theories of ascites formation
The underfill theory proposes that intrahepatic obstruction of blood flow
increases sinusoidal pressure and thus lymph formation. The latter eventually
exceeds the capacity for lymphatic return and accumulates in the peritoneal
cavity as ascites (Greenway and Lautt, 1970; Witte et al, 1971; Henriksen and
Ruig-Larsen, 1984b). As a consequence the intravascular plasma volume is
reduced and intrathoracic and arterial mechanoreceptors activated, signalling
the kidney to retain salt and water. Renal failure supervenes due to circulatory
hypovolemia.
According to this theory plasma volume and cardiac output should be low and
peripheral resistance high in patients with cirrhosis. However, a hyperdynamic
circulation is seen in patients with both compensated cirrhosis and with cirrhosis
and ascites (Bosch et al, 1980), and in animal models of cirrhosis without ascites
or prehepatic portal hypertension (Vorobioff et al, 1983 and 1984), thus this
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theory does not seem to provide a plausible explanation, although it does
explain the elevated catecholamine levels.
The overflow theory was postulated to explain the aetiology of ascites in the
knowledge of the hyperdynamic circulation of cirrhosis (Lieberman et al, 1970.
This theory holds that renal sodium retention is the primary event rather than a
decrease in intravascular volume and is mediated via a hepatorenal reflex
involving intrahepatic mechanoreceptors (Kostreva et al, 1980). As salt and
water are retained, plasma volume expands, cardiac output increases and
peripheral vascular resistance falls to accommodate the high blood volume.
Higher pressure in the hepatic and splanchnic beds would result and lead to
"overflow" ascites. Unfortunately, this theory does not explain the relative
hypovolemia, systemic hypotension and elevated catecholamines noted in
cirrhotic patients.
Peripheral arterial vasodilation theory
Like the underfill theory this most recent theory, considers sodium retention as
a secondary event with portal hypertension as the initial event. Splanchnic and,
later, systemic arteriolar vasodilatation causes underfilling of the arterial
vascular compartment, stimulates baro-receptors and subsequently of the
renin-angiotensin-aldosterone system, sympathetic nervous system and
antidiuretic hormone production leading to renal sodium and water retention.
In the early stages of cirrhosis when splanchnic vascular resistance is moderately
reduced and the lymphatic system is able to return to the circulation the
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increased amounts of hepatic and splanchnic lymph produced, arterial vascular
underfilling is corrected by transient periods of sodium and water retention.
The fluid retained by the kidneys remains in the intravascular compartment,
increases intravascular volume and cardiac output, refills the dilated arterial
vascular bed, suppresses the signals that stimulate endogenous neurohormonal
mechanisms, and normalises sodium and water excretion. With progression of
liver disease however, splanchnic arteriolar vasodilation increases and
simultaneously affects the general, hepatic and splanchnic microcirculations. In
the general circulation, it accentuates arterial vascular underfilling while in the
other two it causes more deterioration of the mechanisms that control
transvascular fluid exchange. The higher splanchnic blood flow increases the
hydrostatic pressure in the hepatic sinusoids and splanchnic capillaries. In
addition, arteriolar vasodilation increases the filtration coefficient of the
splanchnic microvascular barrier by affecting capillary permeability and the
number of perfused capillaries (Granger and Barrowman, 1984). As a result
along with hypoalbuminaemia, capillary hyperfiltration is enhanced and a
critical level is reached at which the amount of fluid leaving the sinusoids and
splanchnic capillaries exceeds the lymphatic return and the fluid accumulates in
the intraperitoneal compartment. The renin-angiotensin-aldosterone system,
sympathetic nervous system and secretion of antidiuretic hormone must then be
continuously stimulated to maintain arterial pressure, which perpetuates sodium
and water retention and the formation of ascites.
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This hypothesis is compatible with all the haemodynamic changes observed to
date in cirrhosis - only time will tell if it is the full story.
HAEMODYNAMIC ASSESSMENT OF THE PORTAL AND SYSTEMIC
CIRCULATION AND THE ACTION OF DRUGS IN VIVO
The relationship between electrical current, electrical resistance and voltage is
described by Ohm's law: V = I R.
When it is applied to a haemodynamic system, V is the pressure, I is the blood
flow and R is the resistance. All components can be measured in an electrical
system, but in haemodynamic studies, resistance cannot be measured and must
be calculated indirectly from the measures of flow and pressure.
The effect of drugs on the haemodynamic system of humans may be evaluated if
the limitations imposed on in vivo studies are accepted, which include the fact
that isolation of individual parameters is often not possible and that
measurements of the variables are sometimes indirect.
Methods for the assessment of portal pressure
Various methods for the measurement of portal pressure have been developed.
There are direct and indirect techniques:
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a) INDIRECT METHODS






Transhepatic puncture (Chiba needle)
Umbilical vein catheterisation
The one most commonly used to evaluate the degree of portal hypertension in
vivo is hepatic vein catheterisation with a balloon catheter.
Balloon catheterisation of the hepatic vein allows measurement of the portal
pressure gradient with one procedure.
Myers and Taylor introduced the technique of hepatic vein catheterisation in
1951 and having been extensively used and modified since, it is generally
regarded as safe, simple and capable of giving reproducible results. It can be
performed in patients who have a bleeding tendency or ascites, but is of no
value in patients with presinusoidal portal hypertension, in whom the wedged
hepatic venous pressure (WHVP) is normal (Hoefs et al, 1990).
During this procedure the hepatic vein is occluded with a balloon-tipped
catheter to create a stagnant vascular segment within the liver (Groszmann et
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al, 1979). The catheter is known to be properly wedged if the pressure tracing
shows tiny regular oscillations related to transmission of hepatic arterial
pressure. When the balloon is deflated, the free hepatic vein pressure can be
measured, which approximates to inferior vena cava pressure.
The difference between "wedged" (WHVP) and "free" (FHVP) pressure is the
hepatic venous pressure gradient (HVPG) and is normally 5-6 mmHg. Values
exceeding 10 mmHg indicate portal hypertension.
The WHVP closely reflects portal pressure in patients with alcoholic cirrhosis
but is lower than portal pressure in patients with nonalcoholic causes of
cirrhosis because of pre-sinusoidal factors (Boyer et al, 1977). During acute
administration of vasoactive drugs, WHVP may not always provide a reliable
measure of the absolute change in portal pressure but the direction of the
change can adequately be assessed (Valla et al, 1984a).
Intra oesophageal variceal pressure (IOVP) can be determined either by direct
puncture of a varix (Staritz et al, 1985) or indirectly using a pneumatic pressure
gauge fixed to the tip of an endoscope (Mosimann, 1982). IOVP is lower than
WHVP but correlates well with it (Rigau et al, 1989). It is not well suited for
short term haemodynamic studies.
Splenic pulp pressure measurement (Atkinson and Sherlock, 1954) requires
placement of a needle into the spleen and causes intra-splenic haemorrhage in
about 1% of those studied. It therefore is not performed today except in the
assessment of splenic or portal venous thrombosis.
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Of the direct methods, transhepatic puncture of a portal vein-branch with a thin
needle is unable to give prolonged measurements and is contra-indicated in
patients with ascites. It is the technique of choice in the Budd-Chiari syndrome
and in the assessment of patients with presinusoidal portal hypertension
(Groszmann et al, 1979; Groszmann, 1984).
In portal hypertension, the umbilical vein is often patent and dilated, serving as
a portasystemic collateral. It can be exposed by dissection of the pre-peritoneal
fat cephalad to the umbilicus and a catheter can be manipulated through it into
the left intrahepatic portal vein and ultimately the main portal vein to allow
portal pressure measurement (Hoefs et al, 1990).
Direct methods of measurements of portal pressure have the limitation that
inferior vena cava pressure is not measured. This is an important parameter to
measure in an individual study as it provides the internal reference point and
eliminates problems associated with poor reproducibility due to variations in
the external zero point. Therefore, by measuring the inferior vena cava
pressure as an internal reference point, an accurate assessment of any changes
in the venous haemodynamic system may be described. This allows for
comparisons ofmeasurements made in different laboratories.
Assessment of hepatic blood flow
a) Indirect methods
- clearance technique
- inert gas washout
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- angiography - radionuclides
- contrast dyes
- fractional distribution of microspheres





- timed collection of hepatic venous output
The oldest method for determination of hepatic blood flow is the clearance




where IR is the infusion rate of a highly extracted substance and Ca and Chv
are the concentrations of this substance in the artery and hepatic veins,
respectively. This method becomes unreliable when the extraction falls below
20% (Bradley et al, 1945) and it is therefore vitally important that extraction is
determined hepatic vein catheterisation.
The ideal substance for estimation of liver blood flow has yet to be found but
would have little extra hepatic metabolism and a constant volume of
distribution. The extraction of taurocholate and indocyanine green (ICG) are
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affected, to a similar extent, by liver cirrhosis (Paumgartner et al, 1979) while
that of galactose seems to be slightly less affected (Henderson et al, 1982). ICG
has the advantage of being removed only by the liver, its enterohepatic
circulation is minimal, and it is therefore the substance most commonly used.
The inert gas washout method, although reliable and relatively non-invasive, is
greatly limited in its application to man by the fact that the partition coefficient
of the inert gas must be known, and is affected to different extents in different
liver diseases; even within a single liver there may be regional differences.
In those patients where the diameter of the portal vein can accurately be
estimated, calculation of portal flow is possible with Doppler ultrasonography
i.e. duplex Doppler (Ohnishi et al, 1986). Satisfactory results depend on
meticulous attention to detail and on technical expertise (Sabba et al, 1990).
The method is most useful in measuring rapid, large, acute changes in flow
rather than monitoring chronic changes in portal haemodynamics (Sabba et al,
1990, Alvarez et al, 1991).
Flows in exposed vessels may be measured directly using the square wave
electromagnetic flow meter enabling those in the portal vein and hepatic artery
to be measured separately.
The other methods listed above are either only semi-quantitative, for example
angiographic methods, or too invasive for use in humans.
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Assessment of portal-systemic collateral flow
Measurement of portal-systemic collateral flow is difficult.
The fraction of portal blood that is shunted may be computed by direct injection
of isotope into the splenic or mesenteric vein and measurement of the area of
an isotope dilution curve recorded in the hepatic vein.
Trans-hepatic catheterisation allows injection of isotopically labelled materials
into the splenic or portal vein and differential counting over the liver and lungs
allows calculations of intra- and extra-hepatic shunts. These values correlate
well with the size of collaterals opacified by portography.
Most of the blood flowing through gastro-oesophageal varices drains into the
azygos system. Measurement of blood flow in the azygos vein may therefore
reflects blood flow in varices. Much of the flow is probably from
para-oesophageal vessels rather than from endoscopically visible varices but
since they are interconnected and have no valves, it is reasonable to assume that
changes in azygos flow reflect changes in variceal blood flow.
Measuring azygos blood flow may help predict the risk of bleeding.
Propranolol, reduces the risk of bleeding and HVPG in only about 60% of
patients but reduces azygos flow in all patients (Lebrec et al, 1981; Westaby et
al, 1984; Mills et al, 1984; Bosch et al, 1984a; Cales et al, 1984).
Vasopressin and octreotide do likewise.
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The original manual method described for measuring azygos blood flow
employed a reverse thermodilution technique with calculations derived from a
Wheatstone bridge and was cumbersome and time consuming, particularly
when rapid changes in flow were recorded (Bosch and Groszmann, 1984b).
Azygos blood flow can be now measured by a computerised system employing a
continuous thermodilution technique (Hayes et al, 1992a) which allows real
time measurement of the rapid changes in collateral blood which may occur
with respiration, exercise, Valsalva manoeuvres etc. A catheter containing a
calibrated thermistor (Webster Lab Inc) is placed under fluoroscopic control
into the azygos vein, so that its tip is proximal to the arch of the vein. Flow in
the vein can then be measured by the thermodilution principle using 5%
dextrose at room temperature. The signals from the internal (injectate) and
external (mixed blood) thermistors are transferred through a custom built
interface and processed in an IBM model PS2-286 microcomputer to give real
time values for blood flow.
The primary role of azygos blood flow studies are in the evaluation of new
pharmacological therapies for portal hypertension.
Assessment of cardiac output
Cardiac output is defined as the volume of blood ejected by one ventricle in one
minute: it equals the stroke volume multiplied by heart rate. In humans it can
be measured by a variety of methods, which either measure cardiac output per
se (the Fick principle and dilution methods) (Hamilton, 1962) or measure
48
stroke volume and heart rate separately (Doppler and radionuclide methods).
It can also be assessed indirectly by echocardiography.
i) Fick's principle
Adolf Fick observed in 1870 that the rate at which the circulation takes up
oxygen from the lungs must equal the change in oxygen concentration in the
pulmonary blood multiplied by the pulmonary blood flow. Since the pulmonary
blood flow is the output of the right ventricle, this offered a way of determining
cardiac output. In practice this only became possible in the 1940s, when
progress in cardiac catheterisation allowed sampling ofmixed venous blood to
from the right ventricle. Peripheral venous samples are unsuitable because
their oxygen content varies; venous blood only becomes fully mixed and uniform
in the right ventricle outflow tract and pulmonary artery. The problem of
obtaining mixed venous blood was first solved by the German physician Werner
Forssman, who in 1929 passed a ureteric catheter through his own arm vein and
into the heart, watching its progress on an X-ray screen. This act won him the
disapproval of his head of department and, later, the Nobel prize.
The Fick method is currently as follows. The subject's resting oxygen
consumption is measured over 5 to 10 minutes by collection of expired air in a
Douglas bag. During this period an arterial blood sample is taken from the
brachial, radial or femoral artery, and a mixed venous sample from the
pulmonary artery or right ventricle outflow tract via cardiac catheter, introduced
through the femoral or antecubital vein. The oxygen content of each blood
sample is measured and the cardiac output (litres/min) calculated as:
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Oxygen uptake (mL/min)
Arterial O2 conc. - Venous O2 conc.
While Fick's method is the yardstick by which new methods are judged, it has
certain limitations. It is slow, and beat-to-beat changes in stroke volume cannot
be followed. The method is only valid in the steady state, so that transient early
responses to exercise or haemodynamically active drugs cannot be measured. It
is also invasive and cannot be used during vigorous exercise because the cardiac
catheter may provoke arrhythmias.
An indirect version, in which catheterisation is avoided and the O2 content of
mixed venous blood is estimated by analysis of rebreathed gas, is less accurate
and rarely used today.
ii) Indicator dilution method
In Hamilton's indicator dilution method (1962), a known mass of an indicator is
injected rapidly into a central vein or into the right heart. The indicator must
be one that is confined to the bloodstream and easy to assay, for example
indocyanine green, or albumin labelled with radioiodine. The bolus of indicator
becomes diluted in the returning venous blood, passes through the heart and
lungs and is ejected into the systemic arteries from which samples are taken at
frequent intervals. The radial or femoral artery, is commonly used. The
concentration of the indicator in the arterial plasma is measured and plotted
against time. This gives the time (t) needed for a bolus to pass a given point
and the mean concentration of indicator in the bolus over that period. Thus:
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Mass of indicator
Cardiac output of plasma =
mean concentration X time t
The plot of concentration against time is a curve which rises to a peak and
decays exponentially (Figure 5). The exponential decay is caused by the
ventricle ejecting only a fraction of its content with each systole, leaving some
indicator behind. Indicator-free venous blood returning to the heart during
diastole dilutes the residual indicator, which in turn is only partially ejected in
the next systole, and so on. After about 15 seconds the decay curve is disrupted
by a "recirculation hump" (Figure 5) caused by blood with a high indicator
concentration returning to the heart after completing one transit of the
myocardial circulation (the shortest route back). To find the area under the
concentration: time curve uncomplicated by recirculation, extrapolation is made
of the early part of the decay curve, before the recirculation hump (for example
by semi-log plotting and extrapolation to 1% of the peak value).
The results using this method agree to within 5% of Fick's direct method and
has the advantages of improved time resolution (30 seconds versus more than 5
minutes for Fick's method) and ability to be used in exercise, since ventricular
catheterisation is not required. The error involved in extrapolating the decay
curve can be a serious limitation, particularly in patients with diseased hearts in


















The concentration:time curve for Hamilton's dye
dilution method for estimation of cardiac output
Concentration is plotted on a logarithmic scale to
linearize the decay and allow extrapolation past the
recirculation hump (asterisk).
Area under the extrapolated curve is used to calculate the
cardiac output.
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iii) Thermal dilution method
This is a variation of the dye dilution method above, is widely used in cardiac
departments and is our method of choice for these studies.
A known volume of cold saline is injected quickly into the right atrium, right
ventricle or pulmonary artery, and the dilution of the cold saline by warm blood
is recorded by a thermistor-tipped catheter (Swan-Ganz catheter) in the more
distal pulmonary artery. Cardiac output can then be calculated from the area
under the temperature versus time plot and the amount of cold injectate.
The major advantage of this method is that the recirculation problem is
circumvented because the saline warms up to body temperature long before it
returns to the right side. Another is that the ejection fraction can be calculated
from the step rise in temperature that follows each refilling of the heart by
warm blood. One problem is that heat transfer across the walls of the right
ventricle and pulmonary artery can cause over-estimation of the distribution
volume and therefore cardiac output: a computed correction is usually made
for this.
iv) Pulsed Doppler method (Loeppky et al, 1981; Tincani et al, 1993)
A pulse of ultrasound is directed down the ascending aorta from a transmitter at
the suprasternal notch. Some of the ultrasound is reflected back by the red
cells, and is collected. Since the cells have high velocity, the frequency of the
returning sound waves is different from that of the transmitted signal; this is the
Doppler effect.
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The mean blood velocity across the aorta at each instant is computed from the
spectrum of frequencies in the returning signal, and the velocity is plotted
against time. To convert the time-averaged velocity (cm/s) to flow (cm^/s) the
diameter of the aorta must be measured by echocardiography and the cross
sectional area multiplied by mean velocity. The result, aortic flow, represents
cardiac output minus coronary blood flow. Doppler has calibration and "noise"
problems, but is quick and non-invasive.
v) Other methods
Technetium 99m binds to red cells and when given intravenously allows
estimation of cardiac output by counting over radioactivity the ventricles with a
gamma camera. Such radionuclide angiography allows stroke volume and
ejection fraction to be calculated from the difference between the radioactive
content of the ventricles in diastole and in systole (Schelbert et al, 1978).
Echocardiography allows estimation of end-diastolic and end-systolic diameters
of the ventricle which can be converted into stroke volume if some assumptions
are made about chamber shape.
The electromagnetic flowmeter utilises a curved magnet with its poles directed
on either side of the aorta or pulmonary artery. Since blood is an electrical
conductor its flow induces an electrical potential when it intersects the magnetic
field: the measured potential being proportional to velocity. The internal
diameter of the vessel must be known to convert mean velocity to flow.
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Use of the Swan-Ganz catheter
The development of the balloon tipped flow-directed catheter has greatly aided
the precise measurements of cardiac output, pulmonary free and wedged
pressure measurements and allowed sampling for oxygen utilisation studies. In
our studies a triple lumen device was used. One lumen was used to inflate the
balloonwith air thus enabling the balloon to be carried by the blood flow
through the right atrium and right ventricle into the pulmonary artery.
A second lumen opens at the tip of the catheter and is used for recording
pressures and for withdrawing mixed venous blood.
A third lumen is positioned to open into the right atrium when the tip of the
catheter is placed within the pulmonary artery. This permits the simultaneous
determination of atrial and pulmonary capillary wedge pressure. A thermistor
located approximately 4 cm from the catheter tip senses the temperature of the
pulmonary arterial blood to permit determination of the cardiac output, as
described previously.
Errors in estimation ofmixed venous O2 saturation and tension could occur if
the blood is drawn rapidly or if the catheter is positioned peripherally within the
pulmonary artery. These errors result from contamination of the mixed venous
pulmonary blood with arterialised blood drawn from the pulmonary capillaries
and veins.
The catheter frequently tends to migrate distally after insertion, causing the
production of a continuous wedge pressure pattern with the balloon deflated.
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The pressure must therefore be monitored continually so that the catheter may
be repositioned immediately should a wedged trace appear. Pulmonary
infarction could result from distal catheter migration.
The use of the Swan-Ganz catheter is not associated with high risk to the
patient; however, the complications of pulmonary infarction, pulmonary artery
rupture and air embolism are real.
PULMONARY SHUNTS IN CIRRHOSIS
Patients with cirrhosis show a wide range of arterial oxygen tension
(Rodriguez-Roisin et al, 1992) despite normal pulmonary function tests. The
pC>2 may be normal, yet as a result of hypocapnia there is an increase in the
alveolar/arterial pC>2 difference. Alternatively some patients have
mild-moderate arterial hypoxaemia and some may even need long-term oxygen
therapy. The transfer factor for carbon monoxide may be normal or reduced.
Patients with cirrhosis have pulmonary shunting (Rodriguez-Roisin et al, 1992)
but the exact form of such shunting has been highly controversial as emphasised
by Berthelot et til, (1966);
" The tantalising problem of the connective link in cirrhotic patients between
oxygen unsaturation and possible arteriovenous shunting in the lungs remains
unsolved and any relation between arterial unsaturation and pulmonary
vasodilation remains obscure".
Rydell and Hoffbauer (1956) were the first to identify at post-mortem numerous
intrapulmonary arteriovenous anastomoses in a young patient with juvenile
cirrhosis which were sufficient to cause cyanosis noted in life. The anastomoses
56
were seen between large arteries and veins near the hilum as well as in the
peripheral vascular bed. Berthelot et al (1966) were the first to document
post-mortem structural changes using a gold standard method ofmicrogelatin
injections into the vascular tree. Their finding was of dilation of the fine
peripheral branches of the pulmonary artery at both the pre-capillary and
capillary levels of the lung affecting arterial vessels up to 160 um in diameter
and pleural spider naevi. Obvious arteriovenous communications as described
by Rydell and Hoffbauer (1956) were found only in one patient however
(Berthelot et al, 1966). Many studies have failed to identify precise anatomical
pathways for intrapulmonary shunts and have postulated extra-pulmonary sites,
for example, portal and pulmonary venous systems (Calabressi and Abelman,
1957; Rodman et al, 1959; Georg et al, 1960). All these studies however point
to structural derangement of the pulmonary microcirculation sufficient to allow
mixed venous blood to pass directly into the pulmonary veins in cirrhosis.
In addition physiological mechanisms almost certainly contribute to the
hypoxaemia of cirrhosis. A right shift in the oxygen dissociation curve occurs in
many patients (Rodriguez-Roisin et al, 1992) due to an increase in 2,3
diphosphoglycerate but is insufficient to explain the degree of hypoxaemia. The
multiple gas elimination technique (Evans and Wagner, 1977) has shown that
ventilation/perfusion mismatching may also be responsible in some patients.
Patients with lower pulmonary vascular resistance appear to have a greater
mismatch (Rodriguez-Roisin et al, 1992).
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Therefore a wide range of gas exchange abnormalities may occur in patients
with chronic liver disease. Whether the mechanism underlying some of these is
related to failure ofmetabolism or of production of one of several circulating
vasoactive substances by the damaged liver cells or to altered metabolism of
paracrine factors synthesised by endothelial cells is unknown (Rodriguez-Roisin
et al, 1992).
THE EFFECT OF INTRA-ABDOMINAL PRESSURE ON PORTAL
PRESSURE, VARICEAL PRESSURE AND AZYGOS BLOOD FLOW
This concept is critical to an understanding of, for example, the role of ascites
with respect to splanchnic haemodynamics and oesophageal variceal pressure.
If intra-abdominal pressure is increased by either ascites or air (for example,
during laparoscopic liver biopsy), this pressure is transmitted to the
intra-abdominal venous system (the muscular arterial walls limit pressure
transmission to arteries).
Intra-abdominal pressure is usually identical to inferior vena cava pressure.
Hence as intra-abdominal pressure increases, the IVC pressure rises in similar
proportion, as does portal vein pressure, WHVP and FHVP. Thus, the portal
pressure gradient and HVPG remain the same (Iwatsuki and Reynolds, 1973).
With increased intra-abdominal pressure there are significant decreases in
cardiac output and hepatic blood flow - whereas azygos blood flow increases
markedly (Luca et al, 1993). Pressure within the oesophageal varices is not
however increased in response to increased intra-abdominal pressure as the
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varices are located downstream from the portal circulation. This may be
explained by Figure 6. If a thin-walled tube is placed through a box in which the
pressure can be varied and pressures are recorded at PI, P2 and P3, when the
pressure in the box is increased, PI and P2 increase since these are upstream
from the site of resistance. P3 will not increase since it is downstream from the
site of resistance. This concept is critical when interpreting the information
derived from haemodynamic studies.
Therefore, ascites will increase the pressure within the portal system but not in
the oesophageal varices. The increased abdominal pressure will be transmitted
equally throughout the abdomen. Itwill not change the gradient between the
sinusoidal pressure and the hepatic vein. When the intra-abdominal pressure is
increased, the transmural pressure, a determinant of variceal rupture, is
unchanged.
THE NATURAL HISTORY OF VARICES
The average risk of variceal bleeding for patients with cirrhosis and varices is
30%, with a 50% mortality rate within 6 weeks of the bleed (Burroughs et al,
1986). This mortality rate gives the rationale for prophylaxis to prevent the first
variceal bleed.
Portal and intravariceal pressure (Burroughs et al, 1986), the appearance of
endoscopically visible varices (Dagradi, 1972), severity of liver disease,







Schematic diagram of blood flow and pressure
relationships to illustrate the effect of
intra-abdominal pressure on portal pressure and
variceal pressure
Pj, P2 and P3 represent separate sites of pressure
measurement while pressure (P) in the box is variable.
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(Dagradi, 1972) are independent risk factors for the occurrence of the first
bleeding episode.
Although HVPG tends to be higher in patients who bleed or have large varices,
bleeding risk is not related linearly to pressure above a threshold of 12 mmHg
(Garcia-Tsao et al, 1985). Tension in the wall relative to varix radius may be
critical and increasing variceal size, in conjunction with wall thinness, may
favour rupture at lower intraluminal pressures (Polio and Groszmann, 1986;
Kleber et al, 1991). The North Italian Endoscopic Club in 1988 formulated an
index of risk for bleeding based on 3 independent risk factors; Child's-Pugh
class, size of varices and presence of red wale markings on varices. This model
has been validated by others and is the most useful prognostic index to date.
The justification for the use of prophylaxis in patients with their first variceal
haemorrhage has been based on the well-documented high rate of recurrent
bleeding that occurs in those patients who survive the first haemorrhage (Jones
et al, 1973; Graham and Smith, 1981; Jensen and Krarup, 1989; Kahn et al,
1989). Over a two-year period this ranges between 50% and 100%, the variation
largely reflecting different definitions of a rebleeding episode (Ollson, 1972;
Westaby et al, 1985). The greatest risk of rebleeding occurs within the first 30
to 42 days of first presentation, a period that is associated with the highest
mortality, and the most important factor predicting the incidence of rebleeding -
the severity of underlying liver disease (Graham et al, 1981; Burroughs et al,
1986), with endoscopic findings such as variceal size and appearance being far
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less significant; in contrast to their value at predicting first variceal
haemorrhage (North Italian Endoscopy Club, 1988; Henderson et al, 1990).
The natural history of variceal bleeding, as described above, requires planned
prophylaxis. The optimum treatment is one that is highly effective at preventing
bleeding and is also applicable to patients with severe liver disease. Since
60-70% of patients with cirrhosis will never bleed from varices it is essential that
prophylactic treatment is safe and free from side-effects.
NON-PHARMACOLOGICAL METHODS FOR THE PREVENTION OF
VARICEAL BLEEDING OR REDUCTION OF THE HEPATIC VENOUS
PRESSURE GRADIENT (HVPG)
TIPSS (Transjugular Intrahepatic Portasystemic Shunts)
This procedure was first described by Roesch and Hanafee in 1969. Portal
decompression is achieved by percutaneously creating a channel between the
hepatic vein and the portal vein with an expandable stent (Palmaz et al 1985;
LaBorge et al, 1993). It main use has been in the control of acute variceal
bleeding (Zemel et al 1991, Ring et al 1992). Procedural problems are
infrequent but serious life-threatening bleeding may occur. Long-term
complications include encephalopathy and delayed shunt occlusion (Conn,
1993; Simpson et al 1993; McCaughan, 1994).
Surgical methods
Surgical options for prophylaxis of recurrent variceal bleeding include
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decompressive shunts, devascularisation procedures such as splenectomy,
oesophageal transection and oesophageal/gastric devascularisation and the
ultimate surgical treatment of liver transplantation.
The use of total portal systemic shunts was popularised by Whipple in the 1940s
but realisation of the cost of accelerated liver failure came in the next two
decades (Jackson et al 1971, Resnick et al 1974, Reynolds et al 1981). The
indications for this procedure are now limited to decompression the sinusoids of
patients with acute Budd-Chiari syndrome and necrosis.
Various methods have however been used to perform partial portal systemic
shunts. Selective shunts, such as the distal splenorenal shunt (DSRS), aim to
compress the variceal system selectively and can reduce intravariceal pressure
to less than 12 mmHg, but at the same time maintain portal flow to the cirrhotic
liver. In studies comparing selective shunts and total shunts bleeding control
and survival was found to be equivalent and encephalopathy was significantly
lower, though not zero, in three of the six trials in the DSRS group (Conn et al
1981, Fischer et al 1981, Harley et al 1986, Langer et al 1985, Millikan et al
1985, Reichle et al 1979).
The rationale of devascularisation procedures, for example oesophageal
transection, is that most varices bleed from the distal 5cm of oesophagus.
However, this rationale might be questioned in light of data following chronic
sclerotherapy that obliteration of varices at this high risk zone merely moves the
bleeding sites to the gastric mucosa. In contrast to the shunt procedures in
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which the primary risk is loss of portal flow and liver function, devascularisation
procedures have rebleeding as their highest risk factor. Procedures range from
very simple to very complex and the choice is determined by timing and the
Child's-Pugh grading of the patient. Data to date suggest that whilst rebleeding
is higher thanwith shunt procedures, liver failure is not being accelerated.
Devascularisation procedures have had very variable success however (Idezuki
Y et al 1990, Inokuchi et al 1985, Keagy et al 1986, Spence and Johnston, 1985).
The physiological goal of liver transplantation is to both relieve portal
hypertension and restore a normal functioning hepatocyte mass. Rather than
balancing the risk of bleeding against liver failure as with other surgical
therapies, liver transplantation balances a normal liver and control of bleeding
against immunosuppression. Interestingly, recent evidence suggests that prior
variceal haemorrhage does not appear to adversely affect survival after liver
transplantation (Ho et al, 1993). Ultimately whether to operate or not for
variceal bleeding is based on the clinical pattern of variceal bleeding and the
likelihood of survival. Not all patients with variceal bleeding could or should be
transplanted.
Because superior mesenteric arterial blood flow is increased in portal
hypertension and plays an important role in elevated portal pressure,
mechanical reduction of artery diameter should decrease both portal pressure
and superior mesenteric arterial blood flow. In rats superior mesenteric artery
stenosis significantly reduced the degree of portal hypertension and the
hyperdynamic circulation of rats with extrahepatic portal hypertension
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(Soubrane et al, 1992). We can therefore speculate that superior mesenteric
artery stenosis might provide a new therapeutic approach for portal
hypertension in the future, though potentially at the risk of tissue ischaemia.
Endoscopic techniques
Endoscopic therapy (sclerotherapy or banding ligation) is the treatment of
choice for control of acutely bleeding oesophageal varices. However its value in
primary and secondary prophylaxis against that of pharmacological treatment
has been the subject of much research. Sclerotherapy attempts to obliterate
varices to prevent recurrent bleeding (Westaby and Williams, 1983). Injection
may be intravariceal or paravariceal and in experienced hands the results of the
two techniques appear similar. The number of sclerotherapy sessions necessary
to achieve oesophageal ablation varies considerably which may be attributed to
variations in the venous anatomy of the oesophagus (Westaby et al 1992). After
variceal obliteration has occurred it is usual to follow patients at 3 month
intervals for the first year and yearly thereafter.
A summary of the trials comparing beta-blocker with sclerotherapy in the
primary prophylaxis and secondary prophylaxis of variceal haemorrhage is
discussed below under beta-blockade.
Three studies examined the effects of adding propranolol to chronic
sclerotherapy. In one study (Avgerinos et al, 1993), the combination was more
effective at preventing bleeding from oesophageal varices, gastropathy and
gastric varices than sclerotherapy alone. However, in the other two studies,
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propranolol did not confer additional benefits (Acharya et al, 1993; Lo et al,
1993). Complications with sclerotherapy were more frequent and severe than
with medical therapy and the technical requirements greater.
The most frequent complication of long-term injection sclerotherapy is due to
oesophageal mucosal damage; ulceration at the site of previous injections is a
very common finding (Terblanche 1983; Soderlund and Ihre 1985; Westaby et
al 1985; Kitano et al 1988). However, recurrent bleeding due to mucosal
ulceration occurred in almost 20% patients (Poison et al 1989). This does not
appear to be affected by the type of sclerosant used but there is evidence from a
large controlled trial that sucralfate reduces the frequency of rebleeding (Poison
et al 1989). Deep ulceration may be associated with formation oesophageal
strictures, a complication which occurs in about 10% of patients undergoing
serial sclerotherapy. Omeprazole has been shown to be of value in the healing
of the ulceration (Shepherd and Barkin, 1993). Oesophageal perforation has
been reported in up to 5% of cases undergoing sclerotherapy, but the frequency
has almost certainly been reduced since the introduction of fibreoptic
techniques (Kahn et al 1989).
The incidence of pulmonary sequelae from sclerotherapy is high and includes
effusions, infiltrates, atelectasis, and mediastinal enlargement; many are
clinically silent. Serious pulmonary problems, including the adult respiratory
distress syndrome, have however been reported in association with
sclerotherapy and bacteraemia may also occur in 5-10% of patients. Other
common effects include chest pain which lasts from 24-48 hours in up to 40% of
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patients. Long term sequelae of sclerotherapy may include effects on
oesophageal motility.
Six prospective trials compared sclerotherapy with shunt surgery. One was
restricted to high risk actively bleeding patients and demonstrated that
sclerotherapy was not superior to portocaval shunt placement. The remaining
trials compared stable patients initially treated by sclerotherapy with those
initially treated with portocaval or selective splenorenal shunt operations.
Patients who failed sclerotherapy had salvage shunt operations. The Emory trial
showed that survival and preservation of hepatic function were superior in
patients initially treated with sclerotherapy, in spite of the fact that 35% of
sclerotherapy patients eventually required a shunt operation (Millikan et al
1985). The Nebraska study showed that patients who were non-compliant or
lived long distances from the treatment centre were better treated with a
selective shunt but the other trials showed no differences between treatments.
Two other local endoscopic measures have been developed with the aim of
overcoming some of the limitations of sclerosing agents. One involves the direct
injection of the tissue adhesive cyanoacrylate (Histacryl) directly into the
varices, with the aim of immediate luminal occlusion, without widespread
mucosal damage (Soehendra et al 1986). This technique has been most widely
adopted in the management of active variceal haemorrhage, particularly when
this originates from fundal gastric varices. This technique is also currently being
evaluated for long-term repeated injection.
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Banding ligation is performed using a ligating device which attaches to a flexible
gastroscope. Selected oesophageal varices are aspirated into the device and
ligation is accomplished by small elastic rings. Strangulation of the tissue
appears to take place with subsequent thrombosis of the submucosal varix
(Marks et al, 1993).
Banding (Van Steigman and Goff 1988) can eradicate oesophageal varices with
a median of 5 sessions, with recurrent acute variceal haemorrhage occurring in
47% of cases so treated (Van Steigman et al 1989). The technique is very safe
with no reported incidence of oesophageal perforation.
Trials of variceal band ligation versus sclerotherapy in acute bleeding and the
prevention of rebleeding are now beginning to be published (Stiegmann et al,
1992; Laine et al, 1993; Gimson et al, 1993). Gimson et al (1993) reported
reduced incidence of rebleeding with banding, Laine et al (1993) reported fewer
complications and Stiegmann et al (1992) reported increased survival in the
banding group.
As stated above endoscopic ligation appears to eradicate varices with fewer
treatments than sclerotherapy, a finding which may in part explain the lower
incidence of recurrent bleeding observed in ligation treated patients and may
result in an economic advantage for the new method. Prophylactic banding has
also been reported, though has not yet been compared with medical therapy in a
randomised controlled setting (Hashizumo et al, 1993).
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Successful treatment of bleeding from oesophageal varices and prevention of
recurrent bleeding remains a difficult problem. A number ofmedical, surgical,
radiological and endoscopic treatment options are available. The choice of
treatment should be based on local experience of methods and individual
patient considerations such as compliance, proximity to treatment centre and
whether the patient would be a candidate for eventual liver transplantation.
However, pharmacological agents have the advantage of being the easiest to
administer.
THE PHARMACOLOGY AND HAEMODYNAMIC EFFECT OF DRUGS ON
THE PORTAL AND SYSTEMIC CIRCULATION AND THEIR USE IN
TREATMENT AND PROPHYLAXIS OF VARICEAL BLEEDING
Interest in the pharmacological therapy of portal hypertension has recently
gained momentum because of the introduction of new drugs into clinical
practice and their efficacy in prophylaxis and treatment of variceal bleeding.
However, no perfect drug has been found to date and much remains to be
discovered about the best dosing regimens for the drugs which are currently
available.
The drug treatment of portal hypertension is based on the assumption that a
sustained reduction in portal pressure reduces the incidence of complications.
Studies have shown that when HVPG is reduced below the threshold of 12
mmHg, the patient is no longer at risk for variceal haemorrhage, and survival is
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increased (Groszmann et al, 1990). This appears to be because of reduced
variceal wall tension, which is directly related to variceal pressure when even in
patients in whom the HVPG falls but remains more than 12mmHg, the risk of
bleeding is reduced the tension exceeds a critical value the wall ruptures (Polio
and Groszmann, 1986; Rigau et al, 1989). For example propranolol reduces the
risk of bleeding but does not reduce the HVPG in 40% of patients (Lebrec et al
1982).
Pharmacological agents can be divided into vasoconstrictors (vasopressin,
somatostatin, beta-blockers) and vasodilators (nitroglycerin, isosorbide mono or
dinitrate, molsidomine, ketanserin). The vasoconstrictors cause splanchnic
arterial vasoconstriction which leads to reduction of portal blood flow and
pressure. The vasodilators can also lower portal blood flow and pressure by
producing a peripheral vasodilation which causes reflex splanchnic
vasoconstriction and a reduction in portal venous blood flow. Vasodilators also
reduce intrahepatic resistance and importantly, dilate the porto-collateral
circulation. The use of vasodilators, such as nitrates, to reduce portal
hypertension has attracted a lot of research interest over the past few years as
they have a theoretical advantage over vasoconstrictors, such as beta-blockers,
in that they may allow reduction of portal pressure without impairment of liver
perfusion (Navasa et al, 1989).
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PHARMACOLOGICALAGENTS OTHER THAN NITRATES SHOWN TO
ACHIEVE REDUCTION OF THE HEPATIC VENOUS PRESSURE
GRADIENT OR PREVENT BLEEDING FROM VARICES
Beta-Blockers
Lebrec was the first to report the beneficial effect of beta-blockade on variceal
bleeding. Acute or chronic administration of beta-blockers to patients with
portal hypertension has been shown to induce acute or chronic reduction in
HVPG and azygos blood flow (Lebrec et al 1982; Cales et al 1984; Groszmann
et al, 1990; Weinshel et al, 1994). This effect, when using non-selective
beta-blockers (such as propranolol), appears to be due to a decrease in cardiac
output as well as other factors such as vasoconstriction in the portal territory
due to unopposed alpha-vasoconstriction (Hillon et al 1982).
The changes in HVPG do not appear to be greatly affected by the dose of
beta-blocker used; however, the response varies widely from one patient to
another. Propranolol affects HVPG less than WHVP (Valla et al 1984a) and
has no effect in some cirrhotic patients (Bosch et al 1984a, Braillon et al 1986,
Garcia-Tsao 1986). Even in patients showing no WHVP response, azygos blood
flow is decreased (Braillon et al 1986, Garcia-Tsao 1986). This suggests, as with
organic nitrates (discussed below) that beta-blocking agents may have
differential effects on the portal and azygos systems.
The haemodynamic action of propranolol in patients with Child's Class
heterogenous and controversial. Down-regulation of beta-receptors has been
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described in cirrhotic patients with ascites (Gerbes et al 1986) and may explain
the heterogeneous response in such patients.
Propranolol is a beta-blocker with both beta 1- and beta 2- blocking
characteristics i.e a non-selective beta-blocker. Nadolol is a less lipophilic
non-selective beta-antagonist which is eliminated by renal excretion, does not
cross the blood brain barrier and therefore may be less likely to cause central
nervous system effects, although this has yet to be proven in patients with
cirrhosis. It has a long half-life allowing once daily administration. Both nadolol
and propranolol are accepted therapeutic agents for the prevention of variceal
bleeding or rebleeding (Pagliaro et al 1989, Poynard et al 1991a, Conn et al
1991, Ideo et al 1988, Lebrec et al 1988).
A certain degree of beta 2- antagonism appears to be needed to achieve portal
pressure reduction; thus metoprolol, a selective beta 1- antagonist, reduced
WHVP only to the extent predicted by its reduction in cardiac output but
mepindolol, an agent with predominant beta 2- antagonism, reduced WHVP to
a greater degree. In contrast to propranolol however it markedly reduced
hepatic blood flow (Braillon et al 1985). No evaluation has therefore been made
of these selective drugs in long-term, randomized, controlled clinical trials.
The merits of the different beta-blocking agents in the prevention of
oesophageal variceal bleeding have been reviewed (Ohara et al 1986,
Groszmann et al 1985, Bosch 1985, Hayes et al 1990, Pagliaro et al 1992). From
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these reviews it would appear that both beta 1- and beta 2- antagonism are
required for an agent to be clinically useful.
PREVENTION OF FIRST VARICEAL HAEMORRHAGE
There are to date 9 placebo-controlled studies of the prevention of first variceal
bleeding (Pascal et al, 1987; Colman et al, 1988; Strauss et al, 1988; Lebrec et
al, 1988; Ideo et al, 1988; The Italian Multicenter Project for propranolol in
prevention of bleeding, 1989; Andreani et al, 1990; Conn et al, 1991; the
PROVA study group, 1991).
In four of these studies, all the patients had large varices; in the remaining 5
studies patients with either small or large varices were included. Follow up was
for a period of 1 year in 2 studies and 2 years in the other studies. 7 studies used
propranolol or Inderal (LA) at doses that decreased heart rate by
approximately 25% (40-300 mg/day). In the other 2 studies nadolol was used
instead (Ideo et al, 1988; Lebrec et al, 1988). In patients who received placebo,
the incidence of bleeding reported ranged from 12% to 30% at 1 year and from
5 to 61% at 2 years. The incidence of bleeding in the beta-blocker group ranged
from 0 to 18% at 1 year and from 6 to 26% at 2 years. 4 studies showed that
beta-blocker use significantly decreased the incidence of initial gastrointestinal
bleeding (Pascal et al, 1987; Ideo et al, 1988; Andreani et al, 1990; Conn et al,
1991). One other study observed this difference only among compliant patients
(Lebrec et al, 1988) and another only when patients without ascites were
considered (The Italian Multicenter Project, 1989). Of great importance was
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that only one study showed a significant difference in survival rate at 2 years
between patients who received propranolol and those who received placebo
(Pascal et al, 1987).
Three published meta-analyses (Pagliaro et al, 1989; Hayes et al, 1990: Poynard
et al, 1991a) conclude that the use of beta-blockers significantly decreased the
risk of initial gastrointestinal bleeding in patients with cirrhosis and varices.
Fatal bleeding was also significantly less frequent in patients who received
beta-blockers than in those who received placebo (Poynard et al, 1991a).
When patients were tapered off their propranolol after the 2 years of study
follow-up observation was continued by the Boston-New Haven-Barcelona
Liver Group who found that the risk of bleeding recurred in these patients. The
implication was therefore of a need for prolonged beta-blocker therapy to
prevent initial variceal haemorrhage, a conclusion that needs verification in a
long-term prospective trial.
Side-effects occurred in 3-40% of patients who received beta-blockers and use
had to be discontinued for this reason in 5% of the patients (Poynard et al,
1991b). Mild and transient encephalopathy (1.4%) was observed in some
studies. Perhaps surprisingly, in all trials resuscitation after bleeding was not
more difficult in patients who received beta-blockers than those who did not.
The efficacy of beta-blockers and endoscopic sclerotherapy in prevention of the
first episode of gastrointestinal bleeding were compared in 2 controlled clinical
trials (Andreani et al, 1990; The PROVA Study Group 1991). Andreani et al
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(1990) showed the risk of bleeding was significantly lower in patients with
endoscopic sclerotherapy, whilst the PROVA group showed no statistical
difference; neither showed a significant difference in survival between the two
treatment groups.
PREVENTION OF RECURRENT VARICEAL HAEMORRHAGE
As with the trials for prevention of first variceal haemorrhage, only nonselective
beta-blockers have been evaluated for the prevention of rebleeding from
oesophageal varices. The time interval between haemorrhage and inclusion in
the studies described below ranged from 1 day to more than 1 month.
Eleven randomized, controlled trials with follow up over 1 or 2 years have
shown that nonselective beta-blockers were effective in preventing recurrent
variceal bleeding with a reduction in risk of rebleeding from 65.9% in the
control groups to 44.7% in the beta-blocker treated patients (p < 0.0001)
(Burroughs et al, 1983; Lebrec et al, 1984; Cerbelaud et al, 1986; Villeneuve et
al, 1986; Gatta et al, 1987; Queuniet et al, 1987; Colman et al, 1988; Colombo et
al, 1989; Sheen et al, 1989; Garden et al, 1990; Rossi et al, 1991).
The risk of rebleeding differed widely among studies in both placebo and
beta-blocker groups. In the placebo groups the risk of rebleeding at 1 year
ranged from 10-71% and at 2 years from 21-72%. 6 studies found the risk of
recurrent bleeding was significantly lower in patients on beta-blockers than
placebo; 5 studies showed no difference. In only one study was a significant
difference in survival observed at 2 years (Lebrec et al, 1984).
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Two meta-analyses confirmed that beta-blocker use significantly reduced the
risk (by about 20%) of recurrent gastrointestinal bleeding in patients with portal
hypertension (Pagliaro et al, 1989; Hayes et al, 1990).
9 studies compared the efficacy of beta-blocker use with that of endoscopic
sclerotherapy in the prevention of recurrence of gastrointestinal bleeding in
patients with cirrhosis (Fleig et al, 1987; Alexandrino et al, 1988; Dollet et al,
1988; Westaby et al, 1990; Qureshi et al, 1990; Andreani et al, 1990; Rossi et al,
1991; Martin et al, 1991; Teres et al, 1993). Six randomized, controlled trials
have found no significant difference between the two groups, two studies found
that the risk of rebleeding was lower in patients who received beta-blockers
than in those treated with endoscopic sclerotherapy (Alexandrino et al 1988;
Andreani et al, 1990) and one study found that patients treated with
sclerotherapy had a significantly lower incidence of rebleeding than patients
who received beta-blockers (Westaby et al, 1990).
It has been shown that the combination of endoscopic sclerotherapy with
beta-blockade is more effective in preventing recurrent gastrointestinal bleeding
than either form of therapy alone (Jensen and Kuarup, 1989; O'Connor et al,
1989; Vinel et al, 1990; Ink et al, 1990).
Contra-indications and side-effects of beta-blockers
The limitations of therapy with non-selective beta-blockers are related to their
contraindications and side effects. Contraindications include chronic obstructive
airways disease, asthma, congestive heart failure, atrio-ventricular heart block,
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arrhythmias and psychosis (Conn et al 1991). Side effects occur in up to 15% of
patients, but serious events such as bronchospasm are rare (Conn et al 1991).
The more frequent complaints are fatigue and sleep disorders. Side effects are
however extremely important as they alter compliance.
As 30-40% of patients either have contraindications to the use of nonselective
beta-blockers or develop side-effects requiring cessation of treatment,
alternative pharmacological agents are needed.
Alpha-adrenergic agents
Patients with cirrhosis often show signs of sympathetic nervous system
overactivity with increased plasma noradrenaline levels. Thus it was reasoned
that clonidine, a centrally acting alpha-2-agonist could be used to reduce these,
and may also reduce portal pressure.
Two studies showed that clonidine decreased plasma noradrenaline and the
HVPG (Willett et al 1986, Moreau et al 1987). In both, clonidine significantly
reduced cardiac output and mean arterial pressure. The mechanism of portal
pressure reduction may be due to an affect on post-sinusoidal hepatic vascular
resistance (Willett et al 1986) as well as reduction of cardiac output inducing
splanchnic vasoconstriction (Moreau et al 1987).
Arterial pressure is markedly reduced with clonidine but this does not appear
to affect renal function (Debinski et al 1989) or hepatic function as assessed by
hepatic blood flow, galactose-elimination capacity, hepatic clearance of
indocyanine green and hepatic intrinsic clearance of indocyanine green
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(Albillos et al, 1992b). In none of the patients given clonidine for a mean period
of 64 + /-10 days was the drug withdrawn because of side-effects, although 12
subjects complained of dry mouths (Albillos et al, 1992b).
Phentolamine and prazosin are also alpha-blocking agents which can reduce
portal pressure in man (Mills et al 1981). Prazosin, in contrast to beta-blocking
agents, decreases WHVP without affecting cardiac output (Mills et al 1981).
However, although the alpha-adrenergic antagonists described above are
effective portal hypotensive agents, their systemic hypotensive effect may
preclude use in the already vasodilated cirrhotic subject.
Calcium antagonists
Verapamil was the first such agent to undergo study and rat studies
demonstrated a portal hypotensive action (Reichen and Lee, 1986). Subsequent
human studies were however disappointing (Navasa et al, 1988; Vinel et al,
1989). Nifedipine was shown to be ineffective at portal pressure reduction (Lay
et al, 1987) and possibly harmful (Koshy et al, 1987).
Thus calcium channel blockers, although theoretically likely to be useful have
no role to play in the treatment of portal hypertension.
Serotonin S2 receptor blockers
Ritanserin and ketanserin have been shown to lower portal-collateral resistance
in animal models of portal hypertension and in patients with cirrhosis (Mastai et
al 1990, Nevens et al 1991, Hadengue et al 1987, Vorobioff et al 1989,
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Fernandez et al, 1993). These studies show that selective S2-receptor
antagonists do not cause a decrease in arterial pressure and the potential
clinical use for these drugs requires further evaluation.
Other drugs
Whether angiotensin-2-antagonists or angiotensin-converting enzyme inhibitors
have any role in the pharmacotherapy of portal hypertension remains dubious.
Captopril, an angiotensin-converting enzyme inhibitor, lowers WHVP in
patients with cirrhosis (Eriksson et al 1984); this is due mainly to induction of
systemic hypotension (Pariente et al 1985).
Spironolactone, an aldosterone antagonist, lowers HVPG in patients with
cirrhosis without ascites and reduces plasma volume, which reduces cardiac
output and thus triggers vasoactive mechanisms that decrease splanchnic blood
flow (Okumura et al 1991, Garcia-Pagan JC et al 1994, Katsuta et al, 1993).
Potentially, spironolactone may maintain and enhance the decrease in portal
pressure achieved by nitrates or propranolol as plasma volume contraction may
logically be expected to relieve portal hypertension. Frusemide however does
not reduce HVPG (Katsuta et al 1993).
Molsidomine (SIN-10), a selective reducer of pre-load with nitrate-like effects
but a longer duration of action is not associated with a significant reduction in
blood pressure or development of tolerance (Bassenge, 1982). Vasoactive
SIN-1A is formed only after metabolism ofmolsidomine to SIN-1 in the liver
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although no delay in the onset of action has been reported in patients with
chronic liver disease (Bhome, 1990).
Single doses of molsidomine (eg 2 or 4 mg) given intravenously significantly
reduced HVPG without clinically relevant impairment of systemic
cardiovascular regulation (Huppe et al, 1992). The reduction in HVPG resulted
from vasodilatation in the venous circulation and a reduction in cardiac output,
with a simultaneous slight reduction in MABP. However, there was no
correlation between MABP, cardiac output reduction and the fall in HVPG.
Since SVRI also showed no significant changes, it is assumed that the effect of
molsidomine in reducing HVPG can be mainly attributed to vasodilatation and
a decrease in pressure in the splanchnic region, probably associated with a
decrease in portal resistance (Kukovetz and Holzmann, 1985). However in the
study of Huppe et al (1992), the overall significant reduction in HVPG masked
the fact that 8 patients were non-responders; in 3 there was no change in
HVPG, while in 5, the HVPG actually rose. In general, the non-responders
were characterised by a greater reduction in FHVP than WHVP, and marked
ascites.
Similar results have been published elsewhere; Vinel et al (1990) showed a
15.4% reduction in HVPG 60 minutes after oral administration of 4 mg
molsidomine with a non-responder rate of 23.1%. Ruiz del Arbol et al (1991)
showed a dose dependent reduction in HVPG of 10.7% and 19.2% after 120
minutes. Both groups showed that a significant reduction in hepatic blood flow
was associated with a decrease in HVPG, without any impairment of hepatic
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clearance function. Whether this drug will be effective at prophylaxis of variceal
haemorrhage remains to be established by clinical trials.
THE PHARMACOLOGY AND HAEMODYNAMIC EFFECT OF NITRATES
ON THE PORTAL AND SYSTEMIC CIRCULATION AND THEIR USE IN
TREATMENT AND PROPHYLAXIS OF VARICEAL BLEEDING (1° and 2°)
Isosorbide dinitrate and isosorbide-5-mononitrate (Is-5-Mn) are both
"long-acting" organic nitrates. The mononitrate is the active component and is
formed from the dinitrate by rapid denitration in the liver (Down et al, 1974;
Sporl-Radun et al, 1980; Abshagen et al, 1985).
Is-5-Mn is a powerful venous and mild arterial dilator, with dose-dependent
activity (Bogaert and Rosseel, 1972) and little first pass metabolism (Abshagen
et al, 1981; Abshagen et al, 1992). It has a prolonged half-life (5 hours)
(Abshagen et al, 1981; Taylor et al, 1981; Abshagen et al, 1992) and dose linear
kinetics (Abshagen, 1986) even in the presence of liver disease (Steudel et al,
1983; Akpan et al, 1985) or renal failure (Raue et al, 1985).
In contrast, the dinitrate has a high first pass effect with an apparent oral
bioavailability of 0.2 in normal subjects (Fung, 1985). This increases up to a
mean of 0.65 in cirrhosis because of reduced hepatic extraction and the
presence of portasystemic shunts (Blei et al, 1987). As these show
inter-individual variation, the appropriate dosage of the dinitrate is difficult to
determine and the response is unpredictable in patients with chronic liver
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disease (Blei, 1986a). Such reasons make Is-5-Mn preferable to other organic
nitrates in patients with cirrhosis.
Nitroglycerin (GTN) is a short acting nitrate with no theoretical advantages
over Is-5-Mn unless oral administration is contraindicated, for example, eg
acute variceal bleeding.
Adverse reactions associated with nitrates are unusual other than a mild
headache resolving within 24 hours of the first dose occurring in up to one third
of patients (Blei et al, 1987).
The molecular mechanism of nitrate action is controversial. In 1977 two groups
independently demonstrated that organic nitrates induced a dose-dependent
increase in the levels of cyclic guanosine-monophosphate in smooth muscle cells
(Schultz et al, 1977; Katsuki et al, 1977). Subsequently it was shown that many
other nitrovasodilators, including nitric oxide, activate soluble guanylate cyclase
(Murad et al, 1978; Kukovetz et al, 1979).
Some vasodilators have been shown to generate nitric oxide in a nonenzymic
reaction with cysteine (Moncada et al, 1988). Nitrates do not directly stimulate
nitric oxide synthetase as demonstrated by Vallance et al (1989) who showed
that GTN infusion at 2 and 5 nmol/min to human controls caused a
dose-dependent increase in forearm blood flow which was unaltered by
L-N-monomethyl-arginine administration (L-NMMA), a specific inhibitor of
nitric oxide synthetase. It therefore seems likely that nitrates produce an
increase in cyclic-GMP levels in smooth muscle by direct action rather than via
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nitric oxide synthetase. There is strong evidence for thiol intermediates as
modulators of the cellular events of nitrates (Horowitz et al, 1983).
Acute effects of organic nitrates on portal and systemic haemodynamics -
animal studies
Vatner and colleagues (1978), demonstrated that intravenous nitroglycerin
administration to normal dogs resulted in a significant decrease in mesenteric
blood flow after an initial increase. The fall in mesenteric blood flow was
associated with a reduction in arterial pressure and an increase in heart rate and
it was suggested that nitrate-induced venodilatation resulted in
baroreceptor-mediated mesenteric arterial vasoconstriction, a sympathetic
response to vasodilation and venous pooling (a reduction in preload accounting
for the reduced cardiac output).
In the portal vein ligated rat (an experimental model of portal hypertension)
splanchnic vasoconstriction has been demonstrated after nitrate administration
(Blei et al, 1984; Kroeger and Groszmann, 1985; Blei and Gottstein, 1986b).
Other studies have demonstrated that nitrates may reduce portal pressure by
more than one mechanism, for example, myofibroblasts have been
demonstrated in a perisinusoidal location in the cirrhotic liver and may be
involved in the increased resistance to portal flow (Bhatal and Grossman, 1982).
In the isolated perfused cirrhotic rat liver, administration of nitrates decreased
intrahepatic resistance (Bhatal and Grossman, 1985). Nitrates may also have a
direct vasodilatory effect on the collateral circulation: high dose nitrates given
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to portal vein ligated rats were shown to reduce resistance across collateral
vessels (Blei and Gottstein, 1986b).
Acute effects of nitrates on portal and systemic haemodynamics - human
studies
The techniques available to estimate hepatic venous pressure gradient, azygos
vein blood flow and intraoesophageal variceal pressure are described above.
Five studies have examined the systemic and portal haemodynamic effects of
nitroglycerin in patients with cirrhosis (Table 4) and three showed a reduction
of HVPG following nitroglycerin administration (Garcia-Tsao et al, 1987;
Westaby et al, 1988; Iwao et al, 1991). The effect of nitroglycerin on azygos
blood flow was highly variable including some individuals in whom flow
increased suggesting vasodilatation of portasystemic collaterals. This suggested
that, as observed with experimental animals, the portal hypotensive effect of
nitroglycerin could be due to more than one mechanism. Putative mechanisms
include:
1) Vasorelaxation at a collateral and sinusoidal level leading to reduced
resistance to flow through the portal-collateral circulation and also
reduced portal pressure.
2) Relaxation of arterial smooth muscle which lowers the arterial blood
pressure, therefore triggering high pressure arterial baroreceptors to cause
reflex splanchnic vasoconstriction. This would reduce portal inflow and
hence portal pressure.
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3) Systemic venodilation reduces the cardiac preload and therefore activates
low pressure cardiopulmonary baroreceptors. This would also cause reflex
splanchnic vasoconstriction, reducing the portal venous inflow and thus
reducing portal pressure.
The effect of different doses of nitroglycerin has been found to be
heterogeneous (Rector et al, 1990) suggesting that different doses might act by
different mechanisms.
Seven groups have examined the acute haemodynamic effects on cirrhotic
patients given isosorbide dinitrate by a variety of routes (Table 5a & b). Only
one group (Dawson et al, 1985) showed no effect on HVPG; all others showed a
reduction in HVPG which was accompanied by a fall in cardiac index
and mean arterial blood pressure. The reduction of HVPG was achieved by a
significant fall inWHVP rather than a rise in FHVP.
The amplitude of the haemodynamic response in some patients to isosorbide
dinitrate might vary according to the size of portasystemic shunt; bioavailability
of the dinitrate is increased as the portasystemic shunt increases (Blei et al,
1984).
Table 6 shows that Is-5-Mn has the same portal and systemic haemodynamic
effect as the dinitrate, with the exception of one study (Tsai et al, 1989) of
Hepatitis B Antigen positive patients with cirrhosis. Unlike other studies these
Hepatitis B positive patients were predominantly Childs Grade A, given
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procedural failure rate (Tsai et al, 1989). As Hepatitis B positive cirrhosis and
alcoholic cirrhosis have such similar haemodynamic abnormalities it would
seem unlikely that the difference in results can be explained simply by the
different aetiologies of cirrhosis.
An illustration of different dose dependent mechanisms of the HVPG reducing
action of Is-5-Mn may be seen by the work of Navasa et al (1989). The changes
in cardiac output and systemic resistance were similar with either 20 or 40 mg of
Is-5-Mn but after 40 mg Is-5-Mn there were significantly greater reductions in
HVPG, arterial blood pressure and azygos blood flow.
These results are divergent from the study of Hayes and colleagues (1988)
which indicated that following administration of 20 mg Is-5-Mn the fall in
HVPG was associated with a fall in liver blood flow secondary to baroreceptor
mediated splanchnic vasoconstriction, a response only observed with 40 mg of
nitrate in Navasa's study. However differences between studies may be related
to different severities of liver disease (and different volumes of distribution of
nitrate), different degrees of portasystemic shunting, timing of Is-5-Mn
administration or different variceal bleeding histories.
To confuse the analysis of mechanism of response to nitrates further,
cardiovascular responsiveness to reflex autonomic stimulation is significantly
impaired in patients with cirrhosis compared with control subjects (Moreau et
al, 1989) and response to nitrates may also vary according to baseline cardiac
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filling pressure (Rector et al, 1990) or Child-Pugh classification (Braillon et al,
1986).
Despite the potential complexity of action of nitrates in portal hypertension the
overall results of studies of acute administration of nitrates have been
remarkably uniform (Tables 5a & b and 6).
It is important to note that the fall in HVPG seen after nitrates compares
favourably with the effect of propranolol but that following nitrate
administration the fall in HVPG was achieved by a fall inWHVP alone, unlike
propranolol which reduces HVPG by both a fall inWHVP and a rise in FHVP
(Bosch et al, 1984a; Garcia-Tsao et al 1986; Groszmann, 1984). Reducing
WHVP may be more important than reducing HVPG in protection against
variceal bleeds (Bosch, 1985; Bosch et al, 1988a).
Effect of organic nitrates on liver blood flow and hepatic resistance
Calculations of hepatic resistance from data in Tables 4 to 8 show that
administration of organic nitrates either acutely or chronically induces a
significant fall in portal pressure that is largely due to a reduction in resistance
rather than to a reduction in liver blood flow, which would be undesirable.
This implies either that portal flow is not reduced or that a compensatory
increase in hepatic arterial flow takes place i.e. reciprocity. The difficulty in
distinguishing between these two inputs has long been a problem in studies of
splanchnic haemodynamics and limits our ability to interpret this data further.
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Effect of organic nitrates on azygos (collateral) blood flow
The rationale for the pharmacological treatment of oesophageal varices was
originally based on the observation that drugs could reduce HVPG (Lebrec et
al, 1982). Propranolol, which is discussed above, reduces the HVPG in only
60% of patients with cirrhosis but reduces variceal flow, as measured by azygos
flow, in all (Lebrec et al, 1982). It remains unclear whether the major benefit of
propranolol, which reduces primary and secondary variceal bleeding (Hayes et
al, 1990), is by HVPG reduction or reduced azygos blood flow. Since the
HVPG reduction is small and variable, the effect on azygos flow may well be
more important.
Navasa et al (1989), showed that azygos blood flow remained unchanged after
administration of 20 mg Is-5-Mn despite a significant reduction in HVPG and
cardiac output. As the efficacy of vasoactive drugs in either controlling an acute
variceal bleed or preventing recurrent haemorrhage may be related to their
ability to reduce blood flow through collateral vessels, determination of the
effects of vasoactive agents on both collateral blood flow and HVPG is
important in evaluating their therapeutic potential. In this respect the change in
azygos flow to nitrates is seen to be highly variable and probably
dose-dependent (Tables 5-8) and it would seem important to find criteria which
would make possible the selection of a dose of nitrate for an individual that
both reduces HVPG and azygos blood flow in order to properly assess its
efficacy in reduction of variceal bleeding in future clinical trials. Clinically it
would be advantageous if an end-point for therapy could be determined
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Table 8
THE CHRONIC PORTAL AND SYSTEMIC
HAEMODYNAMIC EFFECT OF ORAL
ISOSORBIDE-5-MONONITRATE






No of patients 6 11
Dose, route 20mg Is-5-Mn bd 40mg Is-5-Mn bd








CO(a) / CI(b) 4.1-3.6 (b) 7.5-7.2 (a)
KEY: * denotes significant difference at least at 95% level; SVRI = systemic vascular resistance index in dynes/sec per
n5; WHVP = wedged hepatic venous pressure in mmHg; HVPG = wedged minus free hepatic venous pressure in
nmHg; AzBF = azygos blood flow in ml/min; ELBF = estimated liver blood flow in ml/min (ICG method); HR = heart
-ate in beats/min; MABP = mean arterial blood pressure in mmHg; CO/CI = cardiac output/cardiac index in 1/min;
Is-5-Mn = iso6orbide-3 -mononitrate
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non-invasively for example by an increase in heart rate or reduction of mean
arterial blood pressure.
Chronic effect of organic nitrates - is tolerance a problem ?
Tachyphylaxis to nitrate preparations is well recognised in patients with heart
disease given nitrates for 18 hours or longer (Elkayam et al, 1987; Jugdutt and
Warnica, 1989). Organic nitrates are metabolised by vascular smooth muscle as
well as by the liver (Fung, 1984) and tolerance has been shown to be associated
with an alteration of the vascular metabolism of the nitrate administered (Fung,
1984; Abrams, 1986); systemic clearance of administered nitrate diminishes and
the systemic arteriovenous nitrate gradient narrows i.e. with long term dosing
plasma nitrate concentrations rise over time. The cyclic-GMP response to
nitrates is also diminished in the presence of tolerance.
Administration of exogenous thiols e.g. N-acetylcysteine enhances the nitrate
vascular effects in the non-tolerant state (Packer et al, 1986) and removal of
organic nitrates from contact with the blood vessel wall for a period of time
restores vascular responsiveness.
Studies with isolated rat abdominal aortic rings (with endothelium) showed they
retained the repair mechanism to overcome tolerance without the need for
exogenous factors which suggests regulation of vascular responsiveness is at the
vascular level. Nitrate tolerance appears to be related to reduced sulphydryl
availability within vascular tissue and SH groups are required for vasodilatation.
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It is important that the effect of nitrate on portal pressure and collateral blood
flow after chronic administration is assessed as tolerance would be of concern in
the use of nitrates for prophylaxis of variceal bleeding . Experience (Tables 7
and 8) to date shows that a sustained fall in HVPG is seen after chronic nitrate
administration in cirrhotic patients which suggests that full tolerance is not of
concern in such patients, although partial tolerance has been reported
(Garcia-Pagan et al, 1990a).
Therapeutic potential of organic nitrates in liver disease
1) Nitrates in the management of acute variceal bleeding
The most effective treatment for an acute variceal bleed is either injection
sclerotherapy (Westaby et al, 1989) or banding (Steigman et al, 1992; Gimson et
al, 1993) but they are only effective if promptly applied by experienced
personnel. Balloon tamponade has been shown to be as effective as
sclerotherapy (Hunt et al, 1982) but is similarly only effective in proficient
hands, many patients tolerate the balloon poorly and rebleeding within hours of
balloon removal is common (Panes et al, 1988).
It would therefore be desirable if drug therapy was easy to use and efficacious in
controlling bleeding, particularly for centres with limited experience of treating
variceal bleeds. Acute bleeding, where the above measures are not available,
has traditionally been controlled by vasoconstrictor therapy e.g. vasopressin but
it is not always effective and has deleterious side-effects (Grace, 1980; Bosch et
al, 1981; Kravetz et al, 1984). Several studies have shown that the addition of
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nitrates to vasopressin maintains splanchnic vasoconstriction while
counteracting some of the deleterious systemic haemodynamic effects such as
reduced cardiac output and hypertension, and provides an additional reduction
in HVPG (Tsai et al, 1986; Gimson et al, 1986; Westaby et al, 1988; Iwao et al,
1992).
The side-effect profile of vasopressin has prompted pharmacological
manipulation in an attempt to maintain efficacy but reduce complications.
Glypressin is an analogue of vasopressin (Kyncl et al, 1974) which may have less
side-effects than vasopressin (Kravetz et al, 1988) but no study comparing them
with vasopressin plus nitrates has yet been reported.
Currently, the combination of vasopressin and a nitrate for treatment of an
acute variceal bleed where experienced help is not immediately available merits
consideration. Transdermal nitrate patches have been advocated but much
more reliable plasma nitrate levels are obtained by the intravenous route (Fung
et al, 1983 and 1984) especially in a shocked patient with compromised skin
blood flow (Blei et al, 1988). In the acute setting vasopressin should be used at
a dose of 0.4-0.8 U/min over 12 hours plus a nitroglycerin infusion at 0.2
mg/min for the duration of the vasopressin infusion.
2) Nitrates for the prevention of rebleeding or prophylaxis of first haemorrhage
Propranolol reduces the frequency of variceal haemorrhage (Lebrec et al, 1981)
but has less influence on mortality rates than might be expected (Hayes et al,
1990). Experience of use of nitrates in these two clinical situations is still
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limited: there is one trial comparing Is-5-Mn with propranolol suggesting that
the two drugs were of similar efficacy in preventing variceal bleeding but further
studies will be required (Angelico et al, 1993).
Most literature to date has focussed on the haemodynamic mechanism of action
of nitrates and this suggests that rather than a fixed dose, nitrates may need to
be individually titrated to obtain maximum benefits without adverse systemic
haemodynamic effects. The long term effects of reducing arterial blood
pressure in cirrhotic patients is unknown.
Because nitrates reduce HVPG in virtually all patients with cirrhosis they may
hold significant advantages over beta-blockade. However, their use as a first
line agent in prophylaxis of bleeding cannot be advocated until randomised,
controlled clinical trials are performed and the appropriate dose to use is
determined.
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THE PHARMACOLOGY OF N-ACETYLCYSTEINE AND ITS CLINICAL
USES
N-ACETYL-L-CYSTEINE (NAC)




It is a synthetic derivative of the naturally occurring amino acid L-cysteine.
Few studies of the plasma concentrations and pharmacokinetics of
N-acetylcysteine in man are available. This has largely been as a result of
methodological difficulties in assay of NAC. Earlier studies in animals and man
used radiolabeled NAC and thin layer chromatography for the separation and
identification of NAC and its metabolites (Scheffner et al, 1966; Rodenstein et
al, 1978; Bonanomi and Gazzaniga, 1980): cysteine and cystine were identified
as the major metabolites of NAC. Inorganic sulphate was the major urinary
product excreted together with small amounts of taurine and unchanged NAC
(Scheffner et al, 1966).
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In animals, N-acetylcysteine is rapidly deacetylated to cysteine and oxidised to
disulphides (Johnston et al, 1983).
N-acetylcysteine may be assayed in plasma and urine by gas liquid (Morgan et
al, 1983) and high performance liquid chromatography (Lewis et al, 1984) with
detection limits of 50 /xg/L. In plasma NAC can be present in its intact, reduced
form as well as in various oxidised forms (Olsson et al, 1988). N-acetylcysteine
appears to be extensively bound to plasma (~ 78%) and to tissue proteins by labile
disulphide bonds. This is not the same kind of protein binding as exhibited by
other drugs (Olsson et al, 1988).
Considerably higher concentrations can be measured by the use of affinity phase
chromatography and other thiols to displace drug bound to plasma proteins
(Morgan et al, 1983). It volume of distribution in healthy volunteers is
approximately 500 ml/Kg.
The drug disappears rapidly from plasma with a half-life of 0.5 to 6.6 (mean 2-6)
hours in healthy volunteers. Previous studies show for healthy volunteers given
intravenous N-acetylcysteine that pharmacokinetics fit either bi or tri-exponential
models (Borgstroem et al, 1986; Olsson et al, 1988).
No data on the pharmacokinetics of N-acetylcysteine in chronic liver disease has
been published prior to our study reported here. The elimination of
N-acetylcysteine has not been found to be impaired in patients with paracetamol
poisoning treated late and who suffered severe liver damage (Prescott et al, 1989).
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Many drugs however have altered pharmacokinetics in the presence of chronic
liver disease, for example, d-propranolol (Passayre et al, 1978) and bisoprolol
(Hayes et al, 1987).
For intravenous use in the treatment of paracetamol poisoning, there is a pyrogen
free solution containing 200 mg N-acetylcysteine per ml in ampoules of 10 ml:
Parvolex (Duncan, Flockart, UK). This is the formulation used in our studies.
Use of N-acetylcysteine in cardiology patients
Evidence has shown that N-acetylcysteine is capable of reversing the nitrate
tolerance seen in patients with stable and unstable angina (Horowitz et al, 1988a;
Boesgaard et al, 1992), although this is controversial (Hogan et al, 1990). The
molecular basis for reversal of tolerance appears to be sulphydryl donation by
N-acetylcysteine (Fung et al, 1988). N-acetylcysteine has also been shown to
potentate the coronary vasodilative effect of nitroglycerin (Winniford et al, 1986).
Recent evidence suggests that combined therapy with nitroglycerin and intravenous
N-acetylcysteine results in potentiation of haemodynamic responses to nitroglycerin
and reduces the incidence of myocardial infarction in patients with severe unstable
angina pectoris (Horowitz et al, 1988a and b and 1991).
This is in contrast to patients undergoing cardiac catheterisation for evaluation of
chest pain where administration of N-acetylcysteine alone intravenously had "no
consistent haemodynamic effect" (Horowitz et al, 1983) and in eight patients with
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severe chronic heart failure where N-acetylcysteine alone "had little haemodynamic
effect in patients not receiving nitroglycerin" (Packer et al, 1987).
In one study N-acetylcysteine appeared not to reverse tolerance to intravenous
nitroglycerin in patients with congestive heart failure (Dupuis et al, 1990) but
another study has shown partial reversal of tolerance (Packer et al, 1987).
There is some evidence that susceptibility to the development of nitrate tolerance in
humans is higher in the venous than in the arterial circulation, and that
N-acetylcysteine is extremely effective in reversing nitroglycerin tolerance in the
venous circulation in humans (Ghio et al, 1992).
N-acetylcysteine in the healthy state
It is controversial whether N-acetylcysteine possesses direct relaxant activity in
normal vascular smooth muscle: Horowitz et al (1983) and Torresi et al (1985)
suggest that it has no direct relaxant activity but a recent study (Sunman et al,
1993) showed N-acetylcysteine caused an endothelium independent relaxation of rat
and human arteries. Three control pigs demonstrated no physiological change after
NAC infusion in a different study (Modig and Sandin, 1988).
Administration of NAC had no significant systemic haemodynamic effect in 4
patients who had fully recovered from hepatic failure at Kings College Hospital
(Harrison et al, 1991).
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Hogan et al (1989) demonstrated tolerance to the haemodynamic effects of GTN
patches in normal volunteers with chronic dosing but concomitant dosing with 200
mg NAC failed to alter this phenomenon. The literature to date therefore, though
not extensive, suggests that NAC has no haemodynamic effect in healthy controls.
Use of N-acetylcysteine in patients with fulminant hepatic failure
Keays et al (1991), in a prospective controlled trial reported that N-acetylcysteine
treated patients with fulminant hepatic failure showed increased survival, a lower
incidence of cerebral oedema and less requirement for inotropic support than
controls not given NAC. However there are a number of criticisms of this study
which make interpretation of all data difficult - there were too many variables
(blood/albumin infusion, haemodialysis/haemoperfusion, ventilation/not), each
patient had treatment beginning at a variable time point from the moment of
ingestion of paracetamol and this interval and the length of treatment with NAC
was not stated in the paper. Requirement for inotropes and renal support may be
less in the NAC treated group than controls because NAC is a positive inotrope
rather than by treatment of underlying disease processes (Harrison et al, 1991).
N-acetylcysteine has been reported to increase cardiac output and tissue oxygen
delivery and utilisation in fulminant hepatic failure (Harrison et al, 1991), mostly
due to paracetamol poisoning. It also resulted in reduction of the pulmonary and
systemic vascular resistance index in such patients (Harrison et al, 1991).
Interestingly, there were no reported changes in arterial p02, calculated
arterio-venous tension gradient and shunt in hepatic failure patients in response to
NAC.
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Use of N-acetylcysteine in paracetamol poisoning
N-acetylcysteine is used primarily for the treatment of paracetamol overdosage
where plasma paracetamol concentrations are above a line on a semi-logarithmic
graph joining plots of 200 /xg/ml at 4 hours and 30 /xg/ml at 11 hours after
ingestion of the paracetamol. Early treatment (8-10 hours post overdose) with
N-acetylcysteine prevents hepatic necrosis, acute renal failure and death following
paracetamol overdosage; use after this time is more controversial. An initial
loading dose of 50 mg/Kg is given over 15 minutes followed by infusion of 50
mg/Kg over 4 hours and 100 mg/Kg over the next 16 hours.
At the dose used for the treatment of paracetamol poisoning NAC has no
hepatotoxic effects, in terms of glutathione-S-transferase rise, a sensitive marker of
hepatocellular integrity (Beckett et al, 1990). It is readily converted to cysteine in
vivo and by stimulating hepatic glutathione synthesis it effectively prevents acute
paracetamol-induced hepatotoxicity (Burgunder et al, 1989). Glutathione plays a
vital protective role by preferential conjugation with the toxic alkylating metabolite
of paracetamol and liver damage does not occur unless it is depleted (Mitchell et
al, 1974).
Other uses
By virtue of its free thiol group, N-acetylcysteine can form stable mercaptides with
heavy metals and has had limited use in the treatment of poisoning with these
agents (Flanagan, 1987).
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Oral N-acetylcysteine reduces sputum viscosity and facilitates expectoration in
patients with bronchopulmonary disease with improvement in symptoms and lung
function tests. It has proven efficacy in combination with hypermellose as eye
drops in keratoconjunctivitis sicca (Absolon and Brown, 1968).
Uncontrolled studies suggest that oral and rectal N-acetylcysteine can relieve the
meconium ileus equivalent in patients with cystic fibrosis (Hodson et al, 1976).
N-acetylcysteine protects against the acrolein-induced haemorrhagic cystitis caused
by cyclophosphamide and isophosphamide without reducing anti-tumour activity
(Slavik and Saiers, 1983).
Recent evidence suggests that N-acetylcysteine is a potent suppressor of human
immunodeficiency virus transcription in persistently infected cells (Kinter et al,
1992). The clinical significance of this observation remains to be established.
Adverse reactions to N-acetylcysteine
There have been occasional reports of "anaphylactoid" reactions to intravenous
N-acetylcysteine in patients with paracetamol overdosage, characterised by rash,
flushing and less commonly, angiooedema, bronchospasm, and hypotension (Mant
et al, 1984; Ho and Beilin, 1983). They are usually readily reversible and mild.
Flushing is a common effect seen in patients given intravenous N-acetylcysteine for
paracetamol poisoning.
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THE PHARMACOKINETICS OF DRUGS IN CHRONIC LIVER DISEASE
The pharmacokinetics of organic nitrates
The pharmacology of isosorbide dinitrate and Is-5-Mn nitrates is well described in
the literature.
Is-5-Mn has a prolonged half-life (5h) (Abshagen et al, 1981; Taylor et al, 1981;
Abshagen et al, 1992) and dose-linear kinetics (Abshagen, 1986) even in the
presence of liver disease (Steudel et al, 1983; Akpan et al, 1985).
In contrast, the dinitrate has a high first-pass effect with an oral bioavailability of
0.2 in normal subjects (Fung, 1985) which increases up to a mean of 0.65 in
cirrhosis because of reduced hepatic extraction and the presence of porta-systemic
shunts (Blei et al, 1987) in which there is interindividual variation. As the
pharmacokinetics of nitrates in the presence of chronic liver disease were so well
described in the literature, we did not undertake further study of this.
The pharmacokinetics of N-acetylcysteine
However the opposite is true for N-acetylcysteine where due to methodological
difficulties with assay of the drug, few studies on pharmacokinetics in man have
been reported and none in the presence of chronic liver disease.
The method of analysis is very important in NAC estimations. For example
Borgstroem et al (1986 and 1990) assayed NAC in deproteinised plasma. As NAC
is bound to thiols and proteins this method does not measure TOTAL plasma NAC.
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However the method of Lewis et al (1984) and the modification of that method
(Prescott et al, 1989) measured TOTAL plasma NAC, ie total oxidised and
reduced NAC and NAC bound to other thiols and proteins, and therefore it is
difficult to make comparisons bewteen different pharmacokinetic studies.
Borgstroem et al (1986) found the kinetics in normal controls conformed to a
triphasic pattern but Prescott et al found a biphasic pattern (2 compartment model)
in patients with paracetamol poisoning. The estimated half-life of the drug is
broadly comparable between the two studies. The volume of distribution of the
drug in normal controls and paracetamol poisoning was consistent with a
distribution mainly to extracellular water.
The metabolism of N-acetylcysteine
Radiolabelled NAC studies and other studies have shown that 20-30% of an
intravenous dose is excreted unchanged in the urine i.e. 70% is cleared by
extra-renal routes (Borgstroem et al, 1986).
NAC is deacetylated in the liver in the rat, mouse and human tissue in vitro (Sjodin
et al, 1989) but it is also rapidly metabolised to cysteine and inorganic sulphate in
the gastrointestinal tract (Cotgreave et al, 1987). It has been shown in rats that only
a small amount (3%) of radioactive NAC is excreted in faeces, even after
intravenous and oral administration (Bonanomi and Gazzaniga, 1980); the low
availability after oral administration is probably due to fast metabolism in the gut
wall and liver. This could be studied by measuring the plasma concentration of
NAC after oral administration in TIPSS patients.
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Once absorbed, N-acetylcysteine appears to be deacetylated to cysteine (Scheffner
et al, 1966) and used in the synthesis of glutathione or other sulphurated
compounds (Lauterburg et al, 1983). This metabolic step is probably a prerequisite
for most of the protective effect of NAC in paracetamol poisoning, since these
effects are thought to be dependent on de novo glutathione biosynthesis (Lauterburg
et al, 1983; Corcoran and Wong, 1986).
The deacetylation appears to be a process with rather specific structural
requirements on the substrate, since the D isomer of NAC and the disulphide of
L-NAC proved resistant to deacetylation (hydrolysis). Other N-acetylated amino
acids have been shown to be stereoselectively hydrolysed (Birnbaum, 1952). The
enzyme responsible for the deacetylation (hydrolysis) of NAC seems uncertain.
Coenzyme A dependent N-acetyltransferase and microsomal deacetylases are
known to acetylate several xenobiotics (Weber and Hein, 1985) but have not been
shown to catalyse deacetylation; they would therefore seem unlikely candidates.
A large number of proteins in animal and plant cells are N-acetylated on their
N-terminal amino-acid (Tsunasawa and Sakiyama, 1984). The enzyme,
acyl-peptide hydrolase from rat liver, liberating the N-acetylated amino-acid has
been reported (Tsunasawa et al, 1975; Kobayashi and Smith, 1987). This appears
to have a physiological role in the regeneration of free L-amino acids during
protein turnover and may well be responsible for the hydrolysis of NAC (Sjodin et
al,1989).
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In vivo, organs other than the intestine most likely contribute to the
biotransformation of NAC but the gut or liver clearly play a significant role since
after intravenous infusion of 600 mg NAC into human volunteers, 30% of
unchanged drug or its disulphide form was found in the urine but after oral intake
around 3% was found in the urine i.e. high first pass clearance (Borgstroem et al,
1986). Deacetylation may be the initial metabolic step, but in vivo other reactions
like S-methylation and S-oxidation may take place as well.
The liver metabolism of drugs and mechanisms of altered pharmacokinetics in
chronic liver disease
Many factors determine the elimination of a drug from the body, including its rate
of absorption, its distribution in body fluids, its binding to plasma proteins and its
metabolism and elimination by particular organs such as the liver and kidneys. The
liver is particularly important in the process as it metabolises most drugs to some
extent.
The extraction ratio of a drug across an eliminating organ can be calculated by
clearance flow through an organ. Drugs may be classified in relation to their
clearance from the blood as highly cleared (> 70% of drug cleared at each passage
through the liver) or poorly cleared (<30%), or intermediate. Examples of drugs
with high and low hepatic clearances are shown in Thble 9.
Hepatic clearance has an important effect on the extent to which drugs become
available in the systemic circulation particularly when drugs are given orally;
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Table 9
Examples of commonly used drugs with high and low
clearances by the liver
















highly cleared drugs have high "first pass" removal and therefore low systemic
availability.
Hepatic clearance of a drug is known to be a function of 2 factors:
i) liver blood flow
ii) ability of the liver to remove the drug from the sinusoids
(Wilkinson and Shand, 1976).
In normal liver, the relative importance of each of these factors for a particular
drug is dependent on its hepatic extraction ratio. For drugs with high extraction
ratios, hepatic blood flow is the major factor determining its elimination. In
contrast, the elimination of drugs with low extraction ratios is determined by
enzyme activity. The elimination of drugs with intermediate extraction ratios is
dependent on both hepatic blood flow and hepatic enzyme activity (Rowland et al,
1973; Nies et al, 1974; Branch et al, 1975) (Figure 7).
However, this concept may be less important in the presence of chronic liver
disease as once believed, as Passayre and colleagues (1978) showed in an elegant
study that in cirrhosis, d-propranolol (a highly extracted drug in normal controls) is
no longer highly extracted and its hepatic clearance depended not only on liver
blood flow but also and predominantly on the ability of the liver to remove drug
from the blood. This was also reported in an study using isolated perfused normal
and cirrhotic rat livers and another "highly extracted drug" meperidine, which is
metabolised by oxidation by the liver (Callaghan et al, 1993). Regression analysis
showed that in normal livers the elimination of meperidine was mainly dependent
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Liver blood flow (ml/min)
Figure 7
Theoretical effects of altering hepatic blood
flow for a drug with a low intrinsic hepatic
clearance (200 ml/minute) and a drug with
high intrinsic hepatic clearance (2000
ml/minute). Cm = maximum drug
clearance (after Branch et al, 1975).
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on flow, but in cirrhotic livers the reduced hepatic clearance of meperidine was
contributed to by reduction in intrinsic clearance or enzyme activity. The study
demonstrated that enzyme activity becomes an important determinant of altered
drug disposition in cirrhosis (Callaghan et al, 1993).
Thus the main factor responsible for the reduced clearance of drugs metabolised by
the liver in patients with cirrhosis appears to be impaired ability of the liver to




iii) reduced amounts of drug metabolising enzyme molecules
iv) reduced hepatic uptake of drugs
In discussion of liver metabolism of any drug it must be remembered that the
metabolic capacity of the liver is not a homogeneous entity but depends on the
metabolic pathways involved. Oxidation (Phase I) takes place in a centrilobular
location (Figure 1; Zone 3) and is thus more prone to hypoxia and more affected in
liver disease than Conjugation (Phase II) which is periportal in location (Zone 1)
and well preserved in liver disease (Callaghan et al, 1993).
Other possible mechanisms which could be responsible for altered kinetics in
chronic liver disease include:
113
i) altered protein binding, affecting the penetration of drugs into tissues and drug
distribution may be altered, changing the proportion of drug available for
metabolism.
ii) acid-base or electrolyte changes.
The relative importance of alterations in hepatic enzyme activity, blood flow and
protein binding to drug elimination in patients with liver disease remains
controversial.
Drugs which show reduced clearance in chronic liver disease
A number of other drugs are metabolised by the liver and demonstrate lower




bisoprolol (Hayes et al, 1987)
diazepam




meperidine (Callaghan et al, 1993)
*
d-propranolol (Passayre et al, 1978)
In those marked with a * reduced clearance has been shown by invasive studies to
be due to reduced hepatic extraction and blood flow (as discussed above). In the
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bisoprolol study (Hayes et al, 1987) it was shown that although clearance was
reduced in cirrhosis, gastrointestinal absorption was reduced thereby reducing the
likelihood of accumulation of the drug.
An interesting study of the effect of liver disease on plasma levels of
amylobarbitone has been reported (Mawer et al, 1972). The serum concentration
and the rate constant for the slower phase of the double exponential graph of the
logarithm of the concentration in serum against time was reduced in the group of
patients with lower albumin concentrations. The slower phase is an indication of
the combined rates of metabolism and excretion (the faster phase is an indication of
tissue penetration by the drug). The body thus appears to compensate for reduced
hepatic function by modification in the rate of drug penetration into tissues and thus
the clinical response was the same in patients with liver disease and normal
controls.
The effect of liver disease on drug metabolism is very difficult to assess, as
explained above, as there are so many confounding variables involved.
Drugs whose pharmacokinetics do not appear to be altered by chronic liver
disease
There are a number of drugs for whom no discernible differences have been
detected in pharmacokinetics in the presence of chronic liver disease.
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These include:
Chloramphenicol (Kunin et al, 1959)
Chlorpromazine (Maxwell et al, 1972)
Digoxin (Marcus and Kapadia, 1964)
Pentobarbitone (Sessions et al, 1954)
Tolbutamide (Nelson, 1964)
In general, these appear to be drugs with low hepatic clearance (Table 9).
ASSESSING EXISTING EVIDENCE
In the review of previous work above, identification of published studies has been
made using computerised searches. Basing reviews solely on publications can be
misleading, however, because published reports tend to favour studies with
"significant" or "promising" results (Simes, 1986). Published trials of treatment
for advanced ovarian cancer, for instance, demonstrated significant survival
advantage for combination chemotherapy over an initial alkylating agent, whereas a
pooled analysis of all trials in a cancer trials registry did not substantiate this
conclusion (Simes, 1986). Although identification of unpublished studies may be
daunting, for clinical trials at least this task is becoming increasingly feasible with
moves to establish prospective registration of all trials.
Identified relevant studies should be therefore critically appraised to assess bias.
Standardised forms are helpful, making clear the criteria used (Mulrow, 1987).
Although the existing data will often be insufficient to merit meta-analysis, such
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pooling should be considered with caution when several good quality studies exist
(Thompson and Pocock, 1991).
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AIMS OF THE RESEARCH
The aim ofmy study was to examine the haemodynamic effect of two
vasodilator drugs, isosorbide-5-mononitrate and N-acetylcysteine in patients
with stable cirrhosis:
to examine the effect of chronic oral administration of
isosorbide-5-mononitrate on portal pressure, liver blood flow and azygos vein
blood flow in patients with cirrhosis, with respect to tolerance and
dose-dependency (Section II). It was also important to study the effect of
rechallenge with the nitrate after chronic therapy.
Extensive work on the pharmacokinetics of isosorbide-5-mononitrate and the
effect of nitrates on the systemic circulation, including forearm blood flow
has already been reported and therefore was not necessary in my study.
to examine if N-acetylcysteine, which has been shown to increase cardiac
output and tissue oxygen consumption in patients with hepatic failure
(Harrison et al, 1991) has the same action in patients with stable cirrhosis
and if, as a vasoactive agent, it has any action on the HVPG or liver
blood flow (Section HI).
Since some of the haemodynamic changes seen in patients with cirrhosis are
similar to those with fulminant hepatic failure , for example peripheral
vasodilation, our hypothesis is that N-acetylcysteine may have the same
action in cirrhosis.
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The main determinants of flow through the liver are the hepatic arterial
resistance, splanchnic resistance and intrahepatic portal resistance. The
regulator with the most physiological variation is splanchnic resistance,
which is under neural and hormonal control as it determines the percentage
of cardiac output reaching the liver. Therefore studies investigating new
drugs need simultaneous determination of cardiac output with the hepatic
haemodynamic evaluation. This is even more important in view of the
frequent hypercirculatory state in patients with cirrhosis of the liver.
to use a forearm blood flow model to examine (without the difficulties of
interpreting reflex actions) the direct vascular action of N-acetylcysteine
on blood flow of patients with stable cirrhosis and compare this with
normal controls (Section IV).
to examine the pharmacokinetics of intravenous N-acetylcysteine
administration in patients with cirrhosis compared with that in normal






to acute and chronic
administration of low and
high dose
isosorbide-5-mononitrate
in patients with cirrhosis
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INTRODUCTION
Previous reports show that both isosorbide dinitrate and
isosorbide-5-mononitrate are capable of reducing the hepatic venous pressure
gradient and/or azygos vein (collateral) blood flow both acutely and with
chronic use but the results have been highly variable (Section I). For example, it
has been reported that azygos vein blood flow may even increase in some
patients in response to nitrates (Navasa et al, 1989; Garcia-Pagan et al, 1990a;
Grose et al, 1994).
The main aim of my study was to investigate this variability further; to establish
if it was related to:
a) nitrate dosage, or to
b) patient factors, such as severity of liver disease.
In addition, no previous studies have examined the chronic effect of Is-5-Mn on
the hepatic venous pressure gradient and azygos blood flow using a 16 hour
nitrate free dosing interval, particularly with regard to tolerance. Rechallenge
with the nitrate after omission of the morning dose following 4 weeks of twice
per day therapy had also not previously been investigated.
In order to establish whether Is-5-Mn was acting to reduce the hepatic venous
pressure gradient (HVPG) by reducing the hepatic vascular resistance, it was
considered highly desirable that measurement of liver blood flow by the




25 patients with biopsy-proven cirrhosis (14 men; 11 women) with a range of
disease severity (8A; 11B; 6C - Childs'-Pugh Grading) were studied (Appendix
la and lb). Exclusion criteria included myocardial infarction, ischaemic heart
disease, valvular heart disease, cardiomyopathy, cerebrovascular disease,
pregnancy, concurrent vasoactive medication, current viral hepatitis B,C or D or
bleeding diathesis (with a prothrombin time ratio greater than 2.5:1).
All patients gave written informed consent and ethical permission was obtained
from the Lothian Health Board Medical Ethics Subcommittee. All studies
conformed to the Helsinki declaration. Each patient was randomised to receive
either lOmg Is-5-Mn or 40mg Is-5-Mn by random number selection from sealed
envelopes.
Investigations prior to each study
Routine investigations prior to undertaking each study included estimation of
serum urea and electrolytes, a full blood count including haematocrit, "liver
function tests" including bilirubin (Bili), alanine aminotransferase (ALT),
gamma-glutamyl peptidase (GGT), alkaline phosphatase (Alk.Phos) and
albumin (Appendix la and lb). Assessment of the severity of each patients'
chronic liver disease was made by Pugh's modification of Child's classification
(Section I - Table 3) (Pugh et al, 1973). The low and high dose study groups (10
and 40 mg Is-5-Mn respectively) were not significantly different in terms of age,
prothrombin time, aetiology of cirrhosis, Child's-Pugh Score, serum bilirubin
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and serum albumin (Appendix II). The sex ratios were different between the
two dosage groups; but there has been no evidence for a different
haemodynamic response to vasoactive drugs between male and female patients
with cirrhosis in the past.
The study procedure
Each patient fasted after a light breakfast on the day of the study. A constant
temperature of 25-27°C and as quiet and relaxed an environment as possible
was kept in the catheter laboratory. Three lead (Lead II) ECG monitoring was
commenced by attachment to a Hewlett Packard HP monitoring system,
(Germany) and mean arterial blood pressure (manual syphygmomanometer)
was checked every five minutes initially until all patients had achieved
haemodynamic stability for at least 20 minutes.
A venflon (21G) was placed in a vein in the antecubital fossa of the right arm
and a sample of venous blood was taken as a baseline, against which
spectrophotonetric measurements were made later. A bolus of lg Cefotaxime
(Roussel Ltd, Uxbridge, Middlesex) in 10ml sterile water was given
intravenously as antibacterial prophylaxis to all patients. A loading dose of 0.2
mg/Kg body weight of indocyanine green dye (ICG, Cardiogreen, Hynson,
Westcott and Dunning Inc, Baltimore, Md) was also given through the venflon
and an infusion of 0.25mg /minute was commenced. 50mg indocyanine green
dye was diluted in 20 ml of supplied solvent solution and 20ml 0.9% saline to a
final concentration of 1.25 mg/ml. The infusion rate of the ICG solution was
12ml/hour i.e 0.25 mg/minute by accurate infusion pump (Gemini).
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A 7.5 F introducer (Edwards, Critical Care Division, Irvine, USA) was then
placed in the right femoral vein under local anaesthesia (approx 10 ml of 2%
lignocaine). The hepatic venous pressure gradient (wedged hepatic venous
pressure minus free hepatic venous pressure) was then estimated by inserting a
sidewinder II catheter (Cordis, USA) into the main right hepatic vein under
fluoroscopic control. Inflating and releasing the balloon enabled repeated
consistent measurements of wedge and free hepatic pressure respectively to be
made by connection of the free end of the sidewinder catheter to the Hewlett
Packard manometer line (containing 2000 units of heparin in 500 ml 0.9%
saline as a "flush"). The Hewlett Packard machine was zeroed for pressure at
the level of the right atrium at the start of each procedure. Examples of wedged
and free hepatic pressure traces are shown in Appendix III.
After a 20-30 minute equilibration period after commencement of the ICG
infusion, three simultaneous samples of peripheral and hepatic venous blood
were drawn into syringes for the determination of estimated liver blood flow
(constant infusion method; Cherrick et al, 1960; Winkler et al, 1965). These six
samples and the "baseline" sample taken earlier were centrifuged at room
temperature, for six minutes at 3000 rpm, in a (Beckmann, bench-top
centrifuge). 1ml of each serum sample was decanted with a disposable pipette
into a cuvette. The ICG concentrations in the serum and the infusion fluid were
estimated by absorption spectrophotometry at 805nm in a Zeiss PMQ II
spectrophotometer against the blank serum sample. The Estimated Liver Blood
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Flow was derived from the equation:
ELBF = R/(A-H)(l-Hct)
where R is the rate of infusion of ICG in mg/min; A and H are the
concentrations of ICG in peripheral and hepatic venous blood respectively in
mg/L; and Hct is the haematocrit. The optical density vs concentration of ICG
graph (data supplied by the manufacturer of ICG) is shown in Appendix IV with
a sample calculation of liver blood flow. The infusion of ICG was discontinued
after the blood samples had been taken.
The sidewinder II catheter was then removed and an azygos catheter (Webster
Lab Inc) was introduced into the azygos vein under fluoroscopic screening. The
anatomical position of the azygos vein is shown in Appendix V. The electrical
integrity of the thermistor was checked prior to insertion into the patient by a
custom built circuit tester made by the Department of Medical Physics.
Estimation of azygos vein blood flow was made by the thermodilution technique
(Hayes et al, 1992) using 5% dextrose at room temperature at 50ml/min as
injectate. The syringe pump (Harvard model 22 modified to meet BS5724
Standard) was used to deliver the dextrose accurately into the distal lumen of
the azygos catheter. The electrical connection of the catheter was connected to
a custom-built IBM model PS2-286 microcomputer interface to give real time
values for blood flow using the algorithm:
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Fb = Fi X C { Tj - 1 }
Tb
Tj = change in injectate temperature
= change in blood temperature
C = constant dependent on heating properties of blood and
saline and the catheter manufacturer's constant.
(Ganz et al, 1971)
A real-time graphic display of blood flow was recorded for up to one minute
until a steady reading was achieved. Data were stored on hard and floppy disks
for later analysis. An example of an azygos venous blood flow trace obtained by
this method is shown in Appendix VI. The position of the catheter was noted for
the next occasion of its use in that patient to minimise any potential effect of
changed catheter position on flow.
A baseline heart rate and blood pressure reading was taken prior to the
administration of either a lOmg or a 40mg tablet of Is-5-Mn orally, with a small
volume of iced water.
Readings of heart rate, blood pressure and azygos vein flow traces were taken
exactly thirty minutes and sixty minutes after administration of the drug. Sixty
minutes after administration of the drug, the azygos catheter was removed and
the Sidewinder catheter was reinserted into the main right hepatic vein and a
further estimation ofwedged and free hepatic venous pressure and liver blood
flow was made by the above methods. The procedure was concluded with the
removal of the sidewinder catheter, the femoral introducer and the venflon.
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Chronic administration of Is-5-Mn
Each patient was given 100 tablets of their randomised dose of Is-5-Mn (kindly
supplied by Boehringer-Mannheim Ltd) and given written instructions to take
one tablet in the morning at 9am and the next tablet at 5pm each day i.e.
allowing for a nitrate free interval of 16 hours overnight. Each patient was asked
to return the box of tablets at the end of the study (for a tablet count). The last
morning dose (on the day of the second haemodynamic investigation) was
omitted. Patients were warned about potential headaches particularly within the
first few days of starting the tablets and were asked to 'phone and report this or
any other symptoms. As each patient was very well known to the staff in the unit
we did not feel that they would be reticent in reporting side-effects. Each
patient was also asked specifically about side-effects on return for the second
estimation of portal pressure and azygos blood flow after one month.
The second procedure
The heart rate, blood pressure, hepatic venous pressure gradient, estimated
liver blood flow and azygos vein blood flow were remeasured after 28 days of
Is-5-Mn therapy both before and after rechallenge with their randomised nitrate
dosage.
A summary of the measurements made on each attendance at the catheter




MADE ON EACH ATTENDANCE AT
Table 10 THE CATHETER LABORATORY
0 mins 30 mins 60 mins DERIVED DATA
HR HR HR




ICG cone ICG cone ELBF
WHERE:
HR= heart rate in bpm
BP = arterial blood pressure in mmHg
MABP = mean arterial blood pressure in mmHg
= diastolic +1/3 (systolic - diastolic)
AzBF = azygos blood flow in ml/min
WHVP = wedged hepatic venous pressure in mmHg
FHVP = free hepatic venous pressure in mmHg
HVPG = hepatic venous pressure gradient in mmHg
ICG cone = ICG concentration in mg %
ELBF = estimated liver blood flow in ml/min
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Statistical analysis
Results are expressed as mean haemodynamic values for each treatment group
+ /- standard error of the mean. Each mean variable at one time point was
compared with the haemodynamic value at time 0 (i.e. baseline value) by a
two-tailed paired students' t-test.
Correlation of change in each haemodynamic variable with serum albumin,
bilirubin and prothrombin ratio (PTR) was made using the Spearman Rank




Completion of the study
Twelve patients were randomly allocated to receive 10 mg and thirteen 40 mg
Is-5-Mn. Four patients (two in each group) failed to attend for the second
invasive procedure and in one patient the procedure was abandoned for
technical reasons.
Baseline haemodynamic characteristics
No significant difference in baseline haemodynamic characteristics between the
two treatment groups was seen (Table 11).
Heart rate response to Is-5-Mn
No significant change in heart rate was seen acutely or after four weeks of lOmg
bd Is-5-Mn (Figure 8 and 9). In contrast, patients given 40mg Is-5-Mn showed a
significant rise in heart rate 30 and 60 minutes after drug administration (Figure
10) which was still present after a month (28 days) of therapy (Figure 11).
The effect of Is-5-Mn on mean arterial blood pressure
Acute administration of either lOmg or 40 mg Is-5-Mn produced a significant
fall in blood pressure after 30 and 60 minutes (Figures 12-15). This fall in blood
pressure was not sustained prior to or after rechallenge with the nitrate at 28
days (one month).
The effect of Is-5-Mn on the Hepatic Venous Pressure Gradient (HVPG)
lOmg Is-5-Mn had no significant effect on free hepatic venous pressure acutely
or after chronic nitrate use (Figure 16). Wedged hepatic venous pressure fell
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The mean heart rate response to acute
administration of lOmg Is-5-Mn in 12 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for











p > 0.5 p > 0.5 p > 0.1
I I Baseline (1st study)
Uli t • 30 (at 1 month)
Time (mins).
I l t • 0 (at 1 month)
liiill!! t ■ 60 (at 1 month)
Figure 9
The mean heart rate response to chronic
administration of lOmg Is-5-Mn in 12 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values from the first study.
The number ofmeasurements possible for


























The mean heart rate response to acute
administration of 40mg Is-5-Mn in 13 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for



















I Baseline (1st study)
t ■ 30 (at 1 month)
I ! t • 0 (at 1 month)
t • 60 (at 1 month)
Figure 11
The mean heart rate response to chronic
administration of 40mg Is-5-Mn in 13 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values from the first study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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Mean arterial blood pressure,
10 mg ls-5-Mn - first study.
p ■ 0.02 p < 0.05
Time (mins).
IV-,. 11 - 0 I 11 - 30 HH t • 60
Figure 12
The mean arterial blood pressure response to
acute administration of lOmg Is-5-Mn in 12
patients with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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Mean arterial blood pressure

















I I Baseline (1st study)
EUsH t ■ 30 (at 1 month)
[ I t ■ 0 (at 1 month)
mill!! t ■ 60 (at 1 month)
Figure 13
The mean arterial blood pressure response to
chronic administration of lOmg Is-5-Mn in 12
patients with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values from the first study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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Mean arterial blood pressure.
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i i t ■ 30 US t ■ 60
Figure 14
The mean arterial blood pressure response to
acute administration of 40mg Is-5-Mn in 13
patients with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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Mean arterial blood pressure.

















I I Baseline (1st study)
t • 30 (at 1 month)
Time (mins).
i t ■ 0 (at 1 month)
t ■ 60 (at 1 month)
Figure 15
The mean arterial blood pressure response to
chronic administration of 40mg Is-5-Mn in 13
patients with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values from the first study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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Free hepatic venous pressure.
10mg ls-5-Mn.
FHVP(mmHg). n>ni
P * 0.5 T p > o.5
Time (mins).
I I Baseline (1st study) I I t • 60 (1st study)
HH t • 0 (at 1 month) Hiilllll t • 60 (at 1 month)
Figure 16
The mean FHVP response to acute and chronic
administration of lOmg Is-5-Mn in 12 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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significantly 60 minutes after lOmg Is-5-Mn given initially and after 1 month of
nitrate use (Figure 17). The pre-rechallenge pressure at 1 month was however
not significantly different from the baseline (1st study) value. The hepatic
venous pressure however gradient showed sustained reduction after acute and
chronic nitrate use (Figure 18).
40mg Is-5-Mn had no statistically significant action on free hepatic venous
pressure (Figure 19). Wedged hepatic venous pressure fell significantly acutely
and after one month of 40mg Is-5-Mn (Figure 20), an increasing effect being
seenwith more exposure to the nitrate. The hepatic venous pressure gradient
showed sustained reduction after acute and chronic nitrate use (Figure 21), the
greatest effect being seen on rechallenge with nitrate after a month of therapy.
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p < 0.05 p > 0.05
I 1 Baseline (1st study)








I ' t ■ 60 (1st study)
t ■ 60 (at 1 month)
Figure 17
The mean WHVP response to acute and chronic
administration of lOmg Is-5-Mn in 12 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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p < 0.01 p < 0.05
Time (mins).
p < 0.05
I I Baseline (1st study)
Hi! t • 0 (at 1 month)
EH] t ■ 60 (1st study)
t ■ 60 (at 1 month)
Figure 18
The mean hepatic venous pressure gradient
changes in response to acute and chronic
administration of lOmg Is-5-Mn in 12 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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I I Baseline (1st study) I I t ■ 60 (1st study)





The mean FHVP response to acute and chronic
administration of 40mg Is-5-Mn in 13 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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I I Baseline (1st study) I I t ■ 60 (1st study)
HH t ■ 0 (at 1 month) IIHIIIII t • 60 (at 1 month)
Figure 20
The mean WHVP response to acute and chronic
administration of 40mg Is-5-Mn in 13 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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I I Baseline (1st study) lZj t ■ 60 (1st study)
Hi t ■ 0 (at 1 month) llilillli t - 60 (at 1 month)
Figure 21
The mean HVPG response to acute and chronic
administration of 40mg Is-5-Mn in 13 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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The effect of Is-5-Mn on azygos vein blood flow
lOmg Is-5-Mn administration produced a significant reduction of azygos flow
within thirty minutes of administration but thereafter no significant reduction
was seen (Figure 22 and 23). Small reductions of azygos flow were seen acutely
(Figure 24) and chronically (Figure 25) after 40mg Is-5-Mn use but these failed
to reach statistical significance.
Most noticeable however was the marked variability of response of azygos
blood flow to either dose of the nitrate as illustrated by the large standard error
values in Figures 22-25. This can be explained by division of all 25 patients (i.e.
both dosage groups) into arbitrary groups at baseline with low (less than 350
ml/min, moderate (350-550 ml/min) and high azygos flows (more than 550
ml/min). Although no statistical analysis between the flow groups would be
valid because of the post hoc nature of the group allocation, Figure 26 shows
that those with low initial values increase in response to nitrate and those with
high initial values reduce in response to nitrate. Those with intermediate values
demonstrate little change in response to nitrate.
Correlation between Childs'-Pugh variables and response to Is-5-Mn
(Spearmans' Rank Correlation Test)
No significant correlation was found between change in heart rate, mean
arterial blood pressure, wedged hepatic venous pressure, free hepatic venous
pressure, hepatic venous pressure gradient and azygos blood flow with serum
bilirubin, albumin and prothrombin ratio in response to 10 mg Is-5-Mn at any
time point in the first study or at 1 month (Appendices VII and VIII).
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Azygos vein blood flow.








p < 0.02 p > 0.1
Time (mins).
□ t-0 dH t * 30 St -60
Figure 22
The mean azygos blood flow response to acute
administration of lOmg Is-5-Mn in 12 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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Azygos vein blood flow.








p > 0.1 p > 0.5
Time (mins).
p > 0.1
I I Baseline (1st study)
HI t • 30 (at 1 month)
i I t • 0 (at 1 month)
t ■ 60 (at 1 month)
Figure 23
The mean azygos blood flow response to
chronic administration of lOmg Is-5-Mn in 12
patients with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values from the first study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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Azygos vein blood flow.















The mean azygos blood flow response to acute
administration of 40mg Is-5-Mn in 13 patients
with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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Azygos vein blood flow.








AzBF (ml/min). P > 0.5
P > 0.1 P > 0.1
I I Baseline (1st study)
MM t • 30 (at 1 month)
Time (mins).
I I t ■ 0 (at 1 month)
t • 60 (at 1 month)
Figure 25
The mean azygos blood flow response to
chronic administration of 40mg Is-5-Mn in 13
patients with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
The number ofmeasurements possible for
technical or attendance reasons is included in
brackets.
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The mean azygos blood flow response to acute
and chronic administration of Is-5-Mn (lOmg &
40mg groups combined) in 25 patients with
cirrhosis.
Patients are arbitrarily divided into three groups -
those with:
low initial azygos flows (< 350ml/min)
moderate azygos flows ( 350-550ml/min)
and high azygos flows (> 550 ml/min)
AzBF (ml/min)
_i i i 1—
t"0 t-60 t»0 t*60
ACUTE CHRONIC
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Prothrombin ratio and serum bilirubin were also found to be positively
correlated in this group (0.775) (Appendices VII and VIII).
Similarly no correlations were found with the 40 mg group of Is-5-Mn except
reduction of free hepatic venous pressure (in the first hour, first study, r = -
0.72) and reduction of azygos blood flow (in the first hour, second study, r =
0.750) were both significantly correlated (p < 0.05) with serum bilirubin
(Appendices IX and X). Also the reduction in wedged hepatic venous pressure
at the end of the second study (at 1 month) was correlated with serum albumin
(r = 0.65) (Appendices IX and X). Azygos blood flow reduction from baseline
to time zero on the first and second study were both correlated with serum
albumin (r = - 0.633 and - 0.667, respectively). Of the haemodynamic variables
measured only the reduction in free hepatic venous pressure after the first hour,
first study correlated with the prothrombin time ratio (r= 0.70) in the 40 mg
group (Appendices IX and X).
In the 40 mg group serum albumin correlated with Prothrombin ratio (-0.692)
and serum bilirubin (0.717) but there was no significant correlation between
serum albumin and serum alanine aminotransferase (0.326) (Appendices IX
and X). Prothrombin time correlated with serum bilirubin in this group (0.650)
(Appendices IX and X).
The effect of Is-5-Mn on estimated liver blood flow (ICG method)
Figures 27 and 28 show that only 40mg Is-5-Mn produces a significant fall in
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Time (mins).
p > 0.5
ill Baseline (1st study)
HH t ■ 0 (at 1 month)
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t • 60 (at 1 month)
Figure 27
The mean estimated liver blood flow (ICG
constant infusion method) after acute and
chronic administration of lOmg Is-5-Mn in 5
patients with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
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IB t • 0 (at 1 month)
I I t • 60 (1st study)
t • 60 (at 1 month)
Figure 28
The mean estimated liver blood flow (ICG
constant infusion method) after acute and
chronic administration of 40mg Is-5-Mn in 7
patients with cirrhosis.
Error bars represent the standard error of the
mean. Statistical comparison is made by paired
t-test between values at each time point and the
baseline values at the start of the study.
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blood pressure). Liver blood flow did not show a significant reduction with
chronic nitrate use.
Side-effects
3 patients receiving lOmg Is-5-Mn bd reported headaches during the first 24
hours of therapy (patient numbers 1, 2 and 7). One patient described persistent
headaches (patient number 8) over the first two weeks and withdrew from the
study.
Five patients reported initial headaches after starting 40mg Is-5-Mn which
passed within 24 hours of starting them (patient numbers 1, 4, 10, 12,13). One
of these five patients experienced headaches for 10 days after commencing the
tablets lasting 10-20 minutes after each tablet and withdrew from the study.
One patient (7) had an itchy maculopapular rash following the initial
haemodynamic study. The nitrate tablets were withdrawn and recommenced 1
week later with no recurrence of the rash. We can only assume that either the
indocyanine green dye or Cefotaxime were responsible. Both were omitted on
the repeat study after one full month of nitrate tablets and no recurrence of the
rash was seen.
Compliance
10 of the 10 mg group of patients (100% of those attending the follow-up
haemodynamic study after 1 month) returned their unused tablets. 9 patients
(90%) had returned the correct number of tablets and one patient had returned
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one tablet too many. All claimed to have taken their nitrate tablets diligently
and had outpatient appointment attendance rates in excess of 85%.
9 of the 40 mg group of patients (81.8% of those attending the follow-up
haemodynamic study after 1 month) returned their unused tablets. 8 patients
(72.7%) had returned the correct number of tablets and the remaining patient
had three tablets too many. Again all patients claimed to have taken their




No evidence for dose-dependency of Isosorbide-5-mononitrate in reduction of
the hepatic venous pressure gradient
Our study suggests that both 10 mg and 40 mg of Is-5-Mn greatly reduce the
hepatic venous pressure gradient acutely and with chronic use. This is of clinical
relevance given the increasing interest in the use of nitrates to prevent variceal
bleeding in cirrhotic patients.
Only two previous groups have shown no effect of nitrates on the hepatic
venous pressure gradient (Dawson et al, 1985; Tsai et al, 1989). All others
showed a reduction in hepatic venous pressure gradient which was accompanied
by a fall in cardiac index and mean arterial blood pressure (Isosorbide dinitrate
(Hallemans et al, 1983; Freeman et al, 1985; Merkel et al, 1987; Blei et al, 1987;
Qureshi et al, 1988; Mols et al, 1989, Is-5-Mn: Hayes et al, 1988; Navasa et al,
1989). In our study there was no apparent advantage of one dose over the other
in achieving HVPG reduction.
How is the reduction in hepatic venous pressure gradient achieved?
The reduction of hepatic venous pressure gradient in previous studies and ours
(by both doses of Is-5-Mn) was achieved by a fall in wedged hepatic venous
pressure rather than a rise in free hepatic venous pressure.
Reducing wedged hepatic venous pressure may be more important than
reducing the hepatic venous pressure gradient per se in protection against
variceal bleeds (Bosch, 1985; Bosch et al, 1988a).
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The evidence for different doses working by different mechanisms
Many haemodynamic studies to date suggest that different doses of nitrate may
act by different mechanisms (Navasa et al, 1989; Rector et al, 1990) and this
may well be the case in our study. Certainly the 40 mg dose appears to induce a
greater haemodynamic disturbance acutely ie. increased heart rate, reduced
mean arterial blood pressure and liver blood flow than the 10 mg dose; only the
increase in heart rate effect was maintained after chronic use. Whether this
translates into greater efficacy of the higher dose in prophylaxis of variceal
bleeding remains to be evaluated by clinical studies.
Heterogeneity in collateral vessel responsiveness to nitrates
Efficacy of drugs in controlling an acute variceal bleed or preventing recurrent
haemorrhage may be related to their ability to reduce blood flow through
collateral vessels, thus determination of the effects of vasoactive agents on both
collateral blood flow and the hepatic venous pressure gradient is important in
evaluating their therapeutic potential.
Our results indicate that the effect of 10 mg or 40 mg Is-5-Mn on azygos blood
flow was highly variable including some individuals in who, flow increased
suggesting vasodilatation of portasystemic collaterals. Those who had a low
azygos flow increased their flow in response to nitrate and vice-versa. Thus the
degree of pre-existing porta-systemic shunting appears important in the
individuals' response to nitrate. Although the azygos flow tends to increase in
those with more advanced liver disease we did not observe a clear correlation
between Childs-Pugh grade (1973) and haemodynamic response (see below).
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The role of severity of liver disease in predicting an individuals' response to
nitrate
Severity of liver disease per se does not appear an important variable in
defining haemodynamic response to nitrates as so few haemodynamic changes
correlated with serum bilirubin, albumin or PTR (which are the best available,
though imperfect measures of severity). A few correlations were positive but
this would be expected by chance alone given the large number of correlations
tested.
Other variables that have previously been suggested to be responsible for
different response to nitrates between individuals may be degree of autonomic
impairment (Moreau et al, 1989) or baseline cardiac filling pressure (Rector et
al, 1990).
Tolerance to nitrates
Tolerance is well recognised in patients with heart disease given nitrates for 18
hours or longer (Elkayam et al, 1987; Jugdutt and Warnica, 1989). Our study
and others (Freeman et al, 1985; Cervinka et al, 1989; Tsai et al, 1989;
Garcia-Pagan et al, 1990; Ikegami et al, 1992; Vorobioff et al, 1992) showed a
sustained fall in hepatic venous pressure gradient after chronic nitrate
administration which suggests full tolerance is not of concern in patients with
chronic liver disease. To postulate why this may be the case we need to first
consider possible mechanisms of tolerance and these will be discussed later
(Section VI).
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The effect of nitrates on liver blood flow
Calculations of hepatic resistance from previous studies described above and
our own study shows that acute and chronic administration of nitrates induce
both a significant reduction in resistance rather than a reduction in liver blood
flow (which would be undesirable). This implies that either portal flow is not
reduced or that a compensatory rise in hepatic arterial flow takes place ie.
reciprocity. This mechanism, although observable in animals, probably has little
effect in man and an increase in hepatic arterial flow would be unlikely in view
of the fall in mean arterial blood pressure and cardiac index caused by nitrates
(Hayes et al, 1988). The difficulty in distinguishing between these two inputs
limits our ability to interpret this data further.
Compliance and side-effects
Our data suggest that the patients were taking their nitrate tablets during this
study; their motivation to attend outpatient clinics was high and the discrepancy
of tablet counts minimal. Side-effects were modest.
Concluding remarks
Our work suggests that chronic administration of either 10 or 40 mg of Is-5-Mn,
allowing for a nitrate free interval each day is effective at achieving hepatic
venous pressure gradient reduction but has a variable effect on blood flow that
appears to depend on baseline azygos flow. Unfortunately no noninvasive
means of assessing the latter is currently available.
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Nitrates potentially have a number of different mechanisms of hepatic venous
pressure reduction which may vary at different doses. Fortunately, by
mechanisms which remain to be elucidated, patients with cirrhosis do not













Administration of intravenous N-acetylcysteine (NAC) has been reported to
increase cardiac output, tissue oxygen delivery and utilisation in fulminant
hepatic failure (Harrison et al, 1991). Since some of the haemodynamic changes
seen in patients with cirrhosis are similar to those with fulminant hepatic
failure, N-acetylcysteine may also increase tissue oxygen use and delivery in
patients with cirrhosis. The aim of this study was to determine the
haemodynamic effects of this agent in cirrhosis with particular reference to
oxygen delivery and consumption.
MATERIALS AND METHODS
The population studied
11 biopsy proven cirrhotic patients (8 men; 3 women; mean age 61.5 years;
range 43-74 years) with a range of disease severity ( 4A, 2B, 5C Child-Pugh
grades (Pugh et al, 1973) and aetiology (2 primary biliary, 1 cryptogenic and 8
alcohol) were studied (Appendix XI). Exclusion criteria included known
myocardial infarction or ischaemic heart disease, valvular heart disease,
pregnancy, vasoactive medication, current viral hepatitis B,C or D or bleeding
diathesis with prothrombin time ratio (PTR) greater than 2.5:1.
The eight alcoholic cirrhotic patients had no evidence of alcoholic
cardiomyopathy.
All patients gave witnessed informed consent and ethical permission was
obtained from Lothian Health Board Medical Ethics Subcommittee.
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Investigations prior to study
Routine investigations prior to undertaking each study included estimation of
serum urea and electrolytes, a full blood count including haematocrit, "liver
function tests" including bilirubin, alanine aminotransferase (ALT),
gamma-glutamyl peptidase (gamma-GT) and albumin (Appendix XI). Each
patient had a prothrombin time estimated prior to the invasive procedure
(Appendix XI).
The study procedure
Each patient fasted after a light breakfast on the day of the study. In the
catheter laboratory a 7.5 F introducer (Edwards, Critical Care Division, Irvine,
USA) was placed in the right femoral vein under local anaesthesia (approx. 10
ml of 2% lignocaine). A Swan-Ganz catheter (7F Edwards, Irvine, USA) was
inserted under fluoroscopic screening and continuous pressure recording into
the pulmonary artery. The tip of the catheter was positioned in a major branch
of the pulmonary artery. The mean heart rate (from the ECG monitor, Hewlett
Packard HP monitoring system, Germany) and mean arterial blood pressure
(manual syphygmomanometer) were checked every 5 minutes initially until all
patients had achieved haemodynamic stability for at least 20 minutes.
Simultaneous femoral artery, pulmonary artery and femoral vein blood gas
samples were then taken into heparinised blood gas syringes and analysed
immediately for oxygen saturation (Co-Oximeter 282, Instrumentation
Laboratory, Lexingham, Mass.), haemoglobin and oxygen tension (pC^) (ABL
2000, Radiometer, Copenhagen). The pulmonary artery free and wedge
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pressure and cardiac output (by Swan-Ganz thermodilution method using 10 ml
of cold 5% dextrose as injectate) were estimated. Cardiac output was measured
in quadruplicate and the results expressed as a mean value. Cardiovascular
pressures were measured with reference to the mid-axillary line.
N-acetylcysteine (Parvolex, Duncan Flockhart, Greenford, UK) was infused
intravenously by accurate infusion pump (Gemini 2, IVAC, USA) at 150 mg/Kg
in 200 ml 5% dextrose over 15 minutes followed by 15 minutes infusion at 125
ml/hour of 50 mg/Kg in 500 ml 5% dextrose, ie identical regime to that of
Harrison and colleagues (1991).
The blood gas analysis, pulmonary artery pressures, mean arterial blood
pressure, cardiac output and heart rate were remeasured 30 minutes after
commencement of N-acetylcysteine (NAC) infusion i.e. during infusion.
Derived haemodynamic variables for each patient were calculated according to
standard formulae (Packer et al, 1985; Appendix XII).
The delivery of oxygen to tissues was calculated as the product of the cardiac index
and the arterial oxygen content. Oxygen consumption was calculated from the
reverse Fick equation (cardiac index x a-v O2 difference) (Bihari, 1993). The
oxygen extraction ratio was calculated by dividing the difference between the arterial
and venous O2 content by the arterial O2 content and expressed as a percentage.
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The hepatic venous pressure gradient (wedged hepatic venous pressure minus
free hepatic venous pressure) and estimated liver blood flow (ICG,
Cardiogreen, Hynson, Westcott and Dunning Inc, Baltimore, Md - continuous
infusion method (Cherrick et al, 1960; Winkler et al, 1965) were measured
immediately before and after NAC infusion in 6 of the 11 patients with cirrhosis
(the last 6 patients studied) using the methods described in Section II -
materials and methods. The intravenous infusion of indocyanine green (ICG)
was made up in saline and infused at a rate of 0.25 mg/min after a priming dose
of 0.20 mg/Kg/ body weight.
Controls
As the systemic haemodynamic effect of this infusion regime of NAC has been
assessed previously in patients without liver disease it was felt that inclusion of
normal healthy controls in an invasive study such as this was unethical (Packer
et al, 1987; Winniford et al, 1986).
The haemodynamic response to infusion of the same volume of 5% dextrose as
above but not containing N-acetylcysteine on a random allocation basis
(random numbers) to 5 of the above 11 patients with cirrhosis (marked by a * in
Appendix XI) was assessed to investigate any potential volume loading effect of
the dextrose infusion on cardiac output etc, ie 11 patients with cirrhosis took
part in these studies; all 11 received the NAC infusion (made up in 5%
dextrose); in 5 of the 11 patients (controls) the effect of dextrose infusion alone
was also studied.
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Statistical analysis of haemodynamic variables
The results after the infusion of NAC were compared with the baseline
haemodynamic values before infusion. All results were expressed as mean + /-
SEM with statistical analysis by a 2-tailed paired student's t-test.
RESULTS
Administration of N-acetylcysteine had no effect on mean arterial blood
pressure (88 +/- 2.7 mmHg before NAC to 85.8 +/- 3.3 mmHg after NAC; p >
0.1 (Figure 29)) or mean heart rate (78.3 +/- 3.2 bpm before NAC to 79.2 +/-
2.68 bpm after NAC; p > 0.05 (Figure 30)).
The infusion of NAC resulted in vasodilatation with a significant reduction in
both mean systemic vascular resistance index (1902 +/- 195 to 1645 +/- 193
dynes x sec/cm5 x m2 ; p < 0.02 (Figure 31)) and pulmonary vascular resistance
index (169.2 + /- 28 to 127 + /- 21.0 dynes x sec/cm5 x m2; p < 0.01 (Figure
32)).
Mean estimated liver blood flow increased from 1161 ( + /-167) ml/min to
1283 ( + /- 92) ml/min in response to NAC infusion; p > 0.1 but this did not
achieve statistical significance (Figure 33). Wedged hepatic venous pressure,
free hepatic venous pressure and HVPG showed no significant change after
N-acetylcysteine infusion (Table 12).
Administration of NAC resulted in a significant increase in mean oxygen






The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on mean arterial blood pressure
(MABP) in 11 patients with cirrhosis.
The vertical bars represent mean values and the









The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on mean heart rate in 11 patients with
cirrhosis.
The vertical bars represent mean values and the
lines above the bars the standard error of the
mean.
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The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on mean systemic vascular resistance
index (SVRI) in 11 patients with cirrhosis.
The vertical bars represent mean values and the
lines above the bars the standard error of the
mean.
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The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on mean pulmonary vascular
resistance index (PVRI) in 11 patients with
cirrhosis.
The vertical bars represent mean values and the








The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on estimated liver blood flow (ELBF)
in 6 patients with cirrhosis.
The vertical bars represent mean values and the















13.3 13.7 p = NS
Table 12
The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on wedged and free hepatic venous
pressure in 6 patients with cirrhosis.









The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on mean oxygen delivery in 11
patients with cirrhosis.
The vertical bars represent mean values and the








The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on mean cardiac index in 11 patients
with cirrhosis.
The vertical bars represent mean values and the
lines above the bars the standard error of the
mean.
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The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on left ventricular stroke work index
in 11 patients with cirrhosis.
The vertical bars represent mean values and the










The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on mean arteriovenous oxygen
extraction ratio (OER) in 11 patients with
cirrhosis.
The vertical bars represent mean values and the









The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on mean oxygen consumption in 11
patients with cirrhosis.
The vertical bars represent mean values and the











artery p02 (kPa) 5.35 5.37 NS
Pulmonary
artery O2 72.1 73.8 NS
saturation (%)
Femoral vein
p02 (kPa) 5.15 5.7 NS
Femoral vein 02 67.9 74.9 NS
saturation (%)
Table 13
The effect ofN-acetylcysteine infusion (NAC)
at 150 mg/kg body weight for 15 minutes in 200
ml 5% dextrose followed by 15 minutes of 50
mg/kg in 500 ml 5% dextrose (set at 125
ml/hour) on mean blood gas values in 11
cirrhotic patients.
Significance is taken at the 95% level.
180
34), due to an increase in the mean cardiac index from 3.85 + /-0.35 L/min/m2
to 4.36 + /- 0.36 L/min/m2; p < 0.01 (Figure 35)). This was associated with a
significant increase in Left Ventricular Stroke Work Index from 60.3 + /-7.3 to
65.9 + /-10.3 gxm/m2;p < 0.05 (Figure 36).
However the arteriovenous oxygen extraction ratio did not rise significantly
(23.6% to 21.3%; p > 0.05, Fig 37) after NAC administration. In addition the
mean oxygen consumption did not rise in response to NAC (Fig 38).
The effect of N-acetylcysteine on mean blood gas values (Table 13) showed a
minor fall in arterial oxygen tension and increase in venous oxygen tension after
NAC administration.
The control group
Five patients who received intravenous dextrose alone showed no significant
change in haemodynamic parameters (Table 14).
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(CONTROL DATA: The haemodynamic response of five of the 11





(bpm) 74.4 ± 4.6 73.2 ±4.1 NS
MABP
(mmHg) 91 ±3.3 89.2 ±3.1 NS
RAP
(mmHg) 3.8 ±0.37 3.8 ±0.37 NS
CI










188 ±44 184.7 ±48.5 NS
Table 14
Values are expressed as mean ± standard error of the mean.
MABP is mean arterial blood pressure, RAP is right atrial
pressure, CI is cardiac index, SVRI and PVRI are systemic
and pulmonary vascular resistance index respectively.
LVSWI is left ventricular stroke work index.
Significance is taken at the 95% level.
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Spearman Rank Correlation Test
There was no significant statistical correlation between Child's variables (PTR,
serum bilirubin and albumin) and degree of change in response to NAC of
cardiac index, oxygen delivery, oxygen consumption and oxygen extraction ratio
(Appendices XIII and XIV).
However serum bilirubin and rise in free hepatic venous pressure were
positively correlated (0.833) and serum albumin and reduction ofwedged
hepatic venous pressure were correlated (0.683).
The prothrombin ratio correlated with reduced wedged hepatic venous pressure
(-0.891) and also correlated with reduced radial artery pC>2 (0.794) and
pulmonary artery pC>2 (0.809).
Amongst the haemodynamic variables correlations were found of right atrial
pressure and reduction of pulmonary artery pressure (0.985), reduction of
pulmonary capillary wedge pressure and reduction of radial artery pC>2 (0.746),
reduction of pulmonary capillary wedge pressure and wedged hepatic venous
pressure (-0.804), reduction of radial artery p02 and reduced wedged hepatic
venous pressure (- 0.891) and reduced pulmonary artery pC>2 and wedged
hepatic venous pressure (-0.792) in response to infusion of N-acetylcysteine.
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PRELIMINARY DISCUSSION
We have demonstrated that administration of NAC resulted in reduction of
pulmonary and systemic vascular resistance in patients with cirrhosis similar to
the effect seen in fulminant hepatic failure (Harrison et al, 1991). This effect
has not been found in patients with cardiac failure, with symptoms of chest pain
nor in those fully recovered from acute liver failure (Harrison et al, 1991;
Packer et al, 1987: Winniford et al, 1986). The reduction in systemic vascular
resistance may represent vasodilation. The reduction in pulmonary vascular
resistance may be due to a variety of mechanisms including pulmonary
vasodilation and shunting which are discussed further in Section VI
(Rodriguez-Roisin et al, 1992).
The 5 patients in the control group showed no vasodilation in response to
dextrose infusion alone. Thus the postulate that the haemodynamic changes in
the 11 patients given N-acetylcysteine infusion were due to effects of volume
loading or patients relaxing after the initial invasive procedures can be ruled out
and the changes seen in patients given NAC infusions result from a drug effect.
In patients with cirrhosis, unlike those with fulminant hepatic failure (Harrison
et al, 1991), the mean arterial pressure did not change (Figure 29), the oxygen
extraction ratio (Figure 37) and C>2 consumption did not rise in response to
NAC infusion (Figure 38). The cardiac index (Figure 35), systemic vascular
resistance index (Figure 31), pulmonary vascular resistance index (Figure 32),
stroke work index (Figure 36) and O2 delivery (Figure 34) percentage changes
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were similar in cirrhotic and fulminant hepatic failure patients (Harrison et al,
1991).
As most drugs that primarily cause afterload reduction increase cardiac index
without affecting left ventricular stroke work index (or rate pressure product, or
other measures ofmyocardial oxygen consumption) the rise in cardiac index in
association with left ventricular stroke work index seen here is suggestive of a
positive inotropic response rather than purely peripheral vasodilation and
reduction in left ventricular afterload.
Although not statistically significant there was a consistent reduction in arterial
pC>2 after NAC infusion in patients with cirrhosis (Table 13). As this was
accompanied by a similar increase in O2 saturation in mixed venous blood the
combined effect was a decrease in the oxygen extraction ratio (OER) (Figure
37). Because the number of patients undertaking such an invasive study was
small and the fall in OER was partially compensated by a substantial rise in
cardiac index in each patient the fall in oxygen consumption failed to achieve
statistical significance. Since the administration of NAC to our 11 patients had
clearly conferred no haemodynamic benefit we felt that to study more patients
would be unethical.
Interestingly, there were no reported changes in arterial p02, calculated a-v
tension gradient and shunt in hepatic failure patients in response to NAC
(Harrison et al, 1991). Errors in estimation ofmixed venous O2 saturation and
tension could occur if the blood is drawn rapidly or if the catheter is positioned
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peripherally within the pulmonary artery. These errors result from
contamination of the mixed venous pulmonary blood with arterialised blood
drawn from the pulmonary capillaries and veins. We are confident that
sufficient care was taken in both sampling and in placement of the Swan-Ganz
catheter to prevent this error occurring in our study. This is supported by the
increasing pC>2 trend seen in peripheral vein samples after NAC infusion,
parallelling the increase in pulmonary artery pC>2 following the infusion (Table
13).
We believe that the difference between our findings of the effect ofNAC on O2
delivery and consumption in patients with cirrhosis from those of Harrison (et al,
1991) in patients with fulminant hepatic failure, may relate to pathophysiological
differences between the two groups of patients (Rodriguez-Roisin et al, 1992), errors
in the Swan-Ganz catheter technique that can occur under certain circumstances
(Bartlett & Dechert, 1990) or the phenomenon ofmathematical coupling (Archie,
1981). It is thus possible that NAC may in fact increase O2 delivery but not O2
consumption with fulminant hepatic failure, and early studies indicate this is the case
(Walsh - personal communication).
The putative mechanism of vasodilatation is also controversial and discussed
later but it should be appreciated that not all vasodilators have the same
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haemodynamic effects in patients with cirrhosis i.e. nitrates cause vasodilatation
but have been reported to cause a fall in liver blood flow, cardiac output and
mean arterial blood pressure and an increase in systemic vascular resistance
(Hayes et al, 1988); this presumably reflects different mechanisms or sites of
action of vasodilating agents.
The splanchnic circulation seems to have been be spared from the
haemodynamic changes seen in the systemic circulation in that estimated liver
blood flow remained unchanged. In addition, the lack of changes inWHVP,
HVPG and FHVP presumably reflects this sparing as any dilatation
unaccompanied by a reduction in pressure would be due to increased inflow
(according to Ohm's law) and this was not observed. Therefore although the
azygos blood flow was not measured in this study it may well not have changed.
There were few correlations noted between change in haemodynamic variables
and serum albumin, bilirubin and prothrombin ratio. These may have occurred
by chance alone as the number of variables tested by Spearman Rank
Correlation was large. That several haemodynamic changes correlated with
each other, for example, reduction of pulmonary artery pressure and right atrial
pressure is expected.
The administration of N-acetylcysteine to patients with cirrhosis is unlikely to be
of therapeutic value and may be detrimental. This study illustrates that
extrapolation of drug use between patients with fulminant hepatic failure and









As described in Section I, patients with cirrhosis of the liver have been shown to
exhibit arterial vasodilatation and moderate systemic hypotension; the so-called
hyperdynamic circulation of cirrhosis.
We have shown that systemic administration of N-acetylcysteine to such patients
(Section III) caused a reduction in the systemic vascular resistance index and a
marked increase in cardiac output.
We believe that the reduction of systemic vascular resistance index may be due
to arteriolar dilatation. By assessing the effect of small doses of N-acetylcysteine
(given locally) on blood flow in the forearm we hope to establish whether its
action is on peripheral arterial blood vessels through, for example, relaxation of
the vascular smooth muscle (rather than a central action which causes
vasodilation). Thus our hypothesis is that N-acetylcysteine acts as a peripheral








4 male, 2 female 6 male -
Mean age
(years) 60.7 ± 2.5 56 ±2.3 p>0.5
Age range
(years) 55-69 47-62 -
MABP (mmHg) 89.8 ±4.7 95.4 ±2.3 p > 0.317
Systolic BP
(mmHg) 123.8 ± 7.8 137.7 ±2.4 p > 0.05
Diastolic BP
(mmHg) 67.8 ±3.9 74.3 ±3.5 p>0.1
Bili ( mmol/L) 15.7 ±2.9 9± 1.46 p< 0.001
ALb (g/L) 41.2 ± 2.0 (n=4) 40 ±1.1 p > 0.5
ALT (u/L) 53.3 ± 17.0 27.2 ± 5.12 p>0.1









Aetiology 4 ALC : 2 PBC -
Table 15
Subject characteristics for the forearm blood
flow study (± SEM).
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MATERIALS AND METHODS
The method was an open, single blind trial using plethysmography to assess
forearm blood flow and its qualitative and quantitative response to local
infusion of N-acetylcysteine in 6 patients with cirrhosis and 6 age matched
controls without cirrhosis. In the absence of any previous studies of this type
with N-acetylcysteine it was not possible to perform power calculations to define
the number of subjects required for this study.
The patients/controls
6 with biopsy proven cirrhosis (5 Child's-Pugh A; 1 B) due to either alcohol or
primary biliary cirrhosis, with proven portal hypertension i.e raised hepatic
venous pressure gradient, ascites or endoscopically proven varices were
recruited from an outpatient clinic (Table 15 and Appendix XV).
6 age matched controls without liver disease were found amongst healthy
volunteers (Table 15 and Appendix XVI). As vascular response was studied,
smoking status was also matched between patient and control groups (Appendix
XV and XVI).
Exclusion criteria for all those taking part in the study included:
Current hepatitis B,C or D
Known cardiovascular disease
Hypertension




Full written informed consent was obtained from each volunteer and patient
and ethical approval for the study was obtained from Lothian Research Ethics
Subcommittee.
Doses ofN-acetylcysteine used for the study
N-acetylcysteine has not previously been administered intra-arterially to
animals or humans and thus the rate of infusions (doses) used for this study i.e.
lmg/min, 3mg/min, lOmg/min, 30mg/min, lOOmg/min and 300mg/min each
administered for consecutive 10 minute periods were chosen to include a dose
1/100th of the systemic standard dose infused (50mg/Kg/min) in paracetamol
poisoned patients/hepatic failure patients (Prescott et al, 1979 and 1989;
Harrison et al, 1991). Approximately one hundredth of the systemic dose was
chosen so that local rather than systemic effects of the drug could be studied.
The N-acetylcysteine (20% w/v, Duncan Flockhart) was diluted in 0.9% saline
for infusion.
The forearm blood flow response to incremental infusions ofN-acetylcysteine
was studied i.e. to determine a cumulative dose/response curve for the drug.
Study protocol
Each subject rested supine in bed with only one pillow under the head in a quiet
warm, temperature controlled room (25-27°C) throughout each study period.
The forearm blood flow in both arms was measured by indium-gallium in
silastic strain gauges arranged within a blood pressure cuff (venous occlusion
plethysmography). The technique of plethysmography was first described by
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Whitney in 1953. The technique involves inflation ofwrist cuffs to 200 mmHg
for periods of 3 minutes and intermittent inflation of upper arm cuffs to 40
mmHg over the same period (for 10s in every 15s cycle). The inflation was
provided by a Junair air compressor. The subject's blood pressure was checked
using a Takeda UA-751 automated blood pressure cuff.
A 10-20 minute equilibration period was used at the start of the study. The
study only proceeded if the blood flow in both arms was similar and consistent.
A small volume of local anaesthetic (0.5 ml of 1% Xylocaine) was placed in the
skin over the brachial artery of the non-dominant arm and a fine (27SWG)
needle was then placed into the artery and a 0.9% (w/v) saline infusion started
at 60 ml/hour, through epidural catheter tubing. The blood flow in both arms
was then checked approximately 3 times over 30 minutes to allow full
equilibration to take place.
Calibration recordings of 0.1% and 1% were made for each patient before small
incremental doses of N-acetylcysteine were infused (doses are shown above)
intra-arterially, each dose being infused for 10 minutes. All doses were infused
at a rate of 60 ml/hour except the final dose of 300 mg/min which had to be
infused at 90ml/hour because the maximum concentration of N-acetylcysteine
available for human use was 200mg/ml (Parvolex, Duncan Flockhart, UK).
Blood flow in both forearms was recorded at 2-5 minutes and 7-10 minutes from
the start of each new dose of NAC being infused. The blood pressure was
checked between 5 and 7 minutes after the start of each new dose infusion.
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Forearm blood flow recordings were made on a Macintosh microcomputer
linked to a MacLab system.
Special precautions taken to achieve accurate recordings from the venous
occlusion plethysmograph
The venous occlusion plethysmograph is an extremely sensitive instrument
which is prone to artefact if special precautions in its use are not taken. Below is
a list of precautions taken with each subject to improve reproduceability of
recordings:
1 Before each study the volunteer was asked to empty their bladder. Thus
there was no "stress" effect of needing to micturate and more
importantly, once in place, the strain gauges did not change position.
2 Tight upper body clothing was exchanged for a light t-shirt and watches,
bracelets etc were removed.
3 Subjects were told that once the equipment is in place they must not
move either arm until the study was finished.
4 Foam pads were placed under each elbow, and doubled pillows were
placed under each hand for support. The arms were at each side,
semi-prone, with the hands 6-12" from the hips.
5 The thin inflation cuffs wound around each wrist were fixed with a 6"
strip of "sleek tape".
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6 The thicker inflation cuffs were wound around each upper arm, midway
between elbow and axilla, as proximal as comfortably possible and fixed
with an 8" strip of "sleek tape". They were just loose enough so that 2
fingers could be slipped between the cuff and the upper arm.
7 Each strain gauge was placed 6cm distal to the olecranon process. The
strain gauge was moderately but not tightly stretched and the two wires
were not crossed or kinked.
Calculation and statistical analysis of data
Forearm blood flow was expressed as ml per minute per 100 ml forearm as
described by Whitney (1953). The blood flow in both the control and infused
arm of the subject was calculated for each dosage. The overall forearm blood
flow response to each drug was measured as the area under the dose-response
curve (Matthews et al, 1990).
The ratio of forearm blood flow (infused arm/control arm) measured in
response to N-acetylcysteine was expressed as a percentage of the ratio (infused
arm/control arm) measured during the control period for each subject
(Greenfield and Patterson, 1954).
All results are expressed as means + /- SEM and were compared using
Student's t-test for paired or unpaired observations as appropriate, where p <
0.05 was considered statistically significant.
195
RESULTS
There was no significant difference in age, blood pressure, serum albumin or
alanine aminotransferase activity between the control and cirrhotic subjects, as
might be anticipated with Childs' grade A patients (Table 15). There were
marked differences in serum bilirubin and gammaglutamyl transferase (GGT)
activity between the two groups which reflects the aetiology of cirrhosis.
Baseline blood flows compared between the control arms of patients with
cirrhosis and control arms of control subjects were not significantly different (p
> 0.317) (Figures 39 and 40; Appendices XVII-XVIII). Also baseline blood
flows compared between the infused arms of the two study groups were not
significantly different (p > 0.317) (figures 39 and 40; Appendices XVII-XVIII).
However, if the mean baseline flow in both arms of all patients in the cirrhotic
group is compared with the mean baseline blood flow in both arms of the
control groups, there is a slight statistical difference (p > 0.046) between the
two groups (mean for both arms of controls = 3.87 + /- 0.5 SEM; mean for both
arms of cirrhotic patients = 3.01 +/- 0.2). This is perhaps surprising and one
might expect the cirrhotic groups to exhibit greater resting flow, however there
are not at advanced stages of the Childs'-Pugh grading system.
However, the main function of this study was to establish if there was
CHANGE in blood flow in the forearm in response to NAC in either groups of
subjects.
196
Individual results of infused and control arm blood flows, infused/control
forearm ratios and percentage change in forearm flow from baseline in
response to NAC results are shown in Appendices XVII-XX. N-acetylcysteine
caused a clearly seen large dose-dependent increase in resting forearm blood
flow in all subjects (Figures 39 and 40 and Appendices XVII and XVIII).
As expected with infusion of a drug locally no significant changes were seen in
mean blood pressure in either the control group or patients with cirrhosis from
the baseline measurement to any time point during infusion of N-acetylcysteine.
Figure 41 shows the forearm blood flow ratios in response to N-acetylcysteine
infusion. Once again the increased forearm blood flow response in each group is
seen; there was no significant difference in haemodynamic response to any dose
ofNAC between the cirrhotic population and controls (Appendix XIX). This
picture is also borne out by analysis of percentage change in blood flow from
the predose value in response to each dose of NAC (Figure 42 and Appendix
XX).
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Forearm blood flow in response
to N-acetylcysteine - controls
Forearm blood flow in ml/dl/min
Log NAC dose in mg/min
Figure 39
Forearm blood flow response to
N-acetylcysteine - the control group.
* = significant difference between the control and
infused arms at least to the 95% level.
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Forearm blood flow in response
to N-acetylcysteine - cirrhotics
Forearm blood flow in ml/dl/min
Log NAC dose in mg/min
Figure 40
Forearm blood flow response to
N-acetylcysteine - the patients with cirrhosis.
* = significant difference between the control and
infused arms at least to the 95% level.
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Forearm blood flow ratios in response
to N-acetylcysteine
Ratio in infused/control arms
Figure 41
Forearm blood flow ratio (infused/control arm)
in response to N-acetylcysteine - controls and
patients with cirrhosis.
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Percentage change in forearm flow
from baseline in response to NAC.
500
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Figure 42
Percentage change in forearm flow from
baseline in response to N-acetylcysteine -
controls and patients with cirrhosis.
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PRELIMINARY DISCUSSION
Measurement of the systemic haemodynamic effect of administration of drugs,
such as described in Section III, does not distinguish between a local effect of
the drug on the vasculature and central or reflex changes. However this study
demonstrates that administration of NAC solution had a direct local
vasodilation action, both in controls and in patients with chronic liver disease
(Figures 39 and 40). From these dose response curves it appears to be a potent
vasodilator.
Thus the action of NAC in Section III (ie reduction in systemic vascular
resistance) is presumed to be due, in part at least, to a local vasodilation action.
We cannot however extrapolate backwards from this and assume that the
systemic haemodynamic effect ofNAC in cirrhotics and controls will be the
same as there are many other factors at play including vascular reflexes and
inotropic action; this is discussed further in Section VI.
It is not clear to what extent the increased cardiac index after N-acetylcysteine
infusion found in patients with cirrhosis (Section III) may be due to
vasodilation but the rise in cardiac index in associationwith left ventricular
stroke work index was suggestive of a positive inotropic response rather than
purely vasodilation and reduction in left ventricular afterload.
The potential mediators for the vasodilatory effect of NAC are legion and will
be discussed further in Section VI. The vasodilatory response to
N-acetylcysteine was similar in patients with cirrhosis and healthy control
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subjects. This implies that patients with cirrhosis, although they are known to be
deplete in sulphurated amino-acids (Martensson et al, 1992), do not appear to
be more sensitive to the effects of sulphydryl repletion by NAC than controls.
Criticisms of this study are that the numbers were small and that patients with
more severe liver disease could not be included (due to logistical problems in
transporting more unwell patients from the Royal Infirmary across the city to
the Clinical Research Centre at the Western General Hospital). We know that
the degree of haemodynamic disturbance and haemodynamic response to drugs
in patients with cirrhosis may be related to the severity of liver disease (Valla et
al, 1984; Braillon et al, 1986; Bendtsen et al, 1990). However, even in these
patients studied with relatively mild cirrhosis, haemodynamic derangements
were present prior to the study as manifest by a lower blood pressure (Table
15).
Unavoidable factors include baseline variability in haemodynamic
measurements which may prevent the detection of differences in response
between the controls and patients with cirrhosis, although as discussed in the
materials and methods section, every effort was made to minimise these and the
degree of variability (or greater) seen in our study was similar to other
published forearm blood flow studies (Vallance et al, Lancet 1989; Calver et al,
1994). The method has been evaluated and found to be both sensitive and
reproducible.
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Several previous studies have however showed no difference in the
haemodynamic action of drugs in patients with chronic liver disease, compared
with healthy volunteers. For example, patients with cirrhosis and a control
group given L-N-monomethyl-arginine (L-NMMA) both showed the same
vasoconstrictor response to the drug and this argues against significant
induction of NO synthase in the forearm arterioles of patients with
mild-moderate cirrhosis (Calver et al, 1994). Interestingly the cirrhotic
population in this study also tended to have mild cirrhosis; there were no Child's
grade C patients in the study (Calver et al, 1994). The results of this study
(Calver et al, 1994) were in contrast with experiments in rats with
carbon-tetrachloride induced cirrhosis (Claria et al, 1992) and point to the
importance of in vivo human studies, although undoubtedly they are hard to
perform and may have many confounding variables, as discussed in detail in
Section VI. The forearm blood flow response to local brachial artery infusion of
noradrenaline in Calver's study (1994) did not differ between patients with
cirrhosis and controls either, and suggests that the direct, local vascular
response to a known potent vasoconstrictor is not diminished in patients with
chronic liver disease.
Blood flow in the hands is predominantly through skin vessels and contains a
high proportion of venous shunts, whereas forearm flow is predominantly
through skeletal muscle. This makes comparisons of forearm blood flow studies
and previous hand vein studies very difficult indeed and for this reason hand
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vein studies are not discussed further; no hand vein studies reporting the action
of N-acetylcysteine have been described in the literature.
This study demonstrated that patients with mild cirrhosis had the same (not
significantly different) basal forearm blood flow as healthy age matched
controls. One might expect the patients with cirrhosis to have increased blood
flow when compared with controls (Murray et al, 1958; Calver et al, 1994).
However the patients studied here had mild cirrhosis, almost exclusively Child's
grade A, and we know that greater haemodynamic changes may be observed in
those with more severe liver disease.
This study however, set out to achieve what was intended, to ascertain if NAC









For more than 25 years N-acetylcysteine (NAC), an analogue of cysteine, has
been in clinical use. It has been used as a mucolytic agent (Scheffner, 1983) and
is an effective antidote in paracetamol poisoning (Prescott et al, 1979). NAC is
reported to offer protection against doxorubicin toxicity (Myers et al, 1983) and
to reduce ifosfamide and cyclophosphamide induced cystitis (Botta et al, 1973;
Holoye et al, 1983). NAC has also been used for reversal of the acquired
tolerance to the cardiovascular effects of organic nitrates (Horowitz et al, 1988).
The biochemical features of N-acetylcysteine have been discussed in the
introductory section (Section I). In Section III we showed that its effect on
oxygen consumption is different in patients with cirrhosis from that reported by
the Kings group (Harrison et al, 1991) in patients with hepatic failure or
patients with cardiac disease.
Little is known about the metabolism of this important therapeutic agent and to
date no-one has examined whether the presence of chronic liver disease alters
its kinetics; of particular importance given its increasing use in patients with
liver problems. It has however been suggested that in impaired liver function
due to acute paracetamol poisoning the pharmacokinetics are not impaired
(Prescott et al, 1989).
Better methods for the determination of NAC in plasma have appeared and
thus the study of its pharmacokinetics is timely.
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Therefore the aim of this study was to assess the primary and secondary
pharmacokinetic parameters of NAC given intravenously to healthy man and
compare these with patients with cirrhosis. Our hypothesis was that the





The study group consisted of 9 patients with biopsy proven cirrhosis and six age
and body weight matched healthy controls. Those with cirrhosis had their Bili,
Albumin and ALT measured by standard laboratory methods in order to derive
a Childs-Pugh score for each (Appendix XXI). Four of the 9 patients with
chronic liver disease were concurrently receiving spironolactone. Patients on
drugs other than spironolactone, and those with renal disease were excluded
from the study. The 6 control subjects were recruited from the Department of
Medicine staff: each drank less than 6 units of alcpohol per week. No control
subjects were taking any drugs or medication (Table 16). All subjects gave
informed written consent and the study was approved by the local ethics
committee.
Method of sample collection
The subjects did not take any other drugs or drink alcoholic beverages during
the study. Following the method of Borgstrom (1986) the study was started at
the same time of day for each subject who ate standardised food at a preset
time.
A 21 G "butterfly needle" was placed in a vein in the antecubital fossa and
secured with tape. A 5ml sample of venous blood was taken as a baseline.Then
3 ml of 200 mg/ml N-acetylcysteine solution (Parvolex, Duncan, Flockhart and








(Kg) 72.5 (±5.8) 67.3 (±3.4) NS
Mean age 39.8 (± 12.0) 51.1 (± 11.1) NS
Age range 28-61 40-74
( ± SEM)
NS = no significant difference at the 95% level
Table 16
Baseline variables of the study population
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the opposite arm by slow injection over 3 minutes (Borgstroem et al, 1986). This
was "flushed" with 20 ml of normal saline.
Venous blood was sampled from the butterfly needle at 20 minutes, 40 minutes,
60 minutes ,90 minutes, 2 hours ,3 hours, 4 hours ,6 hours, 8 hours and 10 hours
after the NAC administration into plain blood tubes. On each occasion 2ml of
venous blood was discarded from the tubing of the butterfly needle (roughly 2
ml) prior to sampling to avoid sample dilution with normal saline inside the
tubing. After each sample the tubing was flushed with 10 ml 0.9% saline to
avoid blockage of the tube.
Each blood sample was immediately centrifuged for 10 minutes at 3000 rpm in a
Beckman bench centrifuge and the plasma was pipetted into a sample tube.
The sample was stored at -40°C until quantitative analysis by HPLC (High
performance liquid chromatography) was performed.
Sample preparation for HPLC
The method was a modification of that of Lewis et al (1984) and that used by
Prescott et al (1989). Precision was improved by the addition of an internal
standard (glycylglycine). Ultrafiltration of the reaction mixture as described by
Lewis et al (1984) was found to be unnecessary and was omitted. The acidic
derivative did not extract from the reaction mixture under the condition
described by Lewis et al; and therefore in the method described by Prescott et
al (1989) it was necessary to acidify the reaction mixture and re-extract it twice
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with ether in order to achieve a satisfactory recovery of the derivative. The
method measures total NAC i.e oxidised, reduced and protein bound drug.
Reagents for 20 determinations were prepared as follows:
1 Dithiothreitol 5g/L. 35 mg dithiothreitol was weighed and dissolved in
7.0 ml distilled water.
2 Stock glycylglycine 2g/L. 10 mg glycylglycine was weighed and dissolved
in 5 ml of distilled water.
3 Glycylglycine working solution (0.1 g/L in 95% ethanol). 0.5 ml stock
glycylglycine was diluted to 10 ml with ethanol.
4 Dinitrofluorobenzene (DNFB) solution (50 g/L). This was handled with
care as it is a carcinogen. 220 mg dinitrofluorobenzene (recrystallised
from ether) was weighed out and dissolved in 4.4ml ethanol.
5 Citrate/EDTA buffer. 29.41 g trisodium citrate dihydrate and 744 mg
EDTA (disodium salt) were weighed and dissolved in 1500 ml distilled
water; adjusted to pH 7.0 with 1 mol/L citric acid (422.03 g/200ml).
This was then diluted to 2.0 L and filtered (0.45 /xm cellulose acetate).
Mobile phase:
methanol 30 } mixed and purged with
citrate/
EDTA buffer 70 } helium.
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Subjects plasma (0.05-0.5mL) was placed in a 10 ml plastic tube; distilled water
was added to a volume of 2 ml, followed by 0.3 mL dithiothreitol solution
(5g/L). The mixture was mixed and incubated at 37°C for 30 minutes.
Sodium hydrogen carbonate solution (20 g/L, 0.7 ml) was then added, followed
by 0.275 mL internal standard/reagent solution, prepared in advance by mixing
0.15 mL2,4-dinitro-l-fluorobenzene, 5 mL ethanol and 1.73 mL glycylglycine
(0.1 g/L in 95% ethanol) and pre-incubating 15 minutes at 60 °C. After
incubating for 30 minutes at 60 °C, the mixture was cooled and centrifuged at
3000 rpm for 5 minutes.
The supernatant (1.0 mL) was transferred to a stoppered glass tube and washed
with 5 ml ether by vortex mixing, centrifuging at 2500 rpm for 5 minutes and
discarding the ether layer by suction at the water pump. Hydrochloric acid (1.0
mol/L, 0.5 mL) was added to the aqueous phase which was then extracted twice
with ether as before: the ether extracts were combined and evaporated under
nitrogen at 50 °C.
The dry residue was dissolved in 100 /u.1 of mobile phase (citrate/EDTA buffer/
methanol) and 10-15 /zl was injected into the HPLC system.
HPLC (High performance liquid chromatography) for N-acetylcysteine
A Waters HPLC system was used using a U6K injector, M-45 pump and Model
441 fixed wavelength detector, 365 nm (sensitivity 0.2 aufs, chart speed 1
cm/min, pump speed 1 ml/min).
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The column used was a 10 cm x 5 mm I.D. stainless-steel column (HETP)
packed with Hypersil-ODS, 5 nm (Shandon) by Capital HPLC specialists.
For each sample the peak height ratio of N-acetylcysteine to glycylglycine was
measured (Appendix XXII). Glycylglycine and NAC eluted in 2.8 and 5.3
minutes respectively. The considerable help of Dr D R Jarvie, in this assay is
acknowledged. A standard curve was plotted for calibration and used to read off
the concentrations in the unknown samples.
Calibration standards
Stock solution (2g/L) was made by weighing 100 mg N-acetylcysteine (Sigma)
and dissolving in 50 ml distilled water. The solution was used immediately.
Calibration standards:
mg/LNAC 10 20 40 60 80 100
2g/L stock
solution 0.25 0.5 1.0 1.5 20. 2.5
All standards were diluted to 50 ml with drug-free serum (tested in the assay).
At the end of each batch of analysis, the column was washed and stored in 70 %
methanol.
Within batch precision
10 replicates of freshly prepared 40 mg/L NAC in plasma.
Results (mg/L) 39.7 42.8 n = 10
40.9 38.0 mean = 39.80
41.3 41.3 SD = 1.89




This was assessed by repeating assays of samples in the next HPLC run; values
were always found to be within 2-5% of the previous estimations (approximately
20 assays).
The detection limit of the assay was 50 ug/L.
Pharmacokinetic and statistical analysis
The plasma concentration against time data for N-acetylcysteine were fitted to
an open two compartment model by weighted non-linear regression analysis
using the SIPHAR (Centre d'Etudes et de Recherches en Statistiques et
Informatique Medicales, Cretail Cedex, France) pharmacokinetic curve fitting
and modelling programme, Version 4.0 and the POWELL minimisation
algorithm.
In addition to the coefficients of the model, this provided estimates of the area
under the plasma concentration-time curve (AUC), total body clearance
(dose/AUC), mean residence time (MRT) and the terminal plasma half-life of
N-acetylcysteine for each subject.
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RESULTS
Baseline variables for the patients with cirrhosis and healthy controls are shown
in Table 16; from this it may be seen that there was no significant difference in
age or weight between the two study groups. All the patients and healthy
volunteers completed the study without adverse reactions.
A table of the estimations of plasma N-acetylcysteine at the time points for each
subject are shown in Appendix XXIII and semilogarithmic plots of these are
shown in Figures 43-45. In no individual (control or patients with cirrhosis) was
endogenous NAC detectable in the baseline blood sample prior to
administration of NAC.
Good fits of the N-acetylcysteine concentration versus time data to a two
compartment model were obtained with all subjects using the POWELL
algorithm. The pharmacokinetic variables for the patients with cirrhosis and the
healthy controls are summarised in Tables 17 and 18 and each subjects
individual pharmacokinetic analysis is shown in Appendix XXV. It can be seen
that there is marked individual variation in pharmacokinetic parameters and
this has also been found with other studies (Rodenstein et al, 1978; Borgstroem
et al, 1986; Olsson et al, 1988; Burgunder et al, 1989; De Caro et al, 1989;
Prescott et al, 1989).
Table 19 compares the pharmacokinetic parameters between the patients with
cirrhosis and normal controls; from this it is clear that the volume of
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NAC controls
Subject tl/2 el AUC-exp Clr tot Vd MRT-exp Vdss-ex Vds-mod
(h) (*) (•••) r> (b) (") r)
c-1 3.03 81.78 4.34 32.03 2.51 18.42 19.41
c-2 3.59 100.88 5.95 30.81 3.90 23.22 23.92
c-3 4.66 92.01 6.52 43.87 4.24 27.64 28.14
c-4 2.41 143.86 4.17 14.52 1.75 7.32 7.95
c-5 3.06 116.35 5.16 22.79 3.41 17.61 15.82
c-6 2.73 101.41 5.92 23.33 3.17 18.75 19.28
N 6.00 6.00 6.00 6.00 6.00 6.00 6.00
Mean 3.25 106.05 5.84 27.89 3.16 18.83 19.09
SD 0.80 21.77 1.10 10.06 0.91 6.8 6.93
Min 2.41 81.78 4 14.52 1.75 7.32 7.95
Max 4.66 143.86 7 43.87 4.24 27.64 28.14
(*) mg /L x h
(*») mg / (mg/1) = litres
(***) mg / (mg/L xh) = litres/h
Table 17
Pharmacokinetic variables determined using the Powell algorithm for NAC
in healthy controls.
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NAC Liver disease patients
Subject t1/2 el AUC-exp Clr tot Vd MRT-exp Vdss-ex Vds-n
(h) n r*) (**) (h) r) r)
P-l 5.08 107.86 5.56 40.78 5.22 29.06 29.52
P-2 2.79 385.20 1.56 6.26 1.40 2.18 6.04
P-3 5.91 190.40 3.15 26.87 6.83 21.52 21.71
P-4 4.48 350.52 1.71 11.06 5.87 10.05 10.16
P-5 4.53 140.93 4.26 27.83 5.62 23.93 24.05
P-6 5.87 189.87 3.16 26.78 7.51 23.75 24.30
P-7 3.47 93.92 6.39 31.98 4.46 28.48 28.61
P-8 3.32 191.61 3.13 14.99 3.33 10.44 12.36
P-9 2.80 126.05 4.76 19.25 2.49 11.83 15.06
N 9.00 9.00 9.00 9.00 9.00 9.00 9.00
Mean 4.25 197.37 3.74 22.87 4.75 17.91 19.09
SD 1.22 103.60 1.64 10.90 2.02 9.50 8.44
Min 2.79 93.92 1.56 6.26 1.40 2.18 6.04
Max 5.91 385.20 6.39 40.78 7.51 29.06 29.52
(*) mg / L x h
(♦♦) mg / (mg/1) = litres
(***) mg / (mg/L x h) = litres/h
Table 18
Pharmacokinetic variables determined using the Powell algorithm for NAC










Controls 3.25 106.1 18.8 5.84
(n = 6) (0.80) (21.8) (6.8) (1.10)
Patients 4.25 197.4 17.9 3.74
(n-9) (1.22) (103.6) (9.5) (1.64)
Unpaired
t-test p > 0.05 p < 0.05 p» 0.5 p < 0.01
(±SD)
tVi elim = elimination half-life
AUC = area under the curve
Vdss = volume of distribution at steady state
CIr tot = clearance
Table 19
A comparison of the mean pharmacokinetic
parameters of patients with cirrhosis and
healthy controls following N-acetylcysteine
administration.
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extracellular water and the volume of distribution was the same in patients with
cirrhosis and normal controls. With 4 cirrhotic patients showing significant
ascites (Appendix XXI) it is a little surprising that the Vdss did not differ
significantly between control and cirrhotic groups, however the standard
deviation is marked.
The area under the curve was significantly different between the two groups and
thus clearance was found to be impaired in cirrhosis compared with controls
(Tables 17-19).
Correlations of the elimination half-life, clearance, volume of distribution at
steady state and area under the curve were tested against serum albumin,
bilirubin and PTR for the patients with cirrhosis using the Spearman Rank
Correlation Test (Appendix XXV). No significant correlations were observed




Pharmacokinetics is the science ofmathematical assessment of drug distribution
in terms ofmodel systems, of rate constants of transfer, of rate constants of
metabolism and excretion, and of apparent volumes of distribution
compartments.
The pharmacokinetics of N-acetylcysteine seen in our study patients and
controls conform to a two compartment model. Single compartment models
appear to be relatively rare in the distribution of foreign compounds such as
drugs.
It will be noted that although Figures 43 and 44 are drawn with semilogarithmic
axes they still have a concave shape; thus the first step in the analysis is the
derivation of a suitable equation for each curve in Figures 43 and 44. With a
two compartment model, it is necessary to postulate that the curve has two
exponential functions:
Cpt = A exp (- alpha t) + B exp (- beta t),
where A and B are the intercepts at the y axis (concentrations at t = 0) obtained
from the semilogarithmic plot of Cp against t, and alpha and beta are the rate
constants of the two exponential components of the curve.
Cpt is the concentration of the drug in plasma and represents but does not
equal the concentration in the body as a whole; in practice it is usual to measure
the drug in plasma, not the whole body.
The constants in the above equation can be calculated by graphical methods
based on trial and error or they can be determined using an appropriately
programmed computer (such as shown in Appendix XXVI). It is possible to
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introduce considerable degrees of error into later pharmacokinetic analysis by
mistakes at this stage. The need to determine the most accurate equation from
a collection of possibilities all of which appear to fit the data quite well cannot
be overemphasised.
Having obtained a double exponential equation it is then appropriate to
consider the details of the two compartment open system model (Figure 46).
There are two compartments: the central compartment consists of plasma,
blood cells and a group of rapidly perfused tissues including lung, brain, liver
and spleen; and the peripheral compartment, consisting of a group of poorly
perfused tissues, principally adipose tissue. Additionally there are at least two
other compartments, of unabsorbed drug (dose) following oral administration
and metabolised drug in urine and the gastrointestinal tract, awaiting final
removal from the body, but these materials are not of importance in the present
analysis.
Details of NAC distribution throughout the system were calculated from the
data obtained from the graph of concentration against time. Thus:
Apparent volume of the central compartment = Vp =
Dose
^o

















k , = k + kel m e
Figure 46
Two compartment model consisting of plasma,
blood cells and a group of rapidly perfused
tissues including lung, brain, liver and spleen.
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K elim ^ e[im
Area under the curve = AUC =
dose given
Vdss x IC glim
Clearance = amount of drug distribution volume totally cleared of drug per unit
of time = Clrtot =
dose given
area under the curve




Rate constant of transfer from the central compartment into the peripheral
compartment = K|2 =
alpha + beta - K21 - K dim
Apparent volume of distribution at steady state = Vdss
K12 + K21
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These equations were derived in classical pharmacokinetic investigations. It is
widely accepted that alpha and beta must differ by a factor of two if a
pharmacokinetic analysis of this type is to be meaningful.
Few studies of the plasma concentrations and pharmacokinetics of NAC in man
are available. Pharmacokinetic studies of NAC have been hampered by the
lack of suitable analytical procedures to determine the compound in plasma.
Previous studies have been performed with NAC labelled with 35 S (Rodenstein
et al, 1978) and thin layer chromatography has been used for the separation and
identification of NAC and its metabolites (Scheffner et al, 1966; Rodenstein et
al, 1978; Bonanomi and Gazzaniga, 1980).
The results of previous studies of the kinetics ofNAC in man have varied
depending on the analytical method used, dose, formulation and route of
administration (Prescott et al, 1989). For example, Borgstroem et al (1986) only
assayed NAC in deproteinised plasma, no estimation of total NAC was thus
made, whereas our study and those of Prescott and colleagues analysed total
NAC i.e. including that bound to plasma proteins. By only measuring NAC in
protein-free plasma, a relatively large fraction (often more than 50%) of the
drug is lost, due to the fact that it is precipitated together with the proteins.




b low-molecular weight disulphides
c disulphides with SH-containing proteins
The three pools have been measured in the studies by Olsson and colleagues
(1988) and Burgunder and colleagues (1989):
a by omitting the incubation with dithiothreitol
b by determining the difference in NAC concentration, measured in the
presence of dithiothreitol, before and after removal of the proteins by
ultrafiltration.
c by subtracting a and b from total NAC.
No free thiol was observed in any sample; this is to be expected since
disulphides form very rapidly during sample storage.
Borgstroem et al (1986) found their pharmacokinetic data best fitted a three
compartmentmodel, however our data and previous studies (Prescott et al,
1989) best fitted a two compartment model. This may reflect the fact that
Borgstroem's group did not measure total NAC and the kinetics reflected by
deproteinised samples may well be different.
Although we have estimated total NAC by the best method available to date the
results however may not reflect its true disposition in vivo. In addition, NAC
may in some cases act by releasing free cysteine though not in a 1:1 molar ratio
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(Burgunder et al, 1989) and the concentration of the total drug may not
therefore be a reliable index of its biological action. In addition NAC may exist
a disulphides in vivo, or the HPLC method may not distinguish these from
simple NAC.
The mean elimination half-life has varied from less than 2 to more than 6 hours
in previous reports (Rodenstein et al, 1978; Borgstroem et al, 1986 [tl/2 = 2.27
hours]; Olsson et al, 1988 [tl/2 = 6 hours]; Burgunder et al, 1989 , De Caro et
al, 1989). This is consistent with the values found for our healthy controls and
patients with cirrhosis i.e our control values compare well with previous small
and full dose studies.
The values for clearance reported in the literature, for example 1.83 ml/min/Kg
(equivalent to 7.68 litres per hour in a 70 Kg man: Olsson et al, 1988) and 3.5
ml/min/Kg (equivalent to 14.7 litres/hour in a 70 Kg man: Borgstroem et al,
1986) were of the same order but greater than the values seen in our study
(Tables 17 & 18). Clearance was impaired in those subjects with cirrhosis.
The estimated volume of distribution in our study was 18.8 ( + /- 6.8) for
controls and 17.9 ( + /- 9.5) for patients with cirrhosis, ie compatible with
extracellular water. This would be expected as NAC is a sulphurated amino acid
and is thus a hydrophilic compound and would be expected to distribute
throughout extracellular water. The volume of distribution was of the same
order as previous reports; Borgstroem et al (1986) report a value of 330 ml/Kg
and Olsson et al, (1988) report a value of 470 ml/Kg. The disposition of NAC
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does not appear to be dose-dependent (Prescott et al, 1989) or dependent of
degree of liver disease (Appendix XXV).
NAC has been shown to have low bioavailability after oral administration
(Borgstroem et al, 1986). This was assumed to be due to fast metabolism in the
gut wall and liver. Our data showing that plasma concentration ofNAC is
higher in patients with liver impairment lends further substantiative evidence to
this hypothesis.
Previous work has shown that NAC is stable when plasma is separated
immediately after collection and stored at -20 °C (Jarvie DR - personal
communication). Furthermore there was no detectable loss of total NAC in
plasma standards stored at -20 °C for 6 months.
Prescott and colleagues used the modification of the method of Lewis et al
(1984), measuring total NAC to show that NAC elimination was not impaired in
patients with severe liver damage due to paracetamol overdosage (Prescott et
al, 1989) but we have shown that patients with chronic liver damage have higher
levels of NAC than controls, with impaired clearance of the drug.
The disparity between these two studies may reflect the fact that maximum
impairment of hepatic function is delayed for at least 3 days after overdosage of
paracetamol and it is possible that the enzymes/pathway involved in the
metabolism of NAC were still functioning at this early stage or perhaps Prescott
et al (1989) did not study severe enough patients to observe a difference. Other
possibilities to explain the differences between this study and that of Prescott et
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al (1989) includes greater utilisation of NAC by the liver in patients with
paracetamol toxicity than those with cirrhosis, elimination from sites other than
the liver, or that porta-systemic shunting is importantin the cirrhotic group. The
reduced clearance but lack of high C max suggests that porta-systemic shunting
is not the major difference (which is just what you would expect from a low
extraction drug).
On the other hand, the metabolism of paracetamol and some other drugs is
impaired from the outset in patients who develop severe liver damage (Prescott
et al, 1989).
NAC has been shown to be deacetylated in the liver in the rat (Sjodin et al,
1989), but it is also rapidly metabolized to cysteine and inorganic sulphite in the
gastrointestinal tract. Other methods of analysis of NAC, clinical implications of
the finding that the pharmacokinetics ofNAC is altered in chronic liver disease,







Pharmacological agents are now widely used in the treatment of acute variceal
bleeding, in the prophylaxis of the first haemorrhage and the prevention of
rebleeding. Investigations continue on the mechanisms by which these drugs
may be effective in portal hypertension.
THE ROLE OF HAEMODYNAMIC STUDIES IN THE ASSESSMENT OF
DRUG ACTION
There is little doubt that in vitro studies of direct action of drugs on vasculature
must be done but they do present significant limitations in the information that
they can yield. A perusal of the discussion of the putative mechanisms of action
of nitrate or N-acetylcysteine action (below) illustrates that in vitro work
concerning drug action may be isolated to the system under study at best or
even misleading to the in vivo situation.
Whilst direct measurement of for example, portal pressure, in animals provides
little technical difficulties; the relevance to patients is of concern, particularly as
animals have to be anaesthetised for measurements to be made and anaesthetic
agents do have haemodynamic actions of their own. There are also the ethical
issues in the use of animals for such studies and one must respect the majority
public view in this regard.
In addition there is doubt whether for example the carbon tetrachloride
exposed rat, provides a good model of the pathology of human cirrhosis; clearly
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there are likely to be greater haemodynamic effects in the chronic alcoholic
human than in the carbon tetrachloride exposed rat.
Thus, although of potential risk, human studies are of no doubt the greatest
relevance to humans. As there appear to be so many variables in the
haemodynamic action of drugs it is useful to be able to measure directly what
action a drug has on various components of the haemodynamic system;
particularly to differentiate between the portal and systemic haemodynamic
effect (or indeed adverse effect). Thus the reason for the methods used in the
studies here. For example, using such methods, adenosine receptor agonists
have been shown to selectively act upon the portal system (Forrest, personal
communication) and this presumably reflects the distribution of adenosine
receptors within the portal system.
The aim of invasive haemodynamic studies is greater however than merely
understanding the mechanism of action of drugs at different vascular beds. The
aim is also to identify whom may benefit the most from drug action and who
may be at risk from the haemodynamic effects; a correlation of benefit with a
non-invasive parameter (such as a Child's-Pugh variable) is sought in an attempt
to identify such individuals.
Haemodynamic studies may also be useful in identifying haemodynamic
end-points for therapy such as a mean arterial blood pressure reduction to 70
mmHg. Bosch et al, 1993 have recently suggested that for the chronic treatment
of portal hypertension, efficacy of therapy is greater when portal pressure is
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reduced by 20% or more; though we feel that the drug's action on the collateral
circulation may well be the most important variable.
CORRELATION BETWEEN CHANGES IN HEPATIC HAEMODYNAMICS
AND OESOPHAGEAL VARICEAL PRESSURE
A recent study (Feu et al, 1993) correlated change in hepatic haemodynamics
and oesophageal variceal pressure (measured with a non-invasive,
pressure-sensitive endoscopic gauge) in cirrhotic patients either receiving
propranolol or a placebo.
In eight patients the HVPG was unaltered or decreased by less than 10% after
propranolol. In the remaining 13 patients treated with propranolol a reduction
in HVPG was seen and this was associated with a significant decrease in
measured variceal pressure and azygos blood flow.
However there was no significant difference between these 13 who did drop
their HVPG in response to propranolol and the group of 8 "non-responders"
with regard to the decrease in variceal pressure and azygos blood flow i.e.
favourable effects are observed in some patients in whom HVPG fails to
decrease by more than 10% of the baseline value and azygos blood flow does
seem to be a good marker for a beneficial effect on oesophageal variceal
pressure (Feu et al, 1993).
Standardisation of haemodynamic studies
During the studies described in Sections II, III and IV great care was taken to
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standardise the invasive procedures as far as possible. Subjects were studied in a
room of constant temperature, care was taken that the subjects were not
actively withdrawing from alcohol or drinking at the time of the study.
Physical exercise during the studies was prevented as it may reduce hepatic
perfusion (Iwao et al, 1993). Patients were standardised to the fasted state for
the study; this was important as it has been shown that eating results in higher
measured hepatic venous pressure gradients and precautionary in case
operative intervention should be required if a complication of the procedure
ensued.
Blood pressure recordings were made by staff in the haemodynamics laboratory
who are well trained and aware of the difficulties of observer error. For each
patient a single member of staff was responsible for measurement of blood
pressure. In our experience a semiautomated device eg Takeda has been less
reliable than a standard mercury syphygmomanometer as it tends to be "fussy"
at crucial time points and thus distracts staff from making other vital concurrent
recordings as they try to determine why it will not inflate the cuff, cannot find
the systolic blood pressure etc. It could be argued that ideally, an intraarterial
line should be used for assessment of mean arterial blood pressure but this is
not without risk, particularly with patients with coagulopathy.
In Section III, the repeat haemodynamic measurement was made during the
NAC infusion, thirty minutes after commencement of the infusion and the
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infusion was continued for the further few minutes required to complete the
haemodynamic measurements.
In Section IV the extensive precautions taken to standardise forearm blood flow
recordings are listed.
THE HAEMODYNAMIC ACTION OF Is-5-Mn IN PATIENTS WITH
CIRRHOSIS
Our study in Section II showed that both 10 mg and 40 mg of Is-5-Mn greatly
reduced HVPG acutely and with chronic use and that there was no apparent
advantage of one dose over the other in achieving HVPG reduction. A very
important finding was the absence of pharmacological tolerance to isosorbide
mononitrate in the patients studied, although a 16 hour nitrate-free interval was
allowed each day.
The 40 mg dose appeared to induce a greater haemodynamic disturbance acutely
i.e. increased heart rate, reduced mean arterial blood pressure and liver blood
flow than the 10 mg dose; only the increase in heart rate effect was maintained
after chronic use.
Only two previous groups showed no effect of nitrates on HVPG (Dawson et al,
1985; Tsai et al, 1989). All others showed a reduction in HVPG which was
accompanied by a fall in cardiac index and mean arterial blood pressure.
As the efficacy of vasoactive drugs in either controlling an acute variceal bleed
or preventing recurrent haemorrhage may be related to their ability to reduce
blood flow through collateral vessels, determination of the effects of vasoactive
agents on both collateral blood flow and HVPG is important in evaluating
therapeutic potential (Feu et al, 1993). Our results indicate that the effect of 10
mg or 40 mg Is-5-Mn on azygos blood flow was highly variable including some
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individuals in whom flow increased suggesting vasodilation of portasystemic
collaterals. This finding has been indirectly confirmed by Forrest et al (personal
communication) who have shown that flow through TIPSS may increase or
decrease in response to Is-5-Mn and by Grose et al (1994) who found in some
patients that azygos blood flow increased and in others it decreased in response
to nitrates. In section II those patients who had low azygos flow increased their
flow in response to nitrate and vice-versa. Thus the degree of pre-existing
porta-systemic shunting appears important and this unfortunately suggests that
there is unlikely to be a non-invasive way of predicting haemodynamic response
to nitrates.
Severity of liver disease per se does not appear an important variable in
defining haemodynamic response to nitrates as so few haemodynamic changes
correlated with Child's-Pugh variables. A few correlations were positive but this
would be expected by chance alone given the large number of correlations
tested.
Other variables that have previously been suggested to be responsible for
different response to nitrates between individuals may be degree of autonomic
impairment (Moreau et al, 1989) or baseline cardiac filling pressure (Rector et
al, 1990) but these variables were not assessed in this study as we felt that two
invasive catheters were enough to manipulate quickly to allow valid correlative
haemodynamic measurements to be made at each time point, particularly with
the need for sampling from the hepatic catheter to allow estimation of liver
blood flow by indocyanine green dye. As passage of a catheter through the heart
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is associated with significant risk of arrhythmias we sought to minimise this,
particularly as this was a chronic study and we felt this information had been
assessed in previous studies.
A detailed comparison of the haemodynamic response to either dose of Is-5-Mn
in our study to the previous literature (Tables 5-9 inclusive: Section I) is now
made. Our study was designed to answer specific questions (Section II) and thus
is different in experimental design to previous studies, in particular the
assessment of effect of rechallenge with Is-5-Mn after one month. Despite these
differences in experimental design it is noticeable that similar patterns of results
emerge in comparison with the previous studies.
The slight (but not significant) increase in heart rate to lOmg Is-5-Mn over 1
hour (Figure 7) compares well with the effect of 5mg sublingual Isdo over 10
minutes (Hallemans et al, 1983), 5mg sublingual Isdo over 30 minutes (Merkel
et al, 1987), lOmg oral Isdo over 1 hour (Blei et al, 1987) and 20 mg oral Is-5-
Mn over 1 hour (Tsai et al, 1989; Navasa et al, 1989). Mols et al (1989) and
Bhatia et al (1990) demonstrated a significantly increased heart rate in response
to 5mg sublingual Isdo over 15-20 minutes. Also Hayes et al (1988)
demonstrated a significant increase in heart rate to 20 mg Is-5-Mn over 60
minutes. Figure 9 shows that no significant heart rate difference from baseline
was present at 1 month, even on rechallenge with lOmg Is-5-Mn. This compares
well with studies using Isdo (Cervinka et al, 1989; Ikegami et al, 1992;
Vorobioff et al, 1992) and Is-5-Mn (Tsai et al, 1989).
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The acute heart rate response to 40mg Is-5-Mn (Figure 10) was greater than
that seen with some smaller doses of Isdo in the literature as expected
(Hallemans et al, 1983; Merkel et al, 1987; Blei et al, 1987) although Mols et al
(1989) and Bhatia et al (1990) demonstrated similar increases in heart rate with
5mg sublingual Isdo. Interestingly, Blei et al (1987) did not demonstrate a
significant increase in heart rate with 40mg Isdo and Navasa et al (1989) with
40mg Is-5-Mn over 1 hour which might have been expected from our results. A
variety of reasons may explain heterogeneity of response to nitrates, as
discussed above and in Section II discussion. Figure 11 showed a marked
increase in heart rate after 1 month of 40mg Is-5-Mn bd ie there was no
evidence of tolerance to the drug at 1 month. Cervinka et al (1989) however did
not find a significant increase in heart rate after 80mg/day Isdo (slow release
formulation) for 14 days, Ikegami et al (1992) after 40mg Isdo per day for 4
weeks or Vorobioff et al (1992) after 82 + /- lOmg/day for 65 + /- 23 days.
Similarly Tsai et al (1989) using 20mg Is-5-Mn bd for 1 week and Garcia-Pagan
et al (1990a) using 40mg Is-5-Mn bd for 3 months failed to observe an increase
in heart rate at 1 month. Several factors could account for this disparity
including heterogeneity of response to nitrates, failure to provide an adequate
"nitrate free interval" in previous studies and compliance with medication.
Figure 12 shows mean arterial blood pressure fell significantly in response to
the acute administration of lOmg Is-5-Mn. This compares favourably with all the
acute Isdo studies (Hallemans et al (1983), Dawson et al (1985), Merkel et al
(1987), Blei et al (1987), Mols et al (1989), Bhatia et al (1990) and indeed with
241
previous Is-5-Mn studies (using higher doses of IS-5-Mn) (Hayes et al 1988; Tsai
et al, 1989; Navasa et al, 1989).
Figure 14 shows mean arterial blood pressure fell significantly in response to
acute administration of 40mg Is-5-Mn; as explained above this compares
favourably with the previous literature.
Figures 13 and 15 show no sign of reduced mean arterial blood pressure after 1
month of either 10 or 40mg Is-5-Mn bd. This is similar to results observed with
Isdo by Cervinka et al (1989), Vorobioff et al (1992) (although Ikegami et al,
1992 found a significant reduction of mean arterial blood pressure after
40mg/day Isdo for 4 weeks) and with Is-5-Mn by Tsai et al, 1989 (although
Garcia-Pagan et al, 1990a found a significant reduction in mean arterial blood
pressure after 40mg Is-5-Mn bd for 3 months).
Figures 16 and 19 show that WHVP fell significantly at all time points (except
lOmg Is-5-Mn at t = 0, 1 month) in response to acute and chronic administration
of either dose of Is-5-Mn. This occurs and is of the same order as the results
found with acute and chronic Isdo administration (Freeman et al 1985; Merkel
et al, 1987; Blei et al, 1987, Qureshi et al, 1988; Mols et al, 1989; Cervinka et al,
1989; Ikegami et al, 1992; Vorobioff et al, 1992) and acute Is-5-Mn
administration (Hayes et al, 1988; Navasa et al, 1989). Although Tsai et al
(1989) and Garcia-Pagan (1990a) reported a fall in meanWHVP after chronic
Is-5-Mn administration, this failed to reach statistical significance. The number
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of patients studied by Tsai et al was small (n=6) and the Garcia-Pagan study was
over 3 months which may account for the differences observed.
Figures 18 and 21 show reduced HVPG at all time points from the baseline level
in response to either dose of Is-5-Mn, ie there was no evidence of tolerance. This
compares well with Isdo (Hallemans et al, 1983; Freeman et al, 1985; Merkel et
al, 1987; Blei et al, 1987; Mols et al, 1989; Ikegami et al, 1992) and Is-5-Mn
(Hayes et al, 1988; Navasa et al, 1989; Garcia-Pagan et al, 1990a). The
remaining studies showed no significant difference in HVPG but none showed a
significant increase after Isdo/Is-5-Mn administration. The reduction ofHVPG
seen in previous studies is very variable and presumably reflects different doses
of nitrate, severities of liver disease, porto-collateral shunting and cardiac filling
pressures.
Unfortunately few studies in the literature have made measurements of azygos
vein blood flow but, unlike other haemodynamic variables, marked differences
in response to nitrates are seen in the two studies which have made such
measurements (Navasa et al, 1989; Garcia-Pagan et al, 1990a). This is in
agreement with the main message of the study in Section II i.e. that the pre¬
existing degree of portal-systemic shunting is important in determining response
to nitrates. In Figure 26, Section II the term "arbitrary" indicates that the azygos
flow groups have no precedent. However, they do have rationale as we have
been aware whilst performing haemodynamic studies that patients with low flow
may respond differently to pharmacological agents than those with high flow.
The range of flows experienced in the haemodynamics laboratory was entirely
arbitrarily divided into three groups and therefore no statistical analysis
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was attempted on this data. Figure 26 is merely a way of visually representing an
observation made in the haemodynamics laboratory that may well be of
relevance in explaining the variability of response to nitrates in different
patients. This is obviously an important idea on which to base a hypothesis for
further studies as this information was not previously available.
Figures 27 and 28 show that there was no significant change in estimated liver
blood flow after either dose of Is-5-Mn. This is similar to reports with Isdo
(Merkel et al, 1987; Mols et al, 1989; Merkel et al, 1990; Ikegami et al, 1992)
and Is-5-Mn (Navasa et al, 1989, 40mg dose only) and suggest that the fall in
HVPG is due largely to a reduction in hepatic resistance rather than reduced liver
blood flow. Clearly a reduction in liver blood flow would be undesirable.
However Hayes et al (1988) demonstrated a significant reduction of estimated
mean liver blood flow from 1940 to 1639 1 hour after 20mg Is-5-Mn and Navasa
et al (1989) demonstrated a significant increase from 890 to 1003 ml/min with
the same dose. Garcia-Pagan et al (1990a) demonstrated a significant increase in
liver blood flow from 1320 to 1510 after 40mg bd Is-5-Mn for 3 months. It
would therefore seem that overall little mean change in liver blood flow can be
anticipated in response to Is-5-Mn but individual differences may occur.
Comparison of Section II results with studies published after our study was
commenced
Our findings in the 40 mg Is-5-Mn group have recently been confirmed by Silva
et al (1993). Hepatic and systemic haemodynamic parameters were measured in
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nine patients in basal conditions, after 1 hour and after 30 days of 40mg Is-5-Mn
bd therapy. Rechallenge with nitrate does not appear to have been made on the
second visit to the haemodynamics laboratory, unlike in our study. HVPG
decreased from 15.1 + /- 3.7 mmHg to 12.1 +/- 5 mmHg at one hour and 11.3
+ /- 5.5 mmHg at 30 days, which was very similar to our figures. Estimated liver
blood flow (ICG clearance method) was not modified thus estimated hepatic
resistance decreased in both periods. The mean arterial blood pressure fell after
1 hour only - in keeping with our data. However, we showed that heart rate
increased after 1 hour and remained significantly elevated at 1 month; data
from Silva et al (1993) showed an initial increase that was not maintained. The
fall in HVPG did not correlate with changes in portal or hepatic blood flow in
our study or Silva et al (1993).
Grose et al (1994) studied the effects of acute and chronic administration of 20
mg bd Is-5-Mn on the portal and systemic circulation in patients with cirrhosis
and portal hypertension. Acute administration (21 patients) reduced the MABP
and HVPG (18.4 + /- 0.9 to 16.5 + /- 0.9 mmHg) whilst having a variable effect
on azygos blood flow, as our data in Section II would suggest. Portal pressure
fell consistently only in patients in whom the azygos blood flow increased
acutely, which was not the case at the higher or lower doses used in our study
(Grose et al, 1994). With chronic administration (8 patients), no reduction in
MABP and HVPG was identified despite a marked and consistent reduction in
azygos blood flow (540 +/- 89 to 306 +/- 60 mls/min). This seems a little
surprising, given our results (Section II) and a review of the previous chronic
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nitrate literature (Tables 7 and 8, Section I). However, Grose et al, 1994 showed
that rechallenge with Is-5-Mn in patients on chronic nitrate therapy reproduced
the haemodynamic effects identified with acute administration, lowering MABP
and HVPG with a variable effect on azygos flow. The number used in the
chronic study was small and the rechallenge effect raises the possibility of
compliance as a factor.
However the differences between the study of Grose et al, 1994, the previous
literature and the results in Section II probably simply reflect the variability in
haemodynamic response that has been the characteristic of all the nitrate
studies reported to date. The heterogeneity may also reflect a dose-dependent
effect with different mechanisms of portal pressure reduction predominating at
different doses; other factors such as cardiac filling pressures and autonomic
effects may also add further to the variability seen.
COMPLIANCE AND SIDE-EFFECTS (NITRATES)
Our data suggest that the patients were taking their nitrate tablets during this
study; their motivation to attend outpatient clinics was high and the discrepancy
of tablet counts minimal. Side-effects were modest.
Adverse reactions associated with nitrates are unusual although mild headache
resolving within 24 h of the first dose occurs in up to one-third of patients (Blei
et al, 1987). In the first clinical trials of Is-5-Mn for prophylaxis of bleeding
which are beginning to be reported, treatment did not have to be stopped
because of side effects (Fassio et al, 1993).
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THE MOLECULAR MECHANISM OF NITRATES
The molecular mechanism of vasodilation by nitrates is controversial. In 1977
two groups demonstrated a dose-dependent increase in the levels of
cyclic-guanosine 5'-monophosphate (GMP) in smooth muscle after nitrate
administration (Schultz et al, 1977; Katsuki et al, 1977).
Subsequently it was shown that many other vasodilators, including nitric oxide,
activate soluble guanylate cyclase (Murad et al, 1978; Kukovetz et al, 1979).
Various possible mechanisms for the activation of soluble guanylate cyclase by
the organic nitrates are discussed by Yeates (1992) but the mechanisms in intact
blood vessels, in vivo and in blood vessel homogenates are probably different.
Nitrates may produce an increase in cyclic-GMP levels in smooth muscle by
direct action or via nitric oxide production, and there is evidence for thiol
intermediates as modulators of these cellular events (Horowitz et al, 1983 and
1988a) (Figure 47). Nitrates may directly stimulate nitric oxide synthetase to
produce nitric oxide as demonstrated by the studies of Persson and colleagues
(1994). They measured NO concentrations in exhaled air in anaesthetised
rabbits and found that infusions of GTN induced dose-dependent increases in
exhaled NO, which were abolished by L-NAME, a specific nitric oxide
synthetase inhibitor. Similarly, the two metabolites of GTN, 1,2 and 1,3-glyceryl
dinitrate were shown to produce a concentration increase in nitrite formation in
an in vitro system, although the effects of NO synthetase inhibition were not
studied (Salvemini et al, 1993).
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Nitric oxide as a vasodilator
Binding of vasodilators to endothelial receptors or
shear stress activate nitric oxide synthase via a
calcium mediated pathway.
Nitric oxide is generated from L-arginine and
diffuses into vascular smooth muscle to cause
relaxation after activation of soluble guanylate
cyclase and generation of cGMP.
248
However, some vasodilators have been shown to generate nitric oxide in a
nonenzymic reaction with cysteine (Moncada et al, 1988).
Nitric oxide may however not necessarily be the cause of the in vivo
vasodilatory response to nitrates as illustrated by Vallance et al (1989) who
showed that GTN infusion to normal volunteers caused a dose-dependent
increase in forearm blood flow which was unaltered by L-NMMA, another NO
synthetase inhibitor. N-acetylcysteine has also been shown to act as a
vasodilator but its action may not be via nitric oxide production (see below).
MECHANISMS OF TOLERANCE TO NITRATES
Our study and others (Freeman et al, 1985; Cervinka et al, 1989; Ikegami et al,
1992; Vorobioff et al, 1992, Tsai et al, 1989; Garcia-Pagan et al, 1990a) showed
tolerance to nitrates is not of concern in patients with chronic liver disease;
several of these studies do not appear to have used a nitrate-free interval
(Freeman et al, 1985; Cervinka et al, 1989; Vorobioff et al, 1992). This is a very
important finding - previous chronic nitrate studies in patients with cirrhosis, and
patients with ischaemic heart disease or cardiac failure have demonstrated
tolerance to the haemodynamic effects of nitrate occur within a few days of
commencing nitrate tablets. Thus follow up after one month was considered a
reasonable time period for our study.
Multiple subcellular mechanisms of nitrate tolerance are postulated including
conversion of the "nitrate receptor" to the disulphide from with lower affinity for
nitrate (Fung et al, 1989), reduction of sulphydryl groups necessary for the
"metabolic activation" of nitrates (Ignarro et al, 1981), reduction of vascular
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production ofnitric oxide (Chung and Fung, 1993), reduction in vascular
metabolism of nitrate (Slack et al, 1989) or molecular alteration of intracellular
guanylate cyclase (Waldman et al, 1986). These mechanisms although attractive
for explaining in vitro phenomena, have been found inappropriate or inadequate
for the in vivo situation. For example nanomolar concentrations of nitrates cause
tolerance in patients versus millimolar concentrations in vitro on blood vessels
(Fung, 1983) and tolerance occurs after several hours in patients yet develops
under an hour in vitro. It is also difficult to see how these cellular biochemical
mechanisms can be used to explain well known clinical phenomena such as
nitrate resistance (Abrams, 1991) and withdrawal rebound (Olivari et al, 1983).
In addition, although sulphydryl donors can partially reverse GTN-induced
tolerance in patients, this is not sufficient to implicate intracellular sulphydryl
depletion as a mechanism of clinical nitrate tolerance (Fung et al, 1992).
However, a recent report suggests that higher than normal concentrations ofN-
acetylcysteine are found in the urine of patients with chronic liver disease and it
would be interesting to speculate (Martensson et al, 1992) that endogenous N-
acetylcysteine might also be a mechanism for less tolerance to nitrates in such
patients, although we have assayed a 12 patients plasma for NAC (detection
limit 50 micrograms/Litre) and failed to detect NAC (Dr David Jarvie - personal
communication). Ifwe had demonstrated tolerance to nitrates in patients with
cirrhosis, it would have been interesting to see the effects ofNAC
administration.
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Increased plasma renin, increased plasma catecholamines and body weight and
sodium retention and shifts in vascular volumes have also been noted in those
given nitrates for several days or more (Packer et al, 1987; Dupuis et al, 1990:
Parker et al, 1991). These findings suggest that in vivo nitrate tolerance might
be brought about by physiological compensatory mechanisms. Recent evidence
suggests, as expected, that both subcellular and physiological mechanisms are
involved in nitrate tolerance in vivo (Dupuis et al, 1990; Watanabe et al, 1993;
Kertland et al, 1993).
A number of studies show that cirrhosis is accompanied by a variety of
compensatory physiological effects eg. raised plasma renin (Bichet et al, 1982a),
increased secretion of catecholamines (Henriksen et al, 1981; Nicholls et al,
1985) which may due to increased central sympathetic outflow (Floras et al,
1991) and alterations in vascular volumes (Henriksen et al, 1992). They
therefore may not be able to develop further compensatory mechanisms of
tolerance.
Strategies for the prevention of nitrate tolerance include the avoidance of
maximum nitrate doses and the use of intermittent dosing regimens. Providing a
relatively brief nitrate-free interval of 8-12 hours restores vascular
responsiveness to nitrates, most likely due to recovery of the metabolic
mechanism responsible for the therapeutic effect of these drugs (Amsterdam,
1992; Cowan, 1992).
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THE RELATIVE SUSCEPTIBILITY OF ARTERIAL AND VENOUS
SYSTEMS TO TOLERANCE TO NITRATES
There is still no general agreement concerning the relative susceptibility of the
arterial and venous system to the development of nitrate tolerance in humans.
Zelis and Mason ,(1975), in a plethysmographic study, have shown that during a
6-8 week treatment with isosorbide dinitrate, cross-tolerance develops to the
venous but not to the arterial dilator effects of nitroglycerin. Manyari et al
(1985) found that during sustained therapy with isosorbide dinitrate, the effects
of sublingual nitroglycerin on both venous volume and blood pressure were
markedly diminished. The authors concluded that cross tolerance between
isosorbide dinitrate and nitroglycerin develops in both the arterial and venous
systems.
However, differing results were found in patients with congestive heart failure
(Leier et al, 1983) who found that tolerance developed only to the systemic
vascular effects without attenuation of venous and pulmonary vascular effects.
Makhoul et al (1990) however found in such patients that the acute
nitroglycerin effects attenuated more rapidly and more extensively during a
24-hour infusion in the venous than in the arterial circulation. Ghio and
colleagues (1992) demonstrated by measuring venous volume and forearm
vascular resistance that after a 24-hour continuous infusion the effect of
nitroglycerin was 50% reduced in the venous circulation in 20 patients with
coronary artery disease but not in the arterial circulation. This is in keeping with
the findings of Zelis and Mason (1975) and experimental data (Stewart et al,
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1986) indicating that venous vessels are more readily susceptible to the
development of nitrate tolerance than arterial vessels.
THE ROLE OF NITRATES IN THE PRIMARY AND SECONDARY
PROPHYLAXIS OF VARICEAL BLEEDING
Preliminary clinical trials suggest a prophylactic benefit of nitrates for variceal
bleeding (Angelico et al, 1993) although larger numbers of patients will be
needed in future studies. Fassio et al (1993) studied 42 patients with cirrhosis
and varices with "red signs" but whom had never bled. The percentage of
patients free of bleeding 61 weeks after inclusion in the study was 62.4% in the
group receiving Is-5-Mn and 43.6% in the placebo group. Such a clinical trial
should examine a variety of doses of isosorbide-5-mononitrate as we have
shown that 40 mg bd causes a sustained alteration in systemic haemodynamics
and this may have long-term implications to patient wellbeing.
COMBINATION PHARMACOTHERAPY FOR ACHIEVEMENT OF
HEPATIC VENOUS PRESSURE REDUCTION OR PROPHYLAXIS
AGAINST VARICEAL BLEEDING
Although beta-blocking agents are accepted therapy for preventing first or
subsequent bleeding episode, propranolol therapy decreases final HVPG to <
12 mmHg in only 12% of patients (Pereira et al 1991), while only 24% of
patients have a > 20% reduction in HVPG and nearly 40% show no reduction
in HVPG (Bosch et al 1984a, Garcia-Tsao et al 1986).
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Therefore if we wish to increase the benefit of drugs to reduce portal pressure
or azygos blood flow we must either select patients who exhibit a better
haemodynamic response or develop combination therapies that can offer
effective reductions in HVPG.
Table 20 shows drug combinations with proven or probable synergistic effects in
reducing HVPG. Use of propranolol and isosorbide-5-mononitrate
(Garcia-Pagan et al 1990b and 1991) achieves a greater reduction in HVPG
than is possible with either drug alone. This may be due to
isosorbide-5-mononitrate preventing the increase in portal resistance that is
caused by propranolol (Bosch et al, 1993). Interestingly, the addition of
isosorbide dinitrate to propranolol, although potentiating the reduction of
HVPG seen with the latter, resulted in greater problems with management of
ascites (Vorobioff et al, 1993). This however was not confirmed in a study of
combination Is-5-Mn and propranolol (Morillas et al, 1994). The beneficial
effect on azygos blood flow is maintained whilst liver perfusion and hepatic
function appear to be unchanged with nitrates plus beta-blocker (Garcia-Pagan
et al 1991; Morillas et al, 1994). Whether the enhanced haemodynamic effects
of this combination therapy translate into better clinical results must be verified
by randomised, controlled studies.
A new agent that combines the effects of beta-blockers with those of nitrates,
nipradilol, was tested in portal hypertensive rats with synergistic action on
HVPG reduction; clinical trials are awaited (Ohsuga et al, 1993).
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Table 20 Drug combinations with probable synergistic effects in reducing
portal pressure - clinical studies
Propranolol and nitrate Haemodynamic response measured
Garcia-Pagan et al, 1990 27% reduction HVPG
(Propranolol: O.lmg/kg,
then 2mg/h iv. Is-5-Mn:
20 or 40mg (1 dose p.o.)
Garcia-Pagan et al, 1991 19% reduction HVPG
(Propranolol: dose increased
until heart rate reduced 25%
for 3 mths p.o. Is-5-Mn:
40mg bd for 3 mths p.o.)
Vorobioff et al, 1993 21.6% reduction in HVPG
(Propranolol bd: dose
increased until heart rate
reduced 25%, mean dose 159 + /- 69mg/d:
Isdo to avoid reductions in MABP
ofmore than 20%, mean dc
40 +/- 17mg/day)
Tincani et al, 1993
(40mg propranolol
and 60mg sustained release




reduced portal vein flow
in more patients on combination
therapy than either drug alone
Propranolol and ketanserin
Hadengue et al, 1987 19% reduction HVPG
(Propranolol: 15mg, 1 dose
iv: ketanserin, 5mg, 1 dose iv)
Spironolactone and propranolol
Garcia-Pagan et al, 1991b 25% reduction HVPG
(Spironolactone: lOOmg/day
for 2 months p.o.: propranolol
0.15mg/kg 1 dose iv)
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Similarly, in another rat study, combination therapy with SMS 201-995 (a
somatostatin analogue) and low dose Isdo may be more effective at reducing
portal influx and portal pressure than either alone (Hori et al, 1994).
Whilst combination therapy is theoretically attractive the difficulty with
compliance, particularly in patients with alcoholic liver disease, must be borne
in mind.
Future research
Better methods are required to identify high risk patients appropriate for
pharmacotherapy of portal hypertension. This is especially important for the
selection of patients for treatment to prevent first variceal haemorrhage as
65-75% of these will not experience variceal bleeding. Further studies are
necessary to evaluate the combination of pharmacological agents and
sclerotherapy or endoscopic variceal ligation. Studies evaluating drug
combinations to lower HVPG more aggressively are also needed.
RENAL EFFECTS OF DRUGS USED IN TREATMENT OF PORTAL
HYPERTENSION
Drugs used to lower HVPG may have adverse effects on sodium and water
metabolism and ascites formation. Propranolol has marked effects on systemic
haemodynamics, the sympathetic nervous system and the renin-angiotensin
system but does not appear to have much effect on renal function, including salt
and water handling (Wilkinson et al, 1977; Bataille et al, 1984; Rector and
Reynolds, 1984; Bernardi et al, 1989; Henriksen et al, 1992; Vorobioff et al,
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1993). Circulating noradrenaline increases during treatment with propranolol,
indicating enhancement of alpha-adrenergic tone (which increases salt and
water retention), but the activation of the renin-angiotensin system decreases
(which decreases salt and water retention), as reflected by reduced circulating
levels of renin, angiotensin II and aldosterone. Thus the overall effect on the
kidney is negligible in Child's A and B patients (Bataille et al, 1984). However,
there is only limited experience of treatment with propranolol in advanced
cirrhosis (Bendtsen et al, 1991).
Clonidine treatment over a prolonged period of time results in a reduction in
arterial blood pressure which theoretically would be expected to have an
adverse effect on renal function. This however was not found to be the case in
one study (Albillos et al, 1992b).
Nitrates have recently been shown to reduce renal blood flow, glomerular
filtration rate, free water clearance and renal sodium excretion (Salmeron et al,
1993). A single oral dose of nitrate produced a significant reduction of renal
function and sodium and water excretion, an effect most likely caused by the
observed reduction in MABP. Despite a comparable reduction in MABP
between compensated and decompensated patients with cirrhosis, a more
severe decrease in kidney function occurred in the decompensated patients,
which may have been caused by greater activation of the sympathetic nervous
system and renin-angiotensin-aldosterone axis and a shift in renal
autoregulation (Henriksen and Ring-Larsen, 1993). It is interesting to note that
in spite on the theoretical benefits of combination nitrate and beta-blocker
257
administration on renal side-effects in portal hypertension that the study of
Vorobioff et al, (1993) demonstrated that the combination still impaired renal
function significantly, probably due to arterial hypotensive effects.
Diuretics or ACE inhibitors have well known adverse effects on renal function
(Daskapoulas et al, 1987a and b). Because the kidneys in cirrhotic patients
behave like bilateral Goldblatt kidneys (Lassen et al, 1986), the fall in renal
perfusion pressure may have a serious adverse effect. A marked hypotensive
effect in patients with an activated renin-angiotensin-aldosterone system has
been observed with ACE inhibitors in cirrhosis (Daskapoulas et al, 1987b).
Although an increase in renal blood flow takes place because of a reduction in
renal vascular resistance, the cause is apparently a decrease in tone of the
efferent glomerular arteriole. The end-result therefore is a decrease in GFR,
the filtration fraction and, finally the urine volume.
Calcium channel blocking agents cause a reduction in mean arterial blood
pressure but renal effects have only been reported in one study (Lay et al,
1987).
Similarly serotonin S-2 receptor-blocking agents reduce mean arterial blood
pressure but the question of impairment of renal function remains to be
answered.
Two adverse effects ofmedical therapy may preclude drug used for portal
pressure reduction; liver dysfunction and adverse renal effects. The
predominant factor that appears to affect renal function is the reduction in
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arterial blood pressure, as further reduction of the already characteristically low
blood pressure will reduce renal blood flow and glomerular filtration rate, with
subsequent reduction in sodium excretion and free water clearance. All this
information must be taken in context that a significant % of patients are
non-responders to portal hypotensive agents (especially beta-blockers) and
therefore we are potentially placing some patients at risk or renal or liver
dysfunction for little-no benefit.
THE HAEMODYNAMIC ACTION OF N-ACETYLCYSTEINE
i) NAC as a vasodilator and positive inotrope
Section IV has shown that NAC acts as a vasodilator in patients with cirrhosis
and in normal controls from a rate of infusion of 30 mg/min into the forearm on
the cumulative dose/response curve (Figures 39-42). There were small changes
seen at an infusion rate of 10 mg/min. The response to NAC has been studied
as a cumulative effect of each test dose being infused over 10 minutes. It is
possible that the dose-response curve may look different if each dose were
tested on separate occasions but this is clearly impractical with 6-8 doses.
The control group showed less vasodilation in response to N-acetylcysteine than
the patient group, although this difference was not statistically significant.
However the patients had relatively mild cirrhosis (mainly Child's group A) and
thus if a more severe group (and perhaps larger numbers) were studied a
statistical difference from healthy volunteers response to NAC might be seen.
This would be expected since patients with cirrhosis are known to be deplete in
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sulphurated amino-acids (Martenssen, et al, 1992). N-acetylcysteine is a
sulphydryl donor and we know that SH donation is important in vasodilatory
mechanisms from in vitro work on vascular rings; thus NAC might be expected
to have a greater vasodilatory effect in cirrhosis.
Whether NAC possesses direct relaxant activity in normal vascular smooth
muscle in vitro is controversial. Torresi (et al, 1985) and Munzel (et al, 1989)
suggested it did not. The work ofMunzel and colleagues however showed that it
potentiated the vasodilatory response to nitroglycerin. A more recent study by
Sunman et al (1993) however showed that NAC caused an endothelium-
independent relaxation of rat and human resistance arteries. What is not always
clear from some in vitro studies is the degree to which intact endothelium was
present in the vessels tested, as absence of endothelium (and hence endothelins,
nitric oxide etc) may well impede vascular response to a drug. In addition the
size of the vessel may be important (Wheatley et al, 1994) and the length of time
ofNAC exposure (Boesgaard et al, 1994a).
Administration ofNAC intra-arterially to rabbits at 20 mg/Kg produced a
significantly lower peripheral vascular resistance but administration at 200
mg/Kg produced no significant change (Knight et al, 1990). Perhaps then some
of the differences between in vivo studies reported in the literature result from
different doses ofNAC used. It may be that at high doses NAC has some toxic
effect.
Although we have shown that normal controls have a local forearm vasodilatory
response to N-acetylcysteine in vivo, this does not mean that systemic
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haemodynamic features would necessarily occur in controls, as reflex changes
which compensate for the vasodilation may occur. Prior to our studies there was
little evidence to suggest that NAC had any haemodynamic action in healthy
controls (as discussed below). However our forearm blood flow study suggests
that given locally, at certain doses, NAC acts as a vasodilator both in healthy
controls and patients with cirrhosis.
In Section III we showed that NAC given at a rate of 150 mg/kg for 15 minutes,
followed by 50 mg/Kg for 15 minutes to patients with cirrhosis resulted in
increased cardiac output and reduced systemic vascular resistance and was
intended to be directly comparable with the work of Harrison (et al 1991) and
Packer (et al, 1987).
As NAC administration to the 11 patients with cirrhosis resulted in raised
cardiac index and peripheral vasodilation and as most drugs that primarily cause
afterload reduction increase cardiac index without affecting left ventricular
stroke work index, the rise in cardiac index in association with left ventricular
stroke work index here is suggestive of a positive inotropic response rather than
purely peripheral vasodilation and reduction in left ventricular afterload.
Positive inotropic action was also found in the study of Harrison (et al, 1991)
and Walsh (unpublished observation). This action is unlikely to be due to
hyperosmolality but may be due to a direct effect of the drug on the
myocardium, eg due to -SH donation, free radical scavenging or nitric oxide
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myocardium, eg due to -SH donation, free radical scavenging or nitric oxide
production. This requires further study. It will be very important to determine if
NAC's action as a positive inotrope is a transient effect or continues throughout
a prolonged infusion period. If the effect were prolonged, this might explain the
reduced need for inotropic agents in patients treated with NAC in fulminant
hepatic failure (Keays et al, 1991). Similarly the time course of the peripheral
vasodilation ofNAC requires evaluation.
We cannot predict whether healthy volunteers would have shown the same
responses to systemic infusion ofNAC as cirrhosis, given this regime, but the
literature to date suggests that NAC would have no haemodynamic action:
Administration to healthy and shocked pigs (Groeneveld et al, 1990; Modig and
Sandin, 1988), patients with ischaemic heart disease (Horowitz et al, 1983;
Winniford et al, 1986), patients with heart failure (packer et al, 1987) and
patients who had recovered fully from fulminant hepatic failure (Harrison et al,
1991) produced no haemodynamic changes.
ii) NAC as an antidote to nitrate tolerance
NAC has been given intravenously (5g in 200 ml 5% dextrose over 15 minutes)
to patients with coronary artery disease who had all received pretreatment with a
nitroglycerin infusion, some of whom had developed tolerance in the arterial and
venous beds to the nitroglycerin. In the patients with "venous tolerance" to NAC
the venous volume increased significantly after N-acetylcysteine infusion
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but in the remaining patients no change occurred (Ghio et al, 1992). No change
in forearm blood flow was seen in response to NAC in these patients (previously
given nitroglycerin) (Ghio et al, 1992). This is seemingly in contrast with
previous studies indicating potentiation of nitroglycerin action with NAC.
Much of the discrepancies in the literature may be attributed to differences in
the protocol ofNAC administration. In this respect it would appear that
pretreatment with NAC potentiates the effects of a subsequent infusion of
nitroglycerin. The increase in coronary blood flow (Winniford et al, 1986) or the
decrease in systemic blood pressure and pulmonary capillary wedge pressure
(Horowitz et al, 1983) in response to a fixed dose of nitroglycerin was
significantly higher after NAC than under control conditions.
However, in a similar study to Ghio et al (1992), where NAC was added to a
previous 24-hour infusion ofnitroglycerin (May et al, 1987), only reversal of
nitrate tolerance without potentiating effect was observed; however these authors
did not carry out a separate analysis in patients who developed and who did not
develop nitrate tolerance.
To confound things further, only partial reversal of tolerance was reported by
Packer et al (1987) when NAC was given in eight nitrate-tolerant patients with
congestive cardiac failure. Also a non-specific potentiation of nitroglycerin
action has been demonstrated (Munzel et al, 1989) and it has been postulated
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to occur at an extracellular site (Fung et al, 1988). We are still unable to explain
fully the conflicting results obtained in humans.
The incubation of tolerant arterial vascular rings with different sulphydryl donors
produced reversal of tolerance in most (Needleman and Johnson, 1972; Torresi et
al, 1985) but not all (Abdollah et al, 1987) studies. Clearly the interactions
between organic nitrates and sulphydryl groups are so complex and incompletely
elucidated that we cannot currently explain the diversity of response dependent on
different patient groups, and when different doses and schedules ofNAC are given
in vivo. The putative subcellular mechanism of action ofNAC are discussed
below.
iii) The effect of NAC on O2 delivery and consumption
Below a critical O2 delivery, systemic O2 consumption is maintained relatively
constant by proportionate increases in tissue O2 extraction (Russell and Phang,
1994), ie O2 delivery decreases in the physiologically normal state.
Many clinical studies of acute respiratory distress syndrome, septic chock and
critical illness purport to show dependence ofO2 consumption on O2 delivery,
even when O2 is delivered in a supranormal range but such dependence is not
replicated in animal models and may only appear to occur due to mathematical
coupling of errors in the measurement of shared variables used to calculate O2
delivery and consumption (Archie, 1981; Russell and Phang, 1994). Ronco (et al,
1993a) demonstrated that sepsis did not alter the critical O2 delivery for anaerobic
metabolism or tissue O2 extraction ability. He also showed that in septic patients
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having therapy withdrawn that the lower end of the delivery of (^/consumption of
O2 relationship was the same as in normal controls (Ronco et al, 1993b).
The Walsh study (personal communication) has demonstrated that O2
consumption does not increase as O2 delivery increases in fulminant hepatic
failure patients given NAC regime, ie the same results as we found with cirrhotic
patients. Why might the Harrison study have found differing results from the
Walsh and our studies? As mentioned previously, the relationship between two
haemodynamic variables may be mathematically coupled when they are assessed,
for example by the Swan-Ganz catheter technique. If either one or both are
derived and/or calculated this can lead to erroneous results (Archie, 1981). Thus
an apparent difference may be seen which is not actually the case. It is possible to
correct for such bias in a linear correlation coefficient by use of the first two terms
of a Taylor Series expansion of the function (Stratton et al, 1987).
It is possible using the Swan-Ganz catheter technique to find a spurious increase
in apparent O2 consumption, because as the arterio-venous gradient narrows and
the cardiac index rises, any sampling error is magnified enormously (Bartlett and
Dechert, 1990).
In additions patients with cirrhosis have functional pulmonary shunting
(Rodriguez-Roisin et al, 1992) and NAC may act as a vasodilator to increase
pulmonary shunting. This hypothesis is supported by the observation that the
pulmonary vascular resistance index fell in response to the NAC infusion and that
the arterial pC>2 fell in certain patients.
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The exact nature of such shunting is controversial (Berthelot et al, 1966) and
may be physical or physiological. Recent evidence of normalisation of
ventilation/perfusion relationships after liver transplantation in patients with
decompensated cirrhosis indicates that these changes have a direct functional
relationship to the diseased liver (Eriksson et al, 1990).
Physiological mechanisms contributing to the hypoxaemia of cirrhosis include a
right shift in the oxygen dissociation curve which occurs in many patients
(Rodriguez-Roisin et al, 1992) due to an increase in 2,3 diphosphoglycerate but
this alone is insufficient to explain the degree of hypoxaemia.
The multiple inert gas elimination technique (Evans and Wagner 1977) has
shown ventilation/perfusion (V/Q) mismatching may be responsible in some
patients. Patients with lower pulmonary vascular resistance have greater V/Q
mismatch (Rodriguez-Roisin et al, 1992). Increased ventilation/perfusion
mismatch might be expected to be the most likely mechanism for the blood gas
changes observed in our 11 cirrhotic patients in response to NAC infusion
(Section III; Table 13).
A wide range of gas exchange abnormalities may occur in patients with chronic
liver disease. Whether the mechanism underlying some of these is related to
failure ofmetabolism or of production of one of several circulating vasoactive
substances by the damaged liver cells or to altered metabolism of paracrine
factors synthesized by endothelial cells is unknown (Rodriguez-Roisin et al,
1992). Many potential pulmonary vasodilators including prostacyclin, ANF and
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PAF have been detected therefore potentially contributing to depression of
hypoxic pulmonary vasoconstriction.
iv) Other reasons for differences between the action of NAC in cirrhosis and
fulminant hepatic failure
Haemodynamic differences in response to NAC between these two groups of
patients may also be due to the fact that some of the fulminant patients had
encephalopathy ( + /- neurohumoral factors) and were on mechanical
ventilation (volume controlled) with continuous intravenous infusion of muscle
relaxant (Atracurium 50 mg/hr). Pulmonary capillary wedge pressure had to be
stabilised at 8-14 mmHg by infusion of 4.5% human albumin solution before the
study.
v) NAC as a protective agent
Reduced glutathione (GSH) is the main intracellular low molecular weight thiol
which acts as a nucleophilic scavenger and as an enzyme-catalyzed antioxidant
in the event of electrophilic/oxidative tissue injury. Therefore, GSH has a major
role as a protector of biological structures and functions, for example, GSH
repletion by early administration ofNAC protects the liver from paracetamol
induced liver damage.
Lack of GSH and electrophilic/oxidative injury have been identified among the
causes of the adult respiratory distress syndrome (ARDS), idiopathic pulmonary
fibrosis (IPF) and AIDS. Experimental and early clinical data (in ARDS) point
to the role ofNAC in the treatment of these conditions. Recently oral NAC has
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been shown to enhance the levels of GSH in the liver, in plasma and notably in
bronchoalveolar lavage fluid. In healthy volunteers, the rise in glutathione
following systemic NAC administration, was not due to increased liver
production and splanchnic efflux (Poulsen et al, 1993). Rescue of GSH through
NAC needs to be appreciated as an independent treatment modality for an
array of different diseases, all ofwhich have one feature in common; loss of
GSH.
Although in Section III we have shown that NAC is not of haemodynamic
benefit in cirrhosis, we would still advocate its use in paracetamol poisoned
patients with cirrhosis; however it would seem prudent to monitor arterial
oxygen tension and avoid the use of other positive inotropes if possible.
THE MECHANISM OF ACTION OF NAC AS A VASODILATOR/REVERSER
OF NITRATE TOLERANCE
Sulphydryl groups appear to be required for the relaxation of vascular smooth
muscle. In cirrhotic patients who are known to be deplete in sulphurated
amino-acids (Chawla et al, 1984) NAC may act by sulphydryl repletion to cause
vasodilation (Figure 48). Alternatively, NAC may be acting through production
of nitric oxide. Endothelium derived relaxing factor (nitric oxide), synthesized
by endothelial cells relaxes vascular smooth muscle (Palmer et al, 1988) and
inhibits the aggregation and adhesion of platelets (Radomski et al, 1987); both
actions are potentiated by NAC (Stamler et al, 1989).
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NITRIC OXIDE (NO) SYNTHETASE
Endothelium Vascular muscle
Figure 48
N-acetylcysteine - possible mechanisms





A recent study has shown that significantly enhanced production of nitric oxide
from GTN in plasma was observed with a whole variety of sulphydryl
compounds (Chong and Fung, 1991; Chung et al, 1993). Comparative in vitro
relaxation studies were carried out using isolated (and nitrate tolerant) rat
aortic rings with GTN/thiosalicylic acid (an aromatic thiol) or GTN/NAC, in
the presence of 0.5% plasma. Under these conditions partial reversal ofGTN
tolerance could be achieved with TSA, but not with NAC (Chong et al, 1991).
These data are consistent with the view that extracellular production of nitric
oxide or S-nitrosothiol serves as a tolerance-reversing mechanism of thiols on
GTN. TSA appears to be a more potent sulphydryl compound than NAC in this
biochemical and pharmacological interaction.
Lahera and colleagues (1993) have shown that sulphydryl donors potentiate the
hypotensive effect of acetylcholine in rats; an effect which is inhibited by
L-NMMA. It was suggested that the mechanism was therefore nitric
oxide-dependent but that nitric oxide was protected from free radical
destruction by formation of a S-nitrosothiol compound with NAC.
NAC is unlikely to lead to release of nitric oxide by stimulation of TNF
production however as a recent study from Milan (Peristeris et al, 1992) has
shown that NAC inhibited TNF production and hepatotoxicity in mice treated
with lipopolysaccharide.
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A recent effect of thiol containing agents in reducing prostaglandin I2
production via increased cGMP by cultured human vascular endothelial cells
has been reported (Kobayashi et al, 1991).
Thus NAC may be acting directly on vasculature or indirectly via nitric oxide
(most likely) by sulphydryl donation (Figure 48) (Myers et al, 1990). It is
difficult to test the hypothesis that the mechanism of action of NAC involves
nitric oxide using the forearm blood flow model (for example using L-NMMA)
as there is no haemodynamic change to assess that could be attributed merely to
the NAC working through nitric oxide i.e. there are too many confounding
variables.
The effect of NAC on reversal of nitrate tolerance is steriospecific for the
L-isomer which suggests it is enzyme/ receptor dependent for its mechanism of
action (Newman et al, 1990). Initial claims that it failed to reverse tolerance to
Isdo have recently been refuted and SH groups have been shown to be very
important in reversal of tolerance (Mehra et al, 1994). However, a recent study
suggests that haemodynamic tolerance to nitrates in major vessels is not due to
depletion of vascular thiol compounds (ie cysteine and glutathione) necessary
for the bioconversion of organic nitrates (Boesgaard et al, 1994b). Much about
the role of thiol groups in tolerance and reversal of tolerance to nitrates
remains to be elucidated.
Alternatively, like other vasodilators, NAC may activate endogenous
neurohormonal systems. Boesgaard and colleagues (1993) demonstrated that
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N-acetylcysteine inhibits angiotensin converting enzyme in vivo. Perhaps even
both mechanisms occur but affect different vascular beds eg SH donation might
be the dominant mechanism of action in peripheral veins whereas
neurohormonal activation may be the mechanism of action in arteries. This
concept, though appealing, ignores the possibility that these two mechanisms
can strongly interact. Since nitrate tolerance has been explained by both direct
loss of pharmacological effect due to reduced bioconversion and an indirect
effect due to activation of the renin/angiotensin system and counterregulatory
vasoconstriction, from the mechanisms of action described above, it becomes
easy to see how NAC may ameliorate tolerance.
In addition it has been shown that NAC may also act as an antioxidant (Gressier
et al, 1993), reductant and free radical scavenger or one of its metabolites
notably L-cysteine, glutathione and sulphate may be the active molecular
species (Sjodin et al, 1989). Another possible mechanism of action of NAC as a
vasodilator and positive inotrope has been suggested by our finding that stock
NAC solution (200mg/ml) has an osmolarity of 2400 mOsm/L (checked by
osmometer), of which approximately 1200 mOsm is due to the sodium ion
(standard biochemical assay). The sodium concentration is so high because
NaOH solution is added to NAC to make the solution neutral for injection.
The osmolarity of the solutions ofNAC infused in the forearm blood flow study




100 mg/min NAC = 1.36 mOsm/min 1360
30 mg/min NAC = 0.67 mOsm/min 670
10 mg/min NAC = 0.43 mOsm/min 430
3mg/minNAC = 0.35 mOsm/min 350
lmg/min NAC = 0.32 mOsm/min 320
A review of the literature on the effect of hyperosmolar solutions suggests that
this could be responsible for the vasodilatory action of NAC. Overbeck and
Grega (1970), infused hypertonic sodium chloride solutions at a rate of 1,2 and
4 mOsm/min (of osmolarity 393, 512 and 750 mOsm/L respectively) into the
brachial arteries of control subjects and reported vasodilatation. However, they
used jet infusions at a rate of 8.2 ml/min, which is much higher than our rate of
1 ml/min.
Bank et al, (1992) infused saline of osmolality 280 mOsm/Kg, 480 mOsm/Kg
and 660 mOsm/kg into brachial arteries of control subjects and those with
congestive cardiac failure. Once again the rate of infusion used (5ml/min for 2.5
minutes) was much higher than our infusion rate. However, they demonstrated
that in the normal subjects, hyperosmolal infusions of 480 and 660 mOsm/Kg
increased forearm blood flow by 3.12 + /- 0.4 and 6.8 +/- 0.67 ml/min/dL
forearm volume respectively, both p <0.001 compared with isosmolal infusions.
In contrast, the effect on patients with cardiac failure was less though significant
as compared with isotonic infusions.
It is fascinating to postulate mechanisms by which hyperosmolar solutions could
mediate vasodilation:
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1 Dehydration of cell wall structures or surrounding tissue leading to a
passive increase in vascular lumen. To support this hypothesis a study by
Overbeck et al (1961) demonstrated that dog forelimb weight decreases
during intra-brachial arterial administration of hypertonic solutions in
the face of reduced vascular resistance, indicating movement of fluid
from the extravascular to the intravascular space and extraluminal
dehydration.
2 Inhibition of smooth muscle myogenic tone. There are reports indicating
that hypertonicity produces negative chronotropic and inotropic effects
on isolated vascular smooth muscle (Mellander et al, 1967).
3 Sympathetic inhibition.
4 Electrolyte shifts (Haddy, 1960). This is perhaps unlikely as there is
similarity of the vascular responses to equally hypertonic dextrose and
saline in the limbs ofman (Overbeck and Grega, 1970). However there
is a possibility that an increase in viscosity produced by hypertonic
dextrose and not by hypertonic saline may have masked a difference in
effect. Amore conclusive statement about specific vascular effects of the
sodium ion might be made if you could observe response to changes in
the concentration of the sodium ion alone in the absence of possible
interaction with changes in plasma osmolality, but unfortunately it is
impossible to increase plasma sodium significantly without increasing
plasma tonicity unless some other plasma constituent is simultaneously
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removed and such removal might also produce vasoactive effects or
interaction.
5 Changes in blood viscosity. This would be due to reduced concentration
and size and increased aggregation or deformity of red blood cells.
However the study of Overbeck and Grega (1970) showed no alteration
in haematocrit.
6 Changes in plasma or cellular concentrations of vasoactive chemicals.
Such mechanisms remain to be studied.
In order to test the hypothesis that the hyperosmolarity of NAC solutions could
account for the vasodilation in cirrhotic subjects and normal controls an
experimental design for a further forearm blood flow study is proposed. The
study group would consist of 6 control subjects and 6 patients with cirrhosis
(with a spread of Child's Pugh gradings). Each subject would have to attend on
two occasions:
1 on one occasion they would be given a cumulative incremental dose of
NAC (lmg/min, 3mg/min, lOmg/min, 30 mg/min,100 mg/min and all at
infusion rates of lml/min), for 6 minutes each.
2 on the other occasion they would receive incremental increases in
osmolarity of NaCl solutions for six minutes each, equivalent to the
osmolarities of the NAC infusions:
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Sodium chloride 1.8% for infusion has an osmolarity of 616 mOsm/L
and Sodium chloride 2.7% has an osmolarity of 924 mOsm/L. Therefore,
the following method of making up desirable osmolarities of NaCl in the













26.04 in 50 ml
ie 0.67 mOsm/ml
20 ml of 30 ml of
0.62 mOsm/ml 0.31 mOsm/ml
(Total mOsm
contribution 12.4 + 9.3 in 50 ml
= 430) ie 0.434 mOsm/ml
7 ml of 43 ml of
0.62 mOsm/ml 0.31 mOsm/ml
(Total mOsm
contribution 4.34 + 13.33 in 50 ml
= 350) ie 0.353 mOsm/ml
2 ml of 48 ml of
0.62 mOsm/ml 0.31 mOsm/ml
(Total mOsm
contribution 1.24 + 14.88 in 50 ml
= 320) ie 0.322 mOsm/ml
All solutions would be infused at a rate of 1 ml/minute
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NOT ALL VASODILATORS ARE THE SAME
It is fascinating that both N-acetylcysteine and Isosorbide-5-mononitrate are
vasodilators yet appear to have differing haemodynamic actions in other
respects in patients with cirrhosis.
For example Is-5-Mn causes reduced cardiac index (Hayes et al, 1988) but NAC
increases it (Section III). NAC has no effect on estimated liver blood flow but
Is-5-Mn has been shown to reduce liver blood flow (Hayes et al, 1988). Both
vasodilate; for Is-5-Mn this results in a fall in mean arterial blood pressure that
is dose-dependent (Section II) but for NAC there is no change in overall blood
pressure.
NAC has no effect on mean hepatic venous pressure gradient but either 10 mg
Is-5-Mn or 40 Mg Is-5-Mn were capable of producing a marked sustained
reduction in HVPG. Neither Is-5-Mn or NAC appeared to have significant
action onWHVP.
Thus not all vasodilators are equal and it may not be possible to predict the
haemodynamic effects of one from knowledge of another.
Such haemodynamic differences between different vasodilators may result from:
i) different molecular or subcellular mechanisms of action
ii) actions on different vascular beds
iii) activation of different reflex mechanisms, for example, the marked blood
pressure fall in response to Is-5-Mn triggers splanchnic reflex
vasoconstriction, which lowers the HVPG.
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iv) shifts in central blood volumes may alter the ability to respond to
vasodilators - this may not show up in local vascular studies, such as
section IV, but shows up with systemic haemodynamic studies in vivo
(such as Section III) and points to the importance of such studies.
v) hyperosmolar effects
Also by contrast to nitrate action is the effect of theophylline in patients with
cirrhosis. Theophylline is an adenosine receptor antagonist and at a dose of
6mg/kg induced a significant increase in heart rate and reduction of right atrial
pressure, stroke volume and systolic arterial pressure. In contrast, oxygen
consumption or sympathoadrenal activity and all other haemodynamic values
(including azygos blood flow) were unaltered. Thus theophylline causes a
decrease in stroke volume which lowers systolic arterial pressure but, unlike
nitrates, does not have a reflex vasoconstrictor effect on splanchnic or systemic
circulation (Moreau et al, 1992).
THE PHARMACOKINETICS OF N-ACETYLCYSTEINE
A new method has recently been described for detection ofNAC using
reductive cleavage with tributylphosphine and post-HPLC column derivatisation
with omicron-phthalaldehyde (Gabard and Mascher, 1991). Using this method,
endogenous average concentrations of 0.08 micromol were measured in 10
volunteers participating. After a single oral dose of exogenous NAC (200mg)
the drug was detected in plasma for up to 12h after administration; the Cmax
values were up to 20 times the endogenous levels. The sensitivity of this method,
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though of no value to our intravenous pharmacokinetic study (where the
sensitivity of the assay was adequate to follow drug concentrations for up to 10
hours), should enable the behaviour of smaller doses of NAC after oral
administration to be properly described and bioavailability studies to be
performed (Gabard and Mascher, 1991).
More interestingly perhaps this method could be used to assess if endogenous
NAC concentrations were higher in patients with cirrhosis; this might account
for the apparent lack of tolerance that these individuals show to nitrates. NAC
concentrations have been found in the urine of patients with chronic liver
disease (Martennson et al, 1992). The fact that the Cmax was not significantly
different between our control and patient groups in Section V rules out the
possibility that endogenously high levels are responsible for the
pharmacokinetic differences observed between patients and controls. From the
above we would anticipate that the endogenous NAC concentrations would be
l/60th of that achieved by intravenous dosage in our study (Section V).
We have demonstrated that the pharmacokinetics of N-acetylcysteine are
altered in chronic liver disease. Our assay measures TOTAL plasma NAC i.e.
total oxidised and reduced NAC, and NAC bound to other thiols and proteins.
Borgstroem et al, 1986 and 1990 method assayed NAC in deproteinised plasma,
not total NAC. The variety of forms in which NAC is found make data
comparison with other studies difficult. In addition, administration ofNAC may
displace homocysteine and cysteinylglycine from their protein sites by
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disulphide interchange reactions. This leads to formation of mixed
low-molecular weight cysteine and NAC disulphides with high renal clearance
(Hultberg et al, 1994). Thus studying the kinetics of NAC is very difficult
indeed.
Despite this the normal control results were broadly comparable in terms of
area under the curve and estimated half-life of the drug between previous
studies ours (Section V). Borgstroem however found that the kinetics
conformed to a triphasic pattern whereas we found all our data fitted a biphasic
(2 compartment model). Clearance was impaired and thus the area under the
curve was different in those with cirrhosis (Section V). The volume of
distribution at steady state was consistent with a distribution mainly to
extracellular water. The volume of distribution at steady state was the same in
both our control and cirrhotic patient groups and the control group values were
similar to previous reports.
If hepatic flow were estimated 650 ml/min, the hepatic extraction ratio could be
calculated from previous studies as 0.26 for NAC i.e. NAC is a drug with a low
extraction ratio. In cirrhosis drugs with a high extraction ratio tend to have high
peak values but normal half-lives whereas low extraction drugs have normal
peak values but longer half-lives. Hepatic vein catheter studies (Pessayre et al,
1978) would allow us to calculate the hepatic extraction of N-acetylcysteine
directly and would also allow the estimation of liver blood flow by the ICG
method which would allow an estimation of the importance of flow to altered
hepatic metabolism to be established.
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The data in this study supports the proposal that shunting is not a very
important factor in NAC pharmacokinetics as there is reduced clearance but
not a high Cmax.
Implications of the finding that the pharmacokinetics of N-acetylcysteine is
altered in chronic liver disease for the studies reported in this text
The implications of the finding that the pharmacokinetics of N-acetylcysteine
are altered in chronic liver disease are that haemodynamic comparison with
normal controls is difficult as it would be difficult to model an equivalent
dosage regime for patients with liver disease.
The results seen in the forearm blood flow studies (Section V) were the same in
patients with chronic liver disease as normal controls but the forearm blood
flow model aims to evaluate only the local haemodynamic actions of drugs in
the forearm, and we would not necessarily expect altered metabolism of the
drug for example by the liver in cirrhosis to have a significant impact on this.
The clinical implications of the altered pharmacokinetics of N-acetylcysteine in
chronic liver disease
The study described in Section V may however have clinical implications in the
treatment of paracetamol poisoning in patients with underlying cirrhosis. Bray
et al (1991) have recently shown that chronic alcohol intake above suggested
safe drinking limits is an adverse prognostic feature in cases of severe
paracetamol overdose. This effect is partly related to increased nephrotoxicity.
A recent working group on paracetamol poisoning has therefore suggested that
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patients with induced liver enzymes, including those who drink in excess of the
currently recommended safe drinking limits, should be treated with NAC at
lower plasma paracetamol levels than would normally be considered as a
treatment threshold; thus more patients with chronic liver disease may be
exposed to N-acetylcysteine therapy than were seen in the past.
A recent study has demonstrated that acute ethanol administration reduces the
antidote effect of N-acetylcysteine after acetaminophen overdose in mice
(Dalhoff et al, 1991). In the NAC group the survival rate was 85%. This rate was
significantly reduced to 43% in the NAC + ethanol group (p = 0.0001).
Perhaps the dosage schedule for intravenous NAC requires modification for
patients with chronic liver disease in the light of the findings reported in this
thesis as both the pharmacokinetics and systemic haemodynamics appear to be
altered in the presence of liver disease.
Prescott and colleagues found that "adverse reactions invariably occur early
when plasma concentrations are at their highest, and liver damage was
prevented just as effectively at the lowest as at the highest Cmax" (Ho
and Beilin, 1983; Mant et al, 1984; Donovan et al, 1987; Prescott et al, 1989) i.e
high plasma concentrations ofNAC are likely to predispose to adverse drug
reactions including flushing, urticaria, hypotension and bronchospasm.
Typically, these "anaphylactoid" reactions occur shortly after starting therapy at
a time when the concentration of NAC is at the highest. However it should be
noted in Section V that the Co values were not significantly different between
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patients with liver disease and controls and so an increase in anaphylactoid
reactions would not be expected in chronic liver disease patients.
The dosage regimen for treatment of paracetamol poisoning with intravenous
NAC was originally chosen on an arbitrary basis; its efficacy was known to fall
off rapidly when treatment was delayed beyond 8 to 10 hours and the aim was to
give the highest tolerable dose for a short period in the hope of reversing the
events leading to hepatic necrosis at a critical stage (Prescott et al, 1977). This
regimen, although of proven value in the treatment of paracetamol poisoning, is
unlikely to be the most optimal one.
The results in Sections III and V imply that we should be more vigilant for
adverse effects to N-acetylcysteine in those with chronic liver disease and we
should consider modification of the current paracetamol overdose treatment
regime with N-acetylcysteine for those with chronic liver disease. The last
suggestion would be difficult as a study using "dose-response" to NAC in
paracetamol poisoning would be unethical and whilst it is reasonably simple to
model NAC kinetics it is not easy to model the hepatoprotective effect of the
drug by as yet an unknown mechanism (sulphydryl donation, free radical
scavenging and a variety of other mechanisms of action have all been
proposed).
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CONCLUSIONS OF "HAEMODYNAMIC STUDIES IN CIRRHOSIS"
• Either 10 mg or 40 mg bd oral Is-5-Mn were effective in reducing HVPG
and there was no evidence of tolerance when a nitrate free interval was
used in patients with cirrhosis. The 40 mg dose caused greater systemic
haemodynamic change than the 10 mg dose. The azygos vein blood flow
response to nitrate appeared to relate to initial flow rather than to dose of
nitrate used or severity of liver disease; this requires a prospective study to
confirm the observation.
Further studies need to identify if the greater haemodynamic disturbance
of the 40 mg dose of nitrate compared with the 10 mg dose translates into
greater renal disturbance.
Multicentre large randomised clinical trials are needed to evaluate the
clinical efficacy of Is-5-Ms alone and in combination with propranolol in
preventing variceal bleeding.
Intravenous N-acetylcysteine administration increased cardiac index and
tissue O2 delivery in patients with cirrhosis but tissue O2 consumption was
not increased. NAC had no haemodynamic action on the portal system.
NAC was a potent peripheral vasodilator in patients with cirrhosis and
normal controls.
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Further studies are required to determine if this is due to its
hyperosmolality. As NAC is hypertonic it is vital that one uses hypertonic
solutions as controls for both local and systemic haemodynamic studies in
future, ie 5% dextrose was not, with hindsight, the best possible control
solution for the study in Section III.
Further studies are also required into the mechanism of action ofNAC as a
positive inotrope. The development of a variety of specific inhibitors (eg
L-NMMA) should make this task easier.
The time course of the haemodynamic action ofNAC requires further
investigation as NAC infusions are used over many hours in clinical
medicine. It would be particularly interesting to discover if the
vasodilatation and positive inotropic action persist throughout the time of
infusion.
• The clearance ofNAC was impaired in patients with chronic liver disease.
This lends support to the hypothesis that NAC is cleared by the liver.
Further studies are needed to evaluate if the clearance ofNAC is impaired
in patients with fulminant hepatic failure and if modification of the dosage
regime for such patients is required. Observations for adverse
haemodynamic effects in patients with impaired liver function who are
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BASELINE CHARACTERISTICS OF THE
10 mg AND 40 mg Is-5-Mn STUDY GROUPS







n= 12 n = 13
Mean age ±
SEM
59.4 ±3.3 56.0 ±2.3 p > 0.32 (NS)
Age range (yrs) 42-74 40-71
Sex 8 female: 4 male 10 male: 3 female
Aetiology 10 ALC: 2PBC




8.0 ±0.6 8.1 ±0.6 p > 0.5 (NS)
Serum bilirubin
(umol/L)
55.8 ± 16.0 50.4 ± 12.9 p > 0.05 (NS)
Serum albumin
(g/L)
34.4 ± 1.7 32.2 ± 1.7 p» 0.5 (NS)





















Appendix IV DENSITY AT 805 nm
1
a optical density at
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% concentration in mg
Mean optical density of peripheral venous blood = 0.550
Mean optical density of hepatic venous blood = 0.455
Patients' haematocrit = 0.414
Rate of infusion of ICG = 0.25 mg/min
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Appendix V
The azygos vein
The azygos vein is formed on the right side of the anterior aspect of the twelfth thoracic
vertebral body by the union of the right subcostal vein and the right ascending lumbar vein
which emerges from the upper part of the right psoas major muscle.
The vessel passes directly up the right side of the anterior aspect of the vertebral column,
covered on its lateral side by the most posterior part of the mediastinal pleura In front of
the fourth thoracic vertebral body it turns forwards towards its junction with the superior
vena cava and the anterior part of the mediastinum; it is at this point that the azygos
catheter is introduced, via the superior vena cava.
The azygos vein receives all the right posterior intercostal veins except the first. The
second, third and fourth are received through a common trunk called the right superior
intercostal vein, and other individually. These tributaries leave their respective intercostal
spaces, pass behind the sympathetic trunk and incline forwards across the lateral aspects of
the vertebral bodies. The azygos vein is also joined by visceral tributaries from the right
extrapulmonary bronchi and from the oesophagus.
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Appendix Via
A sample azygos blood flow recording
a = flow prior to 40mg Is-5-Mn
b = flow at 30 minutes after ingestion of 40mg Is-5-Mn
c = flow at 60 minutes after ingestion of 40mg Is-5-Mn
The baseline variations seen in the trace reflect the effect of respiration
on the azygos blood flow.
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Appendix VIb
Before blood flow can be measured, each trace must be expanded (a).
This also allows the artifact of the first few seconds of the recording to
be omitted and the figures taken from the steady part of the trace.
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Key to appendices VII - X
A = heart rate increase (bpm) from baseline value to t=60, 1st study
B = heart rate increase (bpm) from baseline value 1 st study to baseline 2nd
study
C = heart rate increase (bpm) from baseline value 1 st study to t=60, 2nd
study
D = mean arterial blood pressure (mmHg) fall from baseline value to t=60, 1 st
study
E = mean arterial blood pressure (mmHg) fall from baseline value 1 st study to
baseline 2nd study
F = mean arterial blood pressure (mmHg) fall from baseline value 1 st study to
t=60, 2nd study
G = Wedged Hepatic Venous Pressure (mmHg) fall from baseline value to
t=60, 1st study
H = Wedged Hepatic Venous Pressure (mmHg) fall from baseline value 1 st
study to baseline 2nd study
I = Wedged Hepatic Venous Pressure (mmHg) fall from baseline value 1 st
study to t=60, 2nd study
J = Free Hepatic Venous Pressure (mmHg) fall from baseline value to t=60, 1st
study
K = Free Hepatic Venous Pressure (mmHg) fall from baseline value 1st study
to baseline 2nd study
L = Free Hepatic Venous Pressure (mmHg) fall from baseline value 1st study
to t=60, 2nd study
M = Hepatic Venous Pressure Gradient (mmHg) fall from baseline value to
t=60, 1 st study
N = Hepatic Venous Pressure Gradient (mmHg) fall from baseline value 1 st
study to baseline 2nd study
O = Hepatic Venous Pressure Gradient (mmHg) fall from baseline value 1 st
study to t=60, 2nd study
356
P = Azygos vein blood flow reduction (mL/min) from baseline value to t=60, 1st
study
Q = Azygos vein blood flow reduction (mL/min) from baseline value 1st study
to baseline 2nd study
R = Azygos vein blood flow reduction (mL/min) from baseline value 1st study
to t=60, 2nd study
S = serum albumin in g/L
T = prothrombin time (ratio)
U = serum alanine aminotransferase in U/L
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measurements from baseline values
in response to lOmg Is-5-Mn.
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A B C D E
A 1. 000
D <0J)86) l.ogo
C Co. 8327 Co. 7 7 0) 1 . 000
D -0.253 -0.336 -0.287 1 . 000
E -0.031 -0.218 -0.265 0.359 1 . QOQ
F 0. 206 0.218 -0.021 0.177 CO.821)
G -0.191 -0.127 -0.551 0.191 OT251
II 0.088 0.000 -0.265 0.515 0. 605
1 0.338 0.101 0. 000 0 . 530 0.316
J -0.468 -0.110 -0.613 0.111 0. 387
K <Z0.121J -0.319 -0.183 0.159 0.119
I, -O'.l'lB -0.117 -0.017 0 . 622 0.056
II ,.0-118 -0.059 -0.271 0.127 -0.025
N Co. 686.) 0.133 0.276 0.031 0 . 059
0 on i T 0.170 -0.111 -0.151 0.153
F 0.050 -0.317 -0.033 -0.160 -0.092^
O 0.025 -0.000 0.151 -0.227 CO- 6§6-7
R -0.181 -0.033 0.117 -0.160
5
"
-0.382 ' 0.081 """ -0.361 -5.215 -07092
T 0.181 -0.213 -0.009 -0.352 0 .368
11 -0.159 -0.317 0.151 0.378 -0.201



































































S <573 3 T 0. 360 "njrosr -0.198 0 : 11 3 ""
T 0.158 -0.006 -0.316 -0.378 -0.212
11 -0.118 -0.198 -0.111 -0.202 -0.175
V 0.213 0.253 0.075 0.031 -0.161
K L H N 0
K 1 . 000
L 0.126 1 . 000
11 -0.300 -0.502 1 . 000
N -0.601 -0,366 0.563 J.QOO
0 -0.528 <^0.66) (0.786) Cs^8 3l> 1 . 000
F -0.113 -07051 -0.050 -0.233 -0.051
0 -0.117 -0.111 0.126 -0.267 -0.153
































CO . 9QCP 1 . 000
S 0 .285 0 .368 0.203 "■17 000
T 0.151 -0.026 -0.136 0.017
U 0.183 0.533 0.617 -0.151





Appendix VIII u i.ooo
V 0.0671.000
Matrix of Spearmans' Rank Correlation between changes in
haemodynamic variables and plasma bilirubin, albumin, ALT and PTR
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Change in haemodynamic parameters
from baseline values in response
to 40 mg Is-5-Mn.
360
MATRIX OF SPEARMAN CORRELATION COEFFICIENTS
A n C D E
A 1 .000
D -0.321 1.000
C -0.093 (If. 695) 1^000
D -0.268 -07586 CSo • 681) 1 . 000
E 0. 218 -0.580 ^071^2 0.133 1 .000
F -0.151 -0.353 -0.319 0.150 (57555)
G -0.189 -0.312 -0.527 0.541 -0.075
I! -0.178 0.536 0.559 -0.213 -0.612
I -0.378 0.127 0.063 0 .293 -0.477
,1 -0.076 -0.153 -0.110 0.211 0.127
K -0.581 0. 255 0. 132 0 . 035 0.218
L -0.528 0. 205 0. 150 0. 170 0.059
M -0.089 -0.025 -0.246 0.319 -0.269
N 0.215 0.153 (0.7 51) -0.588 <SJL24§)
0 0.102 0.313 0. 597 -0.126 -0.58)
F -0.385 0.211 -0.109 0 . 033 -0.083
Q -0.075 0 .528 0.171 -0.617 0 . 083
R -0.050 (0 77 8 2) 0.179 -0.183 -0.233
sT -0.111 -0.168 -0.034 0.433 -0.400
T 0.119 -0.017 -0.089 -0.414 0.287
U -0.115 0 . 173 0.008 0. 192 -0.561
V 0. 092 0. 370 0. 303 -0.483 -0.100



















































































K L M N 0
K 1 . OQP
L (0. 921) 1 . 000
M -S7D?2 -0.068 1 . 000
M -0.413 -0.291 0.076 1 j.QQO
0 (j 0 . 63^) -0.519 0. 202 Co. 9ih 1 . 000
P "U70IT -0.251 0.588 -07I0T -0.009
0 0.113 -0.111 -0.555 0.101 0 . 051
R 0. 052 -0.127 -0.151 0. 269 0.272
S -0.014 0.136 0 . 269 0.131 0.013
T 0.291 0.099 0. 238 -0.171 -0.185
0 -0.215 -0.102 -0.156 0.152 0.085
V -0.035 -0.093 -0.012 0. 227 0.272
P 0 R s T
F 1 . 000
0 0. 200 1 . 000
R 0.333 CO: 933) 1 . 000
3 -0.000 (P 0. 6J13 Co.itT} 1.03TT
T 0.312 07579 0.388 Cr0.69?) 1 . 000
U -0.075 0.012 0. 109 g.^32 6 -0.364
V 0 . 083 0.550 (5. 750) (=g^nj> (777650)
Appendix X „ IP00
v 0.101 1.000
Matrix of Spearmans' Rank correlations between changes in
haemodynamic variables and plasma bilirubin, albumin, ALT and PTR



















































































































































































































































KEY:CO=cardiacoutputinLVmin,Wtb yweighgramsHtheight ,Priat alpressurem Hg,PAP nfrepul onaryeryrWP arterywedgepr ssureinmmHg,S02=saturationoxygen(%),PO2=tialpressurkP ),a er alvenous.
Key to appendices XIII and XIV
A = serum bilirubin in pmol/L
B = serum albumin in g/L
C = prothrombin time (ratio)
D = heart rate increase (bpm) from baseline to t=30 minutes
E = fall in mean arterial blood pressure (mmHg) from baseline to t=30 minutes
F = fall in right atrial pressure (mmHg) from baseline to t=30 minutes
G = fall in pulmonary artery pressure (mmHg) from baseline to t=30 minutes
H = fall in pulmonary capillary wedge pressure (mmHg) from baseline to t=30 minutes
I = rise in cardiac index (L/min/m2) from baseline to t=30 minutes
J = reduction in femoral artery p02 (kPa) from baseline to t=30 minutes
K = reduction in femoral artery oxygen saturation (%) from baseline to t=30 minutes
L = increase in femoral vein p02 (kPa) from baseline to t=30 minutes
M = increase in femoral vein oxygen saturation (%) from baseline to t=30 minutes
N = reduction in pulmonary artery p02 (kPa) from baseline to t=30 minutes
O = reduction in pulmonary artery oxygen saturation (%) from baseline to t=30 minutes
P = reduction in free hepatic venous pressure (mmHg) from baseline to t=30 minutes
Q = increase in estimated liver blood flow (mmHg) from baseline to t=30 minutes










































































































































































































































































































































































































































AppendixXIV MatrixofSpearmans'R nkCo rela ionsb tweench ngeihae dy amicvariabldpl smailirubi , albuminndprothro br tioinesponsetN-acetylcysteine. (Statisticallysignificantvaluesthe95%le lrr ged)

























































































































































































NAC dose 0 1 3 10 30 100 300
(mg/min) 4.91 4.67 4.68 4.39 4.29 4.8 4.36
3.8 5.7 5.5 4.4 3.57 4.16 4.43
2 2.36 1.58 0.45 0.18 0.64 0.76
4.17 3.66 3.38 4.12 3.89 3.69 3.76
2.52 1.54 1.39 1.54 1.39 1.43 1.86
4.08 3.55 3.93 1.6 1.44 1.48 1.93
Mean blood flow 3.58 3.58 3.41 2.75 2.46 2.7 2.85
± SEM 0.45 0.65 0.67 0.72 0.69 0.7 0.63
p > 0.1 p > 0.5 p > 0.5 p>0.1 p < 0.05 p < 0.05 p<0.01
Statistical comparison between flow in infused and control arm at each dose (paired t-
test)
INFUSED ARM
NAC dose 0 1 3 10 30 100 300
(mg/min) 2.89 4.21 4.58 3.52 4.21 11.39 13.64
4.09 4.20 4.38 4.40 4.60 6.65 10.63
2.23 2.51 1.56 0.37 0.46 0.72 1.26
5.46 5.16 4.58 5.35 5.02 6.22 9.94
5.88 3.52 3.32 3.33 3.40 5.05 6.57
4.47 3.38 3.59 3.35 3.42 5.09 6.61
Mean blood flow 4.17 3.83 3.67 3.39 3.52 5.85 8.81
± SEM 0.58 0.37 0.47 0.68 0.66 1.4 1.75
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NAC dose 0 1 3 10 30 100 300
(mg/min) 2.32 2.00 2.48 2.43 2.56 2.97 3.14
2.69 2.59 2.42 2.57 3.37 3.77 3.45
2.82 3.12 3.15 3.06 3.08 3.00 4.68
3.63 2.85 2.78 2.62 2.68 2.64 3.25
2.75 2.72 2.60 1.99 2.33 2.39 2.17
3.88 3.9 3.51 2.64 2.10 1.92 2.13
Mean blood flow 3.02 2.86 2.82 2.55 2.69 2.78 3.14
± SEM 0.25 0.26 0.17 0.14 0.19 0.26 0.38
p» 0.5 p > 0.5 p > 0.5 p>0.1 p>0.1 p < 0.05 p<0.01
Statistical comparison between flow in infused and control arm at each dose (paired t-
test)
INFUSED ARM
NAC dose 0 1 3 10 30 100 300
(mg/min) 2.19 2.28 2.49 2.64 2.91 5.15 9.83
3.07 3.27 3.15 7.01 6.42 12.38 26.7
3.68 4.06 4.37 4.9 6.06 7.98 13.14
3.0 2.53 2.7 2.83 2.46 3.50 8.41
3.11 2.99 2.72 2.79 2.51 4.63 8.54
2.97 2.74 2.61 1.94 1.70 3.77 9.70
Mean blood flow 3.00 3.00 3.00 3.69 3.68 6.24 12.72
± SEM 0.19 0.26 0.29 0.78 0.83 1.39 2.88
Appendix XVIII
Forearm blood flow response to N-acetylcysteine in patients with cirrhosis
(ml/dL forearm/minute)
CONTROL GROUP (n=6)
NAC dose 0 1 3 10 30 100 300
(mg/min) 0.83 0.93 0.92 1.0 -7.36 1.69 2.85
1.33 1.42 1.36 1.32 1.30 1.69 2.68
2.42 2.33 2.43 2.19 2.47 3.54 3.53
1.09 0.97 0.92 2.12 2.39 3.43 3.41
1.11 1.11 0.74 1.01 10.7 1.4 2.62
0.78 0.74 0.83 0.82 1.18 2.71 3.09
Mean ratio of 1.26 1.25 1.20 1.41 1.78 2.41 3.03
infused/control
arms
+ SEM 0.25 0.24 0.26 0.24 0.27 0.39 0.15
p>0.1 p>0.1 p > 0.5 p > 0.5 p>0.1 p >0.5 p >0.1
Statistical comparison between ratios in cirrhotic patients and controls (unpaired t-test)
CIRRHOTIC PATIENTS (N=6)
NAC dose 0 1 3 10 30 100 300
(mg/min) 0.77 0.71 0.75 1.74 0.82 1.97 5.4
1.14 1.15 1.08 1.43 1.11 2.15 4.12
0.85 0.89 0.98 1.08 0.92 1.33 2.61
1.32 1.32 1.40 1.62 1.98 2.71 2.83
1.15 1.29 1.31 1.38 1.91 3.33 8.23
0.95 1.16 0.99 1.08 1.14 1.76 3.41
Mean ratio of 1.03 1.09 1.09 1.22 1.31 2.21 4.43
infused/control
arms
± SEM 0.08 0.1 0.1 0.13 0.2 0.30 0.86
Appendix XIX
Forearm blood flow ratios (infused / control arm) in response to NAC in
cirrhotic patients compared with controls.
CONTROL GROUP (n=6)
NAC dose 1 3 10 30 100 300
(mg/min) 4.6. 0.27 -3 -4.7 24.3 97.2
8.0 12.7 1.8 14.5 64.6 63.7
-2 -7 115.5 142.4 248.5 246.6
-9.1 -39.4 -17.4 84.9 38 134.6
2.0 6.6 14.1 21.0 58.9 198.2
5.0 7.1 4.8 52.2 249 298
Mean % change 1.42 -3.29 19.3 51.72 113.9 173
in forearm flow in
rsponse to NAC
± SEM 2.5 7.7 19.7 22.3 43.1 36.8
p > 0.5 p > 0.5 p > 0.5 p >0.1 p »0.5 p >0.1
Statistical comparison between % change in flow to NAC between cirrhotic patiei
and controls (unpaired t-test)
CIRRHOTIC PATIENTS (N=6)
NAC dose 1 3 10 30 100 300
(mg/min) -16.8 -11.4 -12.9 -3.1 132.8 539
1.1 -5.9 24.5 -2.8 88.5 261.0
-7.3 1.82 12.8 -4.1 38.0 172.5
11.4 17.7 36.3 67.2 128.0 138.6
16.21 18.1 24.6 72.4 199.8 641.6
14.8 -2 7.55 13.3 74.6 233.7
Mean % change 3.24 3.05 15.5 23.82 110.2 331.9
in forearm flow in
response to NAC
± SEM 5.43 5.02 7.01 14.8 22.9 84.7
Appendix XX
Percentage change in forearm flow from baseline in response to NAC in
































































































































Sample HPLC trace showing glycylglycine and
N-acetylcysteine peaks eluted.
ANAL 14
J ' . O 5
th'C-tyo "C
4.583
S'KNF TIME RRT H I GHT I1K I D110 C 011C II A 11 E
1 3. 058 0.7944 1097644 E
•JC 3.85 1 3 6 2 6 7 V 1 I H T S T D
3 4 . 583 1.1905 5352 1
4 5. 775 1 . 5 1 1029
5 6.425 1 .6683 14O03
6 7.342 1 .9069 23540 2 23.8081 MAC
7 3.358 2.17 1 1 5 3 7 8
8 8.758 2.2749 2 7 4 7 1 V
TOTAL 1279357 23.8081
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Appendix XXIV
Each subjects pharmacokinetic analysis




Data set : C-|
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)*2
Parameters Half-life
<h )
Coef ( 1 ) (mg/1 ) : 9.8780
Exp ( 1 ) (1/h ) : 0.2291 3.0260
Coef ( 2 ) (mg/1 ) : 63.7039
Exp ( 2 ) (1/h ) : 1.6984 0.4081
Dose admin, (mg ) : 600.00
A.U.C. (h *mg/l ) (trapezoidal rule) :
between 0.0000 and 0.3300 : 19.6815
between 0.3300 and 7.0000 : 53.8080
between 7.0000 and infinity : 8.2948
Total AUC : 81.7843
% of total AUC extrapolated : 34.2074
MRT (Trapezoidal rule) : 2.5109
Total clearance/F (*) : 7.3364
Volume of distribution/F (beta phase) (+) : 32.0281




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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SIPHAR/PC : Version 4.0
Date: 12-14-1993 Time: 10:18:3
Title : NAC Data set : C-2
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)"2
Parameters Half-life
<h )
Coef( 1 ) (mg/1 ) : 14.1102
Exp ( 1 ) (1/h ) : 0.1930 3.5908
Coef( 2 ) (mg/1 ) : 61.0256
Exp ( 2 ) (1/h ) : 2.3703 0.2924
Dose admin, (mg ) : 600.00
A.U.C. (h *mg/l ) (trapezoidal rule) :
between 0.0000 and 0.3300 : 19.0964
between 0.3300 and 10.0000 : 70.3915
between 10.0000 and infinity : 11.3970
Total AUC : 100.8849
% of total AUC extrapolated : 30.2259
MRT (Trapezoidal rule) : 3.9047
Total clearance/F (*) : 5.9474
Volume of distribution/F (beta phase) (+) : 30.8100




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
379
SIPHAR/PC : Version 4.0
Date: 12-14-1993 Time: 10:20:0
Title : NAC Data set : C-J
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)"2
Parameters Half-life
(h )
Coef( 1 ) (mg/1 ) : 7.7808
Exp ( 1 ) (1/h ) : 0.1486 4.6631
Coef( 2 ) (mg/1 ) : 40.9172
Exp ( 2 ) (1/h ) : 1.0571 0.6557
Dose admin, (mg ) : 600.00
A.U.C. (h *mg/l ) (trapezoidal rule) :
between 0.0000 and 0.3300 : 14.7507
between 0.3300 and 10.0000 : 65.1525
between 10.0000 and infinity : 12.1093
Total AUC : 92.0125
% of total AUC extrapolated : 29.1917
MRT (Trapezoidal rule) : 4.2387
Total clearance/F (*) : 6.5209
Volume of distribution/F (beta phase) (+) : 43.8684




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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Data set : C-q
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)"2
Parameters Half-life
(h )
Coef ( 1 ) (mg/1 ) : 18.9760
Exp ( 1 ) (1/h ) : 0.2873 2.4129
Coef ( 2 ) (mg/1 ) : 199.8582







*mg/l ) (trapezoidal rule) :
0.0000 and 0.3300 : 54.0926
0.3300 and 8.0000 : 82.8015
8.0000 and infinity : 6.9621
Total AUC : 143.8562
% of total AUC extrapolated : 42.4415
MRT (Trapezoidal rule) : 1.7545
Total clearance/F (*) : 4.1708
Volume of distribution/F (beta phase) (+) : 14.5188




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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Data set : C-g
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s ), after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)"2
Parameters Half-life
<h )
Coef ( 1 ) (mg/1 ) : 19.1485
Exp ( 1 ) (1/h ) : 0.2263 3.0629
Coef ( 2 ) (mg/1 ) : 51.5092






(mg ) : 600.00
*mg/l ) (trapezoidal rule) :
0.0000 and 0.3300 : 22.4165
0.3300 and 12.0000 : 87.7505
12.0000 and infinity : 6.1864
Total AUC : 116.3535
% of total AUC extrapolated : 24.5828
MRT (Trapezoidal rule) : 3.4142
Total clearance/F (*) : 5.1567
Volume of distribution/F (beta phase) (+) : 22.7868




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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SIPHAR/PC : Version 4.0
Date: 12-14-1993 Time: 10:27:4
Title : Data set : C-
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least sguares algorithm
with the weighting factor = l/y(calc)"2
Parameters Half-life
(h )
Coef( 1 ) (mg/1 ) : 19.9982
Exp ( 1 ) (1/h ) : 0.2536 2.7337
Coef( 2 ) (mg/1 ) : 61.6822
Exp ( 2 ) (1/h ) : 2.9925 0.2316
Dose admin, (mg ) : 600.00
A.U.C. (h *mg/l ) (trapezoidal rule) :
between 0.0000 and 0.1700 : 12.0598
between 0.1700 and 8.0000 : 77.9090
between 8.0000 and infinity : 11.4371
Total AUC : 101.4059
% of total AUC extrapolated : 23.1712
MRT (Trapezoidal rule) : 3.1697
Total clearance/F (*) : 5.9168
Volume of distribution/F (beta phase) (+) : 23.3349




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations unit6
Total clearance and Volumes are computed assuming F=1
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Data set : P-J
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)~2
Parameters Half-life
<h )
Coef( 1 ) (mg/1 ) : 9.3748
Exp ( 1 ) (1/h ) : 0.1364 5.0817
Coef( 2 ) (mg/1 ) : 23.9649
Exp ( 2 ) (1/h ) : 0.6224 1.1137
Dose admin, (mg ) : 600.00
A.U.C. (h *mg/l ) (trapezoidal rule) :
between 0.0000 and 0.3300 : 10.1375
between 0.3300 and 10.0000 : 80.1285
between 10.0000 and infinity : 17.5954
Total AUC : 107.8614
% of total AUC extrapolated : 25.7116
MRT (Trapezoidal rule) : 5.2237
Total clearance/F (*) : 5.5627
Volume of distribution/F (beta phase) (+) : 40.7824




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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SIPHAR/PC : Version 4.0
Date: 12-14-1993 Time: 10:34:0
Title : Data set : P-Z
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)*2
Parameters Half-life
<h )
Coef( 1 ) (mg/1 ) : 34.6940
Exp ( 1 ) (1/h ) : 0.2488 2.7865
Coef( 2 ) (mg/1 ) : 722.6889
















Total AUC : 385.2025
% of total AUC extrapolated : 76.3123
MRT (Trapezoidal rule) : 1.3966
Total clearance/F (*) : 1.5576
Volume of distribution/F (beta phase) (+) : 6.2617




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit
(+) Volume unit =
dose units / AUC units
dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
385
SIPHAR/PC : Version 4.0
Date: 12-14-1993 Time: 10:35:0
Title : Data set : P-.1
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least sguares algorithm
with the weighting factor = l/y(calc)"2
Parameters Half-life
<h )
Coef( 1 ) (mg/1 ) : 16.6745
Exp ( 1 ) (1/h ) : 0.1173 5.9105
Coef( 2 ) (mg/1 ) : 29.9241
Exp ( 2 ) (1/h ) : 0.6483 1.0692
Dose admin, (mg ) : 600.00
A.U.C. (h *mg/l ) (trapezoidal rule) :
between 0.0000 and 0.3300 ; 14.5693
between 0.3300 and 10.0000 : 130.6325
between 10.0000 and infinity : 45.1935
Total AUC : 190.3953
% of total AUC extrapolated : 31.3888
MRT (Trapezoidal rule) : 6.8291
Total clearance/F (*) : 3.1513
Volume of distribution/F (beta phase) (+) : 26.8717




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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SIPHAR/PC : Version 4.0
Date: 12-14-1993 Time: 10:36:0
Title : Data set : P-4
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)~2
Parameters Half-life
(h )
Coef( 1 ) (mg/1 ) : 47.6307
Exp ( 1 ) (1/h ) : 0.1547 4.4805
Coef( 2 ) (mg/1 ) : 101.0034
Exp ( 2 ) (1/h ) : 2.7977 0.2478
Dose admin, (mg ) : 600.00
A.U.C. (h *mg/l ) (trapezoidal rule)
between 0.0000 and 0.3300
between 0.3300 and 10.0000




Total AUC : 350.5202
% of total AUC extrapolated : 31.1552
MRT (Trapezoidal rule) : 5.8697
Total clearance/F (*) : 1.7117
Volume of distribution/F (beta phase) (+) : 11.0647




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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SIPHAR/PC : Version 4.0
Date: 12-14-1993 Time: 10:36:5
Title : Data set : P-S
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)"2
Parameters Half-life
<h )
Coef( 1 ) (mg/1 ) : 17.9438
Exp ( 1 ) (1/h ) : 0.1530 4.5304
Coef( 2 ) (mg/1 ) : 41.9979
Exp ( 2 ) (1/h ) : 1.9054 0.3638
Dose admin, (mg ) : 600.00
A.U.C. (h *mg/l ) (trapezoidal rule) :
between 0.0000 and 0.1700 : 9.0900
between 0.1700 and 8.0000 : 95.8925
between 8.0000 and infinity : 35.9479
Total AUC : 140.9304
% of total AUC extrapolated : 31.9576
MRT (Trapezoidal rule) : 5.6219
Total clearance/F (*) : 4.2574
Volume of distribution/F (beta phase) (+) : 27.8264
Parameters computed using the fitted model :
Vdss (Volume at steady state)/F
AUC (0 - infinity)




(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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Data set : P-&
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)~2
Parameters Half-life
<h )
Coef ( 1 ) (mg/1 ) : 19.7529
Exp ( 1 ) (1/h ) : 0. 1180 5.8745
Coef ( 2 ) (mg/1 ) : 55.8024
Exp ( 2 ) (1/h ) : 2.7559 0.2515
Dose admin, (mg ) : 600.00
A.U.C. (h *mg/l ) (trapezoidal rule) :
between 0.0000 and 0.3300 : 19.3306
between 0.3300 and 10.0000 : 118.8435
between 10.0000 and infinity : 51.6978
Total AUC : 189.8720
% of total AUC extrapolated : 37.4086
MRT (Trapezoidal rule) : 7.5143
Total clearance/F (*) : 3.1600
Volume of distribution/F (beta phase) (+) : 26.7814




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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SIPHAR/PC : Version 4.0
Date: 12-14-1993 Time: 10:38:1
Title : Data set : P~7
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s ) , after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)"2
Parameters Half-life
(h )
Coef( 1 ) (mg/1 ) : 16.6456
Exp ( 1 ) (1/h ) : 0.1998 3.4694
Coef( 2 ) (mg/1 ) : 31.0225






(mg ) : 600.00
*mg/l ) (trapezoidal rule) :
0.0000 and 0.1700 : 7.2223
0.1700 and 8.0000 : 69.6810
8.0000 and infinity : 17.0179
Total AUC : 93.9212
% of total AUC extrapolated : 25.8090
MRT (Trapezoidal rule) : 4.4574
Total clearance/F (*) : 6.3883
Volume of distribution/F (beta phase) (+) : 31.9753




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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Data set : P-S
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(s), after I.V. bolus
The model has been fitted to data using weighted least squares algorithm
with the weighting factor = l/y(calc)"2
Parameters Half-life
(h )
Coef ( 1 ) (mg/1 ) : 26.7062
Exp ( 1 ) (1/h ) : 0.2089 3.3188
Coef ( 2 ) (mg/1 ) : 623.2614







*mg/l ) (trapezoidal rule) :
0.0000 and 0.1700 : 62.4723
0.1700 and 8.0000 : 101.3655
8.0000 and infinity : 27.7702
Total AUC : 191.6080
% of total AUC extrapolated : 47.0975
MRT (Trapezoidal rule) : 3.3327
Total clearance/F (*) : 3.1314
Volume of distribution/F (beta phase) (+) : 14.9930
Parameters computed using the fitted model :
Vdss (Volume at steady state)/F
AUC (0 - infinity)




(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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Data set : P-9
The minimization algorithm used is : POWELL
The structural model is :
Two exponential(6), after I.V. bolus
The model has been fitted to data using weighted least sguares algorithm
with the weighting factor = l/y(calc)"2
Parameters Half-life
<h )
Coef ( 1 ) (mg/1 ) : 19 . 3098
Exp ( 1 ) (1/h ) : 0.2473 2.8030
Coef ( 2 ) (mg/1 ) : 453.0135
Exp ( 2 ) (1/h ) : 13 . 1127 0.0529
Dose admin, (mg ) : 600.00
A.U.C. (h *mg/l ) (trapezoidal rule) :
between 0.0000 and 0.1700 : 45.8765
between 0.1700 and 8.0000 : 69.6590
between 8.0000 and infinity : 10.5141
Total AUC : 126.0496
% of total AUC extrapolated : 44.7368
MRT (Trapezoidal rule) : 2.4856
Total clearance/F (*) : 4.7600
Volume of distribution/F (beta phase) (+) : 19.2491




Vdss (Volume at steady state)/F
AUC (0 - infinity)
MRT (Mean residence time)
(*) Clearance unit = dose units / AUC units
(+) Volume unit = dose units / concentrations units
Total clearance and Volumes are computed assuming F=1
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Key to Appendix XXV
A = elimination half-life (hours)
B = total clearance (L/h)
C = mean residence time (h)
D = area under the curve mg/L x h
E = volume of distribution at study state
F = bilirubin (jimol/L)
G = ALT (iu/L)
H = albumin (g/L)
I = PTR ratio
J = age (years)
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Experimental data, fitting a calculated curve and
determining the equation for a pharmacokinetic
study.
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INTRODUCTION
Variceal hemorrhage is a major cause of morbidity
and mortality in cirrhosis. Pharmacological therapy of
portal hypertension aims to arrest acute variceal bleed¬
ing, prevent rebleeding or to provide prophylaxis for
patients who have not bled. The purpose of this review
is to discuss the pharmacology and hemodynamic ac¬
tion of organic nitrates and their clinical use in portal
hypertension.
PHARMACOLOGY OF ORGANIC NITRATES
Isosorbide dinitrate and isosorbide-5-mononitrate
(Is-5-Mn) are "long-acting" organic nitrates. The mon¬
onitrate is the active component and is formed from
dinitrates by rapid denitration in the liver (1-3). It is a
powerful venous and mild arterial dilator with dose-
dependent activity (4) and little first pass metabolism
(5). Is-5-Mn has a prolonged half-life (5 h) (5, 6) and
dose linear kinetics (7) even in the presence of liver
disease (8, 9) or renal failure (10). In contrast, the
dinitrate has a high first-pass effect with an apparent
oral bioavailability of 0.2 in normal subjects (II). This
increases up to a mean of 0.65 in cirrhosis because of
reduced hepatic extraction and the presence of porta-
systemic shunts (12). As these show interindividual
variation, the appropriate dosage of the dinitrate is
difficult to determine and the response is unpredictable
in patients with chronic liver disease (13). Such reasons
make Is-5-Mn preferable to other organic nitrates in
patients with cirrhosis.
Adverse reactions associated with nitrates are un¬
usual although mild headache resolving within 24 h of
the first dose occurs in up to one-third of patients (12).
The molecular mechanism of vasodilation by nitrates
is controversial. In 1977 two groups demonstrated a
dose-dependent increase in the levels of cyclic-guano-
Received June 16. 1993; accepted Sept 20. 1993
sine 5'-monophosphate (GMP) in smooth muscle after
nitrate administration (14, 15). Subsequently it was
shown that many other vasodilators, including nitric
oxide, activate soluble guanylate cyclase (16, 17). Some
vasodilators have been shown to generate nitric oxide
in a nonenzymic reaction with cysteine (18). However,
nitrates do not directly stimulate nitric oxide synthetase
as demonstrated by Vallance el al. (19) who showed
that glyceryltrinitrate infusion at 2 and 5 nmol/min to
human controls caused a dose-dependent increase in
forearm blood flow which was unaltered by L-tV-mon-
omethyl-arginine administration (a specific inhibitor of
nitric oxide synthetase). It therefore seems likely that
nitrates produce an increase in cyclic-GMP levels in
smooth muscle by direct action rather than via nitric
oxide synthetase and there is evidence for thiol inter¬
mediates as modulators of these cellular events (20).
ACUTE EFFECTS OF ORGANIC NITRATES ON
PORTAL AND SYSTEMIC HEMODYNAMICS
Animal studies
Vatner el al. (21) demonstrated that intravenous
nitroglycerin administration to normal dogs resulted in
a significant decrease in mesenteric blood flow after an
initial increase. The fall in mesenteric blood flow was
associated with a reduction in arterial pressure and an
increase in heart rate and it was suggested that nitrate-
induced venodilation resulted in baroreceptor-me-
diated mesenteric arterial vasoconstriction, a sympa¬
thetic response to vasodilation and venous pooling (a
reduction in preload accounting for the reduced cardiac
output).
In the portal vein-ligated rat (an experimental model
of portal hypertension) splanchnic vasoconstriction has
been demonstrated after nitrate administration
(22-24).
Other studies have demonstrated that nitrates may
reduce portal pressure by more than one mechanism,
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e.g., myofibroblasts have been demonstrated in a peri-
sinusoidal location in the cirrhotic liver and may be
involved in the increased resistance to portal flow (25).
In the isolated perfused cirrhotic rat liver, nitrates de¬
crease intrahepatic resistance (26). Nitrates may also
have a direct vasodilatory effect on the collateral cir¬
culation; high-dose nitrates given to portal vein-ligated
rats were shown to reduce resistance across collateral
vessels (24).
Human studies
In humans, noninvasive methods to assess portal
pressure, portal flow, and portal-systemic shunting are
limited. However, an invasive balloon catheter tech¬
nique allows measurement of the hepatic venous pres¬
sure gradient (HVPG = WHVP - FHVP) which is
similar to portal pressure in alcoholic cirrhosis (27) but
lower than portal pressure in nonalcoholic cirrhosis
(28).
A quantitative estimate of esophageal collateral cir¬
culation can be obtained by use of continuous ther-
modilution measurements in the azygos vein (29), the
site of drainage of esophageal varices, but is said to be
no better than portal pressure itself at predicting vari-
ceal bleeding.
Five studies have examined the systemic and portal
hemodynamic effects of nitroglycerin in patients with
cirrhosis (Table 1) and three showed a reduction of
HVPG following nitroglycerin administration (31. 32.
35). The effect on azygos blood flow was highly variable
including some individuals in whom flow increased,
suggesting vasodilation of portasystemic collaterals.
Mechanisms which might be responsible for this vari¬
able response include; 1. Vasorelaxation at sinusoidal
and collateral level leading to reduced resistance to flow
through the portal-collateral circulation and reduced
portal pressure. 2. Relaxation of arterial smooth muscle
lowering the arterial blood pressure and triggering high-
pressure arterial baroreceptors to cause reflex splanch¬
nic vasoconstriction. This would reduce portal inflow
and hence portal pressure. 3. Systemic venodilation
reducing the cardiac preload and thus activating low-
pressure cardiopulmonary baroreceptors. This would
also cause reflex splanchnic vasoconstriction, reducing
the portal venous inflow and thus reducing portal
pressure.
An important aspect of the acute nitroglycerin studies
in man (Table I) is the difference in doses used and the
hemodynamic effect of different doses of nitroglycerin
has been found to be heterogeneous (Table 1). This
suggests that different doses might act by different
mechanisms and raises questions about the compara¬
bility of these studies.
Seven groups have examined the acute hemodynamic
effects on cirrhotic patients given isosorbide dinitrate
by a variety of routes (Table 2). Only one group (37)
showed no effect on portal pressure: all others showed
a reduction in HVPG which was accompanied by a fall
in cardiac index and mean arterial blood pressure. The
reduction of HVPG was achieved by a significant fall
in WHVP rather than a rise in FHVP.
Table 3 shows that ls-5-Mn has the same hemody-
Table i
Acute Effect ofNitroglycerin Administration
Staritz Garcia-Tsao Westaby Moreau Rector lwao
1985(30) 1987 (31) 1988(32) 1989(33) 1990(34) 1991(35)
No. of patients 14 11 12 11 10 14
Dose, route, (1,2-mg spray (0.6 mgSL 2-12 (200 (jg/min iv (7-15 jig/min iv (40 (jg/min iv (Transdermal tape
time onto tongue) min peak change) peak change) peak change) peak change) 10 mg for 60 mini
SVRI* 1887-1784 1537-1581
WHVP 22.5-18.9t 28.7-25.8t 29.2-29.3 28-27 26.0-22.lt
HVPG I7.9-I5.lt 16.4-13.3f 20.9-21.1 16-16 17.9-I5.lt
AzBF 604-437 0.53-0.55 0.46-0.46
ELBF 1.34-1.10 925-919
HR 73—83f 84-97 82-89.5f 84-87 72-71
MABP 96—76t 95—79t 86.8-79.4t 89—74t 106.1-91.3t
CO/CI 4.11-3.29t 4.29—3.9t 7.0-6.3t





* SVRI, systemic vascular resistance index in dynes/s per m'; WHVP, wedged hepatic venous pressure in mm Hg; HVPG, wedged minus free
hepatic venous pressure in mm Hg; AzBF, azygos blood flow in ml/min; ELBF, estimated liver blood flow in ml/min (ICG method); HR. heart
rate in beats/min; MABP. mean arterial blood pressure in mm Hg; CO/CI, cardiac output/cardiac index in L/min; IOVP, interesophageal
variceal pressure in mm Hg.
t Denotes significant difference, at least at 95% level.
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Acute Effect of Isosorbide Dinitrate Administration
Blei Qureshi Mols Bhatia Merkel
1987 (12) 1988(40) 1989 (41) 1990(42) 1990 (43)
No. of patients 7 8 6 17 13
Dose, route, 10 mg oral 40 mg oral 5 mg SL 5 mg SL 5 mg SL 5 mg SL
time 1 h 4 h 1 h 4 h 20 min 15 min 20 min 25-35min
SVRI 1654-1537
WHVP 22.2-20.5$ 22.2-21.4 23.7-20.1$ 23.7-20.7$ 24.6-18.5$ 28-24$
HVPG 15.4-12.3$ 15.4-13.1 16.6-13.7$ 16.6-13.9$ 18-14$
AzBF No change
ELBF 650-710 in plasma
HR 70-72 70-72 82-86 82-81 86-94$ 92.5-102.6$ clearance
MABP 90-76$ 90-86$ 89-72$ 89-81$ 89-74$ 85.8-80.4$ of ICG
CO/CI 4.71-3.63$ 4.71-3.81$ 4.92-4.02$ 4.92-3.95$ 4.2-3.7
(a) (b) (b) (b) (b) (b)
lntrasplenic pulp 43.6 — 35.6$
pressure
* SL, sublingual.
t SVR1, systemic vascular resistance index in dynes/s per m5; WHVP, wedged hepatic venous pressure in mm Hg; HVPG, wedged minus free
hepatic venous pressure in mm Hg; AzBF, azygos blood flow in ml/min; ELBF, estimated liver blood flow in ml/min (ICG method); HR, heart
rate in beats/min; MABP, mean arterial blood pressure in mm Hg; CO/CI, cardiac output/cardiac index in L/min.
$ Denotes significant difference, at least at 95% level.
Table 3
Acute Effect of Is-5-Mn Administration
Hayes Tsai Navasa
1988(44) 1989 (45) 1989(46)
No. of patients 11 10 23
Dose, route, 20 mg Is-5-Mn 20 mg Is-5-Mn
time 60 min 60 min
20 mg or 40 mg ls-5-Mn 6U min
SVRI* 1831-2030$ 1131-1040 899-994$ 785-746
WHVP 33.3-29.8$ 21.8-21.0 23.5-21.9$ 26.9-23.3$
HVPG 23.9-21.8$ 17.8-16.3 18.3-16.5$ 19.9-16.1$
AzBF 0.52-0.51 0.74-0.62$
ELBF 1940-1639$ 890-1003$ 1320-1230
HR 85-89.7$ 71-72 90.4-90.7 85.8-84.8
MABP 90-88.9 92-82$ 88.4-81.3$ 87.8-69.8$
CO/CI 3.89-3.42$ 4.1-3.9 8.0-6.8$ 8.9-7.7$
(a) (b) (b) (a) (a)
* SVRI, systemic vascular resistance index in dynes/s per m5; WHVP, wedged hepatic venous pressure in mm Hg; HVPG, wedged minus free
hepatic venous pressure in mm Hg; AzBF, azygos blood flow in ml/min; ELBF, estimated liver blood flow in ml/min (ICG method); HR, heart
rate in beats/min; MABP, mean arterial blood pressure in mm Hg; CO/CI, cardiac output/cardiac index in L/min.
t Denotes significant difference, at least at 95% level.
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namic behavior as the dinitrate, with the exception of
one study which included mainly Child's A patients
(45).
An illustration of different dose-dependent mecha¬
nisms of portal hypotensive action may be seen by the
work of Nevasa el al. (46). The changes in cardiac
output and systemic resistance were similar with either
20 or 40 mg Is-5-Mn but after 40 mg Is-5-Mn there
were significantly greater reductions in portal pressure,
arterial blood pressure, and azygos blood flow.
These results are divergent from the study of Hayes
et al. (44) which indicated that following administration
of 20 mg ls-5-Mn the fall in portal pressure was asso¬
ciated with a fall in liver blood flow secondary to
baroreceptor mediated splanchnic vasoconstriction, a
response only observed with 40 mg of nitrate in Neva-
sa's study. Differences between studies may be related
to different severities of liver disease (and different
volumes of distribution of nitrate), different degrees of
portasystemic shunting, timing of Is-5-Mn administra¬
tion or different variceal bleeding histories. Other con¬
founding variables include impaired cardiovascular re¬
sponsiveness (33), baseline cardiac filling pressure (34),
and severity of liver disease (47).
Despite the potential complexity of action of nitrates
in portal hypertension, the overall results of studies of
acute administration of nitrates have been remarkably
uniform (Tables 2 and 3). The fall in portal pressure
seen after nitrates compares favorably with the effect of
propranolol but that, following nitrate administration,
the fall in HVPG was achieved by a fall in WHVP
alone [unlike propranolol which reduces HVPG by
both a fall in WHVP and a rise in FHVP (48-50)].
Reducing WHVP may be more important than reduc¬
ing HVPG in protection against variceal bleeds
(51,52).
EFFECT OF ORGANIC NITRATES ON LIVER
BLOOD FLOW AND HEPATIC RESISTANCE
Liver blood flow in hemodynamic studies is usually
estimated by indocyanine green dye (ICG) extraction
(53, 54). Calculations of hepatic resistance from data
in Tables 1-5 suggest that administration of organic
nitrates, either acutely or chronically, induces a signif¬
icant fall in portal pressure that is due largely to a
reduction in resistance rather than to a reduction in
liver blood flow (which would be undesirable) although
such calculation is of limited value as the variable
component of hepatic arterial flow is unknown. The
implication of the hepatic resistance calculation, how¬
ever, is either that portal flow is not reduced or that a
compensatory increase in hepatic arterial flow takes
place, i.e., reciprocity.
EFFECT OF ORGANIC NITRATES ON AZYGOS
(COLLATERAL) BLOOD FLOW
The rationale for the pharmacologic treatment of
esophageal varices was originally based on the obser¬
vation that drugs could reduce portal pressure (59).
Propranolol, the first drug studied, reduces the portal
pressure gradient in only 60% of patients with cirrhosis
but reduces variceal flow, as measured by azygos flow,
in all (59). It remains unclear whether the major benefit
of propranolol, which reduces primary and secondary
variceal bleeding (60). is by portal pressure reduction
or reduced azygos flow. Since the portal pressure reduc¬
tion is small and variable, the effect on collateral (azy¬
gos) flow may well be more important.
Nevasa et al. (46) showed that azygos blood flow
remained unchanged after administration of 20 mg
isosorbide-5-mononitrate despite a significant reduc¬
tion in portal pressure and cardiac output. As the
efficacy of vasoactive drugs in either controlling an
acute variceal bleed or preventing recurrent hemor¬
rhage may be related to their ability to reduce blood
flow through collateral vessels, determination of the
effects of vasoactive agents on both collateral blood
flow and portal pressure is important in evaluating their
therapeutic potential. In this respect the change in
azygos flow to nitrates is seen to be highly variable and
probably dose-dependent (Tables 2-5) and it would
seem important to find criteria, preferably noninvasive,
e.g.. blood pressure or heart rate changes, which would
make possible the selection of a dose of nitrate for an
individual that both reduces portal pressure and azygos
blood flow in order to properly assess its efficacy in
reduction of variceal bleeding in future clinical trials.
Chronic effect oforganic nitrates—Is tolerance a
problem?
Tachyphylaxis to nitrate preparations is well recog¬
nized in patients with heart disease given nitrates for
18 h or longer (61. 62). Organic nitrates are metabolized
by vascular smooth muscle as well as by the liver (63)
and tolerance is associated with an alteration of vascular
metabolism of the nitrate administered (63, 64); sys¬
temic clearance of administered nitrate diminishes and
the systemic arteriovenous nitrate gradient narrows.
i.e., with long-term dosing plasma nitrate concentra¬
tions rise over time. The cyclic-GMP response to ni¬
trates is also diminished in the presence of tolerance.
Administration of exogenous thiols, e.g.. Acetyl¬
cysteine, enhances the nitrate vascular effects in the
nontolerant state (65) and removal of organic nitrates
from contact with the blood vessel wall for a period of
time restores vascular responsiveness. Studies with iso¬
lated rat abdominal aortic rings (with endothelium)
showed they retained the repair mechanism to over¬
come tolerance without the need for exogenous factors,
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which suggests regulation of vascular responsiveness is
at the vascular level. Nitrate tolerance appears to be
related to reduced sulphydryl availability within vas¬
cular tissue and sulphydryl groups are required for
vasodilation.
Experience to date (Table 4 and 5) shows that a
sustained fall in portal pressure is seen after chronic
nitrate administration in cirrhotic patients, which sug¬
gests that full tolerance is not of concern in such pa¬
tients, although partial tolerance has been reported (58).
A recent report suggests that higher than normal
concentrations of A^-acetylcysteine are found in the
urine of patients with chronic liver disease and it would
be interesting to speculate that endogenous A-acetyl-
cysteine might be responsible for patients with cirrhosis
having less tolerance to nitrates than normal controls/
cardiac patients (66).
Clinical studies with cardiac patients indicate that
tolerance can be reversed by a nitrate free/nitrate poor
dosing interval (67, 68). It would seem a reasonable
precaution to observe these rules in prescription of
nitrates for patients with cirrhosis.
THERAPEUTIC POTENTIAL OF ORGANIC
NITRATES IN LIVER DISEASE
Nitrates in the management ofacute variceal bleeding
The most effective treatment for an acute variceal
bleed is injection sclerotherapy (69) or banding (70,
71). Either is effective only if promptly applied by
experienced personnel. Balloon tamponade has been
shown to be as effective as sclerotherapy (72), but is
similarly only effective in proficient hands; many pa¬
tients tolerate the balloon poorly and rebleeding within
hours of balloon removal is common (73).
It would therefore be desirable if drug therapy was
easy to use and efficacious in controlling bleeding,
particularly in nonspecialist centers. The first agent
used, vasopressin, is not particularly effective and has
serious side effects (74-76).
Several studies have shown that the addition of ni¬
trates to vasopressin produces additional reduction in
portal pressure at the same time counteracting some of
the deleterious systemic hemodynamic effects such as
reduced cardiac output and hypertension (32, 77-80).
Glypressin, an analogue of vasopressin (81), may
have less side effects than vasopressin (82) but no study
comparing them with vasopressin plus nitrates has yet
been reported.
Transdermal nitrate patches have been advocated but
much more reliable plasma nitrate levels are obtained
by the intravenous route (63), especially in a shocked
patient with compromised skin blood flow (83). In the
acute setting, vasopressin should be used at a dose of
0.4-0.8 U/min over 12 h plus a nitroglycerin infusion
at 0.2 mg/min for the duration of the vasopressin
infusion.
Nitrates for the prevention of rebleeding or prophylaxis
of first hemorrhage
Propranolol reduces the frequency of variceal hem¬
orrhage (84) but has less influence on mortality rates
Table 4
Chronic Effect of Isosorbide Dinitrate Administration
Freeman Cervinka Ikegami Vorobioff
1985 (38) 1989 (55) 1992 (56) 1992(57)
No. of patients 6 10 9 10
Dose, route, time 20 mg qds 30 days 80 mg/day slow 40 mg/day for 15 mg/day, increasing
3-4 h after AM release for 14 4 wk every 3-4 days to
dose of drug days maximum of 82 ±
10 mg/day dura¬
tion of rx 65 ± 23
days
SVRI* 1308-1178
WHVP l8.9-9.8f 32.9-l7.9f 23.7-21.3f 25.7-22.5f






MABP 80.3-76.8 97-87.Of 95-90
CO/CI 5.7-5.7
(a) (b) (a)
* SVRI, systemic vascular resistance index in dynes/s per m5; WHVP, wedged hepatic venous pressure in mm Hg; HVPG, wedged minus free
hepatic venous pressure in mm Hg; AzBF, azygos blood flow in ml/min; ELBF, estimated liver blood flow in ml/min (ICG method); HR, heart
rate in beats/min; MABP, mean arterial blood pressure in mm Hg; CO/CI, cardiac output/cardiac index in L/min.
t Denotes significant difference, at least at 95% level.
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Table 5





No. of patients 6 11
Dose, route, time 20 mg Is-5-Mn 40 mg Is-5-Mn









(a) (b) (b) (a)
* SVRI, systemic vascular resistance index in dynes/s per m!;
WHVP, wedged hepatic venous pressure in mm Hg; HVPG, wedged
minus free hepatic venous pressure in mm Hg; AzBF, azygos blood
flow in ml/min; ELBF, estimated liver blood flow in ml/min (ICG
method); HR, heart rate in beats/min; MABP, mean arterial blood
pressure in mm Hg; CO/CI, cardiac output/cardiac index in L/min.
t Denotes significant difference, at least at 95% level.
than might be expected (60). Experience of use of
nitrates in these two clinical situations is still limited;
as yet, no data on mortality are available.
We would suggest that nitrates should be considered
for treatment of portal hypertension in patients for
whom /3-blockade is contraindicated. Because they re¬
duce portal pressure in virtually all patients with cirrho¬
sis, unlike propranolol, nitrates might even hold signif¬
icant advantages over 0-blockade. However, their use
cannot be confidently recommended until randomized,
controlled clinical trials are performed.
Combination therapy for prophylaxis
Garcia-Pagan et al. (85) studied the effect of propran¬
olol versus propranolol plus nitrate. At 3 months, the
HVPG decreased more in patients given both nitrate
and /3-blocker than those given /J-blocker alone. The
two treatment regimens caused similar reductions in
azygos flow and cardiac output.
There were significant falls in liver blood flow and
ICG clearance after propranolol therapy, but not after
combined therapy, and acute administration of Is-5-
Mn enhanced the portal pressure reduction by propran¬
olol (85). Whether the greater hemodynamic effect
translates into better clinical efficacy remains to be
determined by randomized controlled trials.
Compliance
Rates of compliance have been variously estimated
at 10-90%, and depend on many factors including the
enthusiasm of the doctor, the disease being treated, and
the patients perception of importance of the disease
(86).
Caron and Roth (87) showed that doctors could not
predict their patient compliance more accurately than
by chance alone, so if compliance is to be accurately
assessed, specific methods (e.g., tablet counts, blood
levels) must be used. It is therefore surprising that only
one chronic nitrate study to date (58) has made any
attempt to assess compliance, despite the aim to assess
any potential tolerance to nitrates.
Compliance can be improved by simplifying thera¬
peutic regimes, using drugs with few side effects—
perhaps in calendar packs, and thorough explanation
and education for the patient. This is a major challenge
in the field of chronic liver disease.
SUMMARY
In conclusion, chronic administration of organic ni¬
trates, allowing for a nitrate-free interval each day, to
cirrhotic patients reduces portal pressure with a vari¬
able, dose-dependent effect on azygos blood flow. The
mechanisms of portal pressure reduction may vary
according to the different doses and severity of liver
disease. No studies to date have used dose-titration to
determine the optimal beneficial effects in an individual
patient, but some have at least compared the effect of
different doses. Perhaps an end-point of mean arterial
blood pressure reduction to 70 mm Hg could be sug¬
gested for future studies.
The prophylactic benefit of nitrates for variceal bleed¬
ing still remains to be tested by controlled clinical trials.
However, several problems in this evaluation need to
be addressed, including patient compliance, selection
of responders. evaluation of treatment, dose, and the
duration of treatment.
In contrast to the diminished expectations of pro¬
pranolol for the prevention of rebleeding, there is
mounting evidence of a major role for nitrates.
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The effects of intravenous A'-acetylcys-
teine on hepatic and systemic haemo-
dynamics were investigated in 11 patients
with stable cirrhosis (eight alcohol; two
primary bilary cirrhosis; one crypto¬
genic). A'-acetylcysteine administration
had no effect on the mean heart rate or
mean arterial blood pressure despite a
significant fall in systemic and pulmonary
vascular resistance. Cardiac index
increased but estimated liver blood flow
and portal venous pressure did not change
significantly. Administration of IV-acetyl-
cysteine resulted in increased oxygen
delivery to the tissues because of the
increased cardiac index but this was not
accompanied by a rise in either arterio¬
venous oxygen extraction ratio or mean
tissue oxygen consumption. Therefore
A-acetylcysteine administration seems to
confer no haemodynamic benefit to
patients with cirrhosis.
(Gut 1994; 35: 1290-1293)
^-acetylcysteine (NAC), a sulphurated amino
acid, has been reported to increase cardiac out¬
put, tissue oxygen delivery, and utilisation in
fulminant hepatic failure.1 As some of the
haemodynamic changes seen in patients with
cirrhosis are similar to those with fulminant
hepatic failure, N-acetylcysteine may also
increase tissue oxygen use and delivery in
patients with cirrhosis. The aim of this study
was to determine the haemodynamic effects of
this agent in cirrhosis with particular reference
to oxygen delivery and consumption.
Methods
Eleven cirrhotic patients proved by biopsy
(eight men; three women; mean age 61.5
years; range 43-74) with a range of disease
severity (4A, 3B, 4C Child's-Pugh grades)
and aetiology (two primary biliary, one
cryptogenic, and eight alcoholic cirrhosis)
were studied. Exclusion criteria included
known myocardial infarction or ischaemic
heart disease, valvular heart disease, preg¬
nancy, vasoactive treatment, current viral
hepatitis B, C, or D or bleeding diathesis with
prothrombin time ratio (PTR) greater than
2.5:1. The eight alcoholic cirrhotic patients
had no evidence of alcoholic cardiomyopathy
and were not actively drinking or withdrawing
from alcohol as monitored by liver function
tests, breath alcohol concentration, and
clinical state. All patients gave witnessed
informed consent and ethical permission was
obtained from Lothian Health Board medical
ethics subcommittee.
Each patient fasted after a light breakfast on
the day of the study. In the catheter laboratory
a 7-5 F introducer (Edwards, Critical Care
Division, Irvine, USA) was placed in the right
femoral vein under local anaesthesia (2%
lignocaine). A Swan-Ganz catheter (7 F
Edwards, Irvine, USA) was inserted under
fluoroscopic screening and continuous
pressure recording into the pulmonary artery.
The tip of the catheter was positioned in a
major branch of the pulmonary artery. The
mean heart rate (from ECG monitor, Hewlett
Packard HP monitoring system, Germany)
and mean arterial blood pressure (manual
syphygomomanometer) were checked every
five minutes initially until all patients had
achieved haemodynamic stability for at least
20 minutes. Simultaneous femoral artery,
pulmonary artery, and femoral vein blood gas
samples were then taken into heparinised
blood gas syringes and analysed immediately
for oxygen saturation (Co-Oximeter 282,
Instrumentation Laboratory, Lexingham,
MA, haemoglobin, and oxygen tension (Po2)
(ABL 2000, Radiometer, Copenhagen). The
pulmonary artery free and wedge pressure and
cardiac output (by Swan-Ganz thermodilution
method using 10 ml of cold 5% dextrose as
injectate) were estimated. Cardiac output was
measured in quadruplicate and the results
expressed as a mean value. Cardiovascular
pressures were measured with reference to the
mid axillary line. N-acetylcysteine (Parvolex,
Duncan Flockhart, Greenford, UK) was
infused intravenously by accurate infusion
pump (Gemini 2, IVAC, USA) at 150 mg/kg
in 200 ml 5% dextrose over 15 minutes
followed by 15 minutes infusion at 125 ml/h
of 50 mg/kg in 500 ml 5% dextrose. The
blood gas analysis, pulmonary artery pres¬
sures, mean arterial blood pressure, cardiac
output, and heart rate were remeasured 30
minutes after the start of N-acetylcysteine
(NAC) infusion - that is, during infusion.
Derived haemodynamic variables for each
patient were calculated according to standard
formulas.2
The O, content was calculated according to
the formula;
(Hbx 1 - 34Xsat % + 02 tensionx0-0031).
The delivery of oxygen to tissues was
calculated as the product of the cardiac index
and the arterial oxygen content. Oxygen con¬
sumption was calculated from the reverse Fick
405
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table i Effect of n-acetylcysteine (NAC) infusion on mean haemodynamic parameters
in 11 patients with stable cirrhosis (eight alcohol; two PBC; one cryptogenic)
Variable Before NAC After NAC p Value
hr 78-3 (3-2) 79-2 (2-7) NS
mabp 88 (2-7) 85-8 (3-3) NS
svri 1902 (195) 1645 (193) p<0-02
pvri 169-2 (28) 127 (21) p<0-01
02 delivery
lvswi
1086 (136) 1214 (140) p<0-01
60-3 (7-3 ) 65-9 (10-3) p<0-05
ci 3-85 (0-35) 4-36 (0-36) p<0-01
Oo consumption 240 (18) 240 (14-5) NS
oBr 23-6 (2-1) 21-3 (1-7) NS (p>0-05)
NAC infusion was at 150 mg/kg body weight in 200 ml 5% dextrose for 15 minutes followed by
15 minutes of 50 mg/kg in 500 ml 5% dextrose (set at 125 ml/h). Mean values (SEM) are
shown. HR is heart rate in beats per minute, MABP is mean arterial blood pressure in mm Hg,
SVRI and PVRI are systemic vascular resistance index and pulmonary vascular resistance index
respectively in dynes Xsec/cm5Xm2. 0-, delivery and consumption are measured in ml/min. CI
is cardiac index in 1/min/m2 and LVSVCm is left ventricular stroke work index in gXm/m2. OER
is the oxygen extraction ratio expressed as a percentage. Statistical significance is taken at the
95% value.
table ii Effect ofn-acetylcysteine infusion at 150 mg/kg body weight for 15 minutes in
200 ml 5% dextrose followed by 15 minutes of 50 mg/kg in 500 ml 5% dextrose (set at
125 ml/h) on mean blood gas values in 11 patients with cirrhosis (eight alcohol; two PBC;
one cryptogenic)
Before NAC After NAC p Value
Femoral artery Po2 (kPa) 11-25 10-32 NS
Femoral artery 02 saturation (%) 94-3 93-7 NS
Pulmonary artery Po2 (kPa) 5-35 5-37 NS
Pulmonary artery 0-> saturation (%) 72-1 73-8 NS
Femoral vein Po2 (kpa) 5-15 5-70 NS
Femoral vein 02 saturation (%) 67-9 74-9 NS
Statistical significance is taken at the 95% value.
table ill Effect of ^-acetylcysteine infusion on estimated liver blood flow, wedged, and
free hepatic pressures and hepatic venous pressure gradient in six of the 11 (randomly
selected) patients with cirrhosis
Variable Units Before NAC After NAC p Value
ELBF ml/min 1161 (167) 1283 (92) NS
WHVP mm Hg 20-7 22-2 NS
FHVP mm Hg 7-3 8-5 NS
HVPG mm Hg 13-3 13-7 NS
N-acetylcysteine infusion was initially at 150 mg/kg body weight in 200 ml 5% dextrose for 15
minutes followed by 50 mg/kg in 500 ml 5% dextrose (at 125 ml/h). Figures are expressed as
means. A significance value of more than 95% is taken. ELBF is estimated liver blood flow,
WHVP is wedged hepatic venous pressure, FHVP is free hepatic venous pressure, and HVPG is
hepatic venous pressure gradient.
TABLE rv Control data. The haemodynamic response offive of 11 patients with cirrhosis




Heart rate (bpm) 74-4 (4-6) 73-2 (41) NS
MABP (mm Hg) 91 (3-3) 89-2 (3-1) NS
RAP (mm Hg) 3-8 (0-37) 3-8 (0-37) NS
CI (1/min/m2) 3-46 (0-30) 3-54 (0-26) NS
SVRI (dynesxsec/cm"5) 2064 (184) 2008 (183) NS
LVSWI (gXm/m2) 59-0 (7-8) 60-2 (5-3) NS
PVRI (dynes X sec/cm 5) 188 (44) 184-7 (48-5) NS
Values are expressed as mean (SEM). MABP is mean arterial blood pressure, RAP is right atrial
pressure, CI is cardiac index, SVRI and PVRI are systemic and pulmonary vascular resistance
index respectively. LVSWI is left ventricular stroke work index. Statistical significance is taken
at the 95% value.
equation (cardiac index x a-v 02 difference);
this technique has been validated against the
direct method of calculation of 02 consump¬
tion by analysis of respired gas.3 The oxygen
extraction ratio was calculated by dividing the
difference between the arterial and venous 02
content by the arterial 02 content.
The hepatic venous pressure gradient
(wedged hepatic venous pressure - free hepatic
venous pressure) and estimated liver blood
flow (ICG, Cardiogreen Hynson, Westcott
and Dunning Inc, Baltimore, MD - con¬
tinuous infusion method4 5) were measured
immediately before and after NAC infusion
randomly in six of 11 patients with cirrhosis.
For hepatic pressure measurements a
sidewinder II catheter (Cordis, USA) was
inserted into the main right hepatic vein under
fluoroscopic control. Inflating and releasing
the balloon permitted repeated consistent
measurements of wedge and free hepatic
pressure respectively to be made. The intra¬
venous infusion of indocyanine green was
made up in saline and infused at a rate of 0-20
mg/m2/min after a priming dose of 0-20 mg/kg
body weight. After a 30 minute equilibration
period three simultaneous samples of
peripheral and hepatic venous blood were
drawn into heparinised syringes for the deter¬
mination of estimated liver blood flow. The
indocyanine green concentrations in the serum
and infusion fluid were estimated by spec¬
trophotometry at 810 nm in a Zeiss PMQ II
spectrophotometer against a blank serum
sample. The estimated liver blood flow was
derived from the equation estimated liver
blood flow =R/(A-H) (1-PCV), where R is the
rate of infusion of indocyanine green in
mg/min; A and H are the concentrations of dye
in peripheral and hepatic venous blood in mg/1;
and PCV is the packed cell volume.4-7
As the systemic haemodynamic effect of
NAC has been assessed previously in patients
without liver disease it was felt that inclusion of
normal healthy controls in an invasive study
such as this was unethical.8 Q The haemo¬
dynamic response, however, to infusion of the
same volume of 5% dextrose as above but not
containing ^/-acetylcysteine to five (randomly
selected) patients with cirrhosis was assessed to
investigate any potential volume loading effect
of the infusion.
STATISTICAL ANALYSIS OK HAEMODYNAMIC
VARIABLES
The results after the infusion of NAC were
compared with the baseline haemodynamic
values before infusion. All results were
expressed as mean (SEM) with statistical
analysis by a two tailed paired Student's t test.
Results
Administration of N-acetylcysteine had no
effect on mean heart rate or arterial blood
pressure (Table I). Infusion of NAC resulted
in vasodilatation with a significant reduction in
both mean systemic vascular resistance index
and pulmonary vascular resistance index
(Table I). No significant changes in right atrial
pressure, pulmonary artery free and wedge
pressure occurred.
Administration of NAC resulted in a signifi¬
cant increase in mean oxygen delivery resulting
from an increase in the mean cardiac index
(Table I). This was associated with a significant
increase in left ventricular stroke work index
(Table I). Both arteriovenous oxygen extrac¬
tion ratio and the mean oxygen consumption
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did not rise in response to NAC (Table I).
The effect ofN-acetylcysteine on mean blood
gas values showed a minor fall in arterial oxygen
tension and increase in venous oxygen tension
after NAC administration (Table II).
There was no significant statistical correlation
between Child's score variables - that is, serum
albumin, bilirubin, and prothrombin ratio - and
degree of change in response to NAC of cardiac
index, oxygen delivery, oxygen consumption,
oxygen extraction ratio or blood gases.
Mean estimated liver blood flow increased
in response to NAC infusion; but did not
achieve statistical significance (Table III).
Wedged hepatic venous pressure, free hepatic
venous pressure, and portal pressure showed
no significant change after N-acetylcysteine
infusion (Table III).
The control group of five patients who
received intravenous dextrose alone showed no
significant change in haemodynamic para¬
meters (Table IV).
Discussion
We have shown that NAC acts as a vasodilator
in patients with cirrhosis, similar to the effect
shown in fulminant hepatic failure.' This has
not occurred in patients with cardiac failure,
with symptoms of chest pain or in those
fully recovered from acute liver failure.18'
NAC is not known to possess direct relaxant
activity in normal vascular smooth muscle10
and given to pigs, both healthy and with septic
shock produced no significant haemodynamic
changes.1112 There is thus convincing evidence
that NAC has no haemodynamic action in
healthy controls. As NAC given to our 11
cirrhotic patients clearly conferred no haemo¬
dynamic benefit we felt that to study more
patients would be unethical.
The five patients in our control group
showed no vasodilation in response to dextrose
infusion alone (Table IV). Thus the postulate
that the haemodynamic changes in the 11
patients given N-acetylcysteine infusion were
caused by the effects of volume loading or
patients relaxing after the initial invasive proce¬
dures can be ruled out.
In patients with cirrhosis, unlike those with
fulminant hepatic failure,1 the mean arterial
pressure did not change and the oxygen extrac¬
tion ratio and 02 consumption did not rise in
response to NAC infusion (Table I). The
cardiac index, systemic vascular resistance
index, pulmonary vascular resistance index,
stroke work index, and 02 delivery % changes
were, however, similar between cirrhotic and
fulminant hepatic failure patients (Table 1).
As most drugs that primarily cause afterload
reduction increase cardiac index without
affecting left ventricular stroke work index (or
rate pressure product, or other measures of
myocardial consumption) the rise in cardiac
index in association with left ventricular stroke
work index seen here is suggestive of a positive
inotropic response rather than purely
peripheral vasodilation and reduction in left
ventricular afterload.
Interestingly, there were no reported
changes in arterial Po2, calculated a-v tension
gradient, and shunt in hepatic failure patients
in response to NAC.1 Errors in estimation of
mixed venous 02 saturation and tension could
occur if the blood is drawn rapidly or if the"
catheter is positioned peripherally within the
pulmonary artery because of contamination of
the mixed venous pulmonary blood with
arterialised blood drawn from the pulmonary
capillaries and veins. We are confident that
sufficient care was taken to prevent this error
occurring in our study. This is supported by
the increasing Po2 trend seen in peripheral vein
samples after NAC infusion, parallelling the
increase in pulmonary artery Po2 after the
infusion (Table II).
We believe that the difference between the
action of NAC to increase 02 delivery in
cirrhosis but not tissue 02 consumption (com¬
pared with fulminant hepatic failure) may be
because patients with cirrhosis have estab¬
lished pulmonary shunts13 and NAC acts as a
vasodilator to increase pulmonary shunting.
This hypothesis is supported by the finding
that pulmonary vascular resistance (Table I)
fell in response to NAC infusion. The exact
nature of such shunting is controversial.14"18
The multiple inert gas elimination technique19
has also shown V/Q mismatching in some
patients with cirrhosis. Patients with lower
pulmonary vascular resistance have greater
V/Q mismatch.13 Our data suggest that
cirrhotic patients, unlike hepatic failure1 and
cardiac failure20 patients, are not dependent on
supply of oxygen to increase consumption.
This may, however, just reflect the well com¬
pensated liver disease in most of these patients
and it might be necessary to evaluate a group of
grade C patients alone before a beneficial effect
ofNAC can be excluded.
Differences between fulminant hepatic
failure patients and our cirrhotic patients
may also result from the fact that some of
the fulminant patients had encephalopathy
(with and without neurohumoral factors)
and were on mechanical ventilation (volume
controlled) with continuous intravenous
infusion of muscle relaxant (atracurium 50
mg/h).1 Pulmonary capillary wedge pressure
had to be stabilised at 8-14 mm Hg by infusion
of 4-5% human albumin solution before the
study.
Sulphydryl groups are required for the relax¬
ation of vascular smooth muscle. Packer's data8
support the hypothesis that sulphydryl deple¬
tion plays a part in the development of toler¬
ance to nitroglycerin and as NAC, and other
sulphydryl donors, can reverse this tolerance
we postulate that in cirrhotic patients who are
known to be deplete in sulphurated amino
acids21 NAC acts by sulphydryl repletion to
cause vasodilatation. NAC may be acting
directly on vasculature or indirectly by nitric
oxide by sulphydryl donation.22 As partial
tolerance to organic nitrates (used to reduce
portal hypertension in cirrhotic patients) has
been reported23 we would speculate that should
longterm tolerance be a problem NAC or its
oral derivative methionine might reverse this
tolerance and thus be of therapeutic value.
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It should be appreciated that not all
vasodilators have the same haemodynamic
effect in patients with cirrhosis, for example,
nitrates cause vasodilatation but cause a fall in
liver blood flow, cardiac output, and mean
arterial blood pressure and an increase in sys¬
temic vascular resistance24; this presumably
reflects different mechanisms or sites of action
of vasodilating agents.
N-acetylcysteine given to patients with
cirrhosis is probably not of haemodynamic
value. This study illustrates that extrapolation
of drug use between patients with fulminant
hepatic failure and chronic liver disease is not
always justifiable. We would still advocate its
use, however, in paracetamol poisoning,
particularly in patients with chronic alcohol
intake (as such patients have increased
susceptibility to paracetamol).2526
This work has been presented in part at the British Society of
Gastroenterology meeting 24-26th March 1993 and appears in
abstract form in Gut 1993; 34 (suppl): S43.
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Portal and systemic haemodynamic response to
acute and chronic administration of low and high
dose isosorbide-5-mononitrate in patients with
cirrhosis
A L Jones, I H Bangash, J Walker, K J Simpson, N D C Finlayson, P C Hayes
Abstract
Oral isosorbide-5-mononitrate (Is-S-Mn)
was given in doses of 10 and 40 mg acutely
and chronically (twice daily for four
weeks), allowing a nitrate free interval to
<i 25 patients with cirrhosis. Both 10 mg
and 40 mg Is-5-Mn reduced the hepatic
venous pressure gradient acutely and
t chronically, without evidence of toler¬
ance. This was achieved by a reduction in
the wedged hepatic venous pressure. The
effect on mean azygos blood flow was
variable with no significant mean change
seen acutely or after chronic use with
either dose. The variability was depen¬
dent not on the dose used but on the ini¬
tial azygos flow; the flow in patients with
initially low values increased and those
with high azygos flows decreased after
nitrate challenge. The development of the
porto-collateral flow seems an important
parameter in predicting haemodynamic
response to Is-5-Mn.
(Gut 1995; 36: 104-109)
Keywords: cirrhosis, isosorbide-5-mononitrate, hepatic
venous pressure.
Variceal haemorrhage is a major cause of
morbidity and mortality in cirrhosis and drug
treatment of portal hypertension aims to reduce
this. Previous reports show that both isosorbide
dinitrate1-12 and isosorbide-5-mononitrate
(Is-5-Mn)13-17 are capable of reducing the
hepatic venous pressure gradient or azygos vein
(collateral) blood flow, or both, both acutely
and with chronic use but the results have been
highly variable. For example we, and others,
have found that azygos blood flow may increase
in some patients in response to nitrate.15-17
Table I Baseline patient characteristics (Values mean (SEM))
ls-5-Mn, Is-5-Mn,
Variable 10 mg (n = 12) 40 mg (n = 13) p value
Mean age (y) 59-4 (3-3) 56 0 (2-3) p>0-32 (NS)
Age range (y) 42-74 40-71 -
Sex (F/M) 8/4 3/10 -
Aetiology 10 ALC: 2 PBC 11 ALC: 1 PBC: 1 SBC -
Child's-Pugh score 8-0 (0-6) 81 (0-6) p>0-5 (NS)
Serum bilirubin (umol/1) 55-8 (16 0) 50-4 (12-9) p>0-05 (NS)
Serum albumin (g/dl) 34-4 (1-7) 32-2 (1-7) p3*0-5 (NS)
PTR ratio 1-25 (0-08) 1-20 (0 05) p3*0-5 (NS)
Serum alanine 36-2 (4-9) 32-6 (5-9) p3*0-5 (NS)
aminotransferase (U/l)
No with ascites 7/12 9/13 -
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This study aimed to examine this variability
to establish whether it was related to nitrate
dose or patient factors. In addition, we wished
to establish whether there was any evidence of




Twenty five patients with cirrhosis proved by
liver biopsy (14 men; 11 women) and with a
range of disease severity (eight A; 11 B; six C
Child's-Pugh grading) were studied. Exclusion
criteria included known myocardial infarction
or ischaemic heart disease; valvular heart
disease; cardiomyopathy; cerebrovascular
disease; pregnancy; vasoactive medication;
current viral hepatitis B, C, or D; or bleeding
diathesis with prothrombin time ratio greater
than 2-5:1. All patients gave written informed
consent and ethical permission was obtained
from the Lothian Health Board Medical Ethics
Subcommittee. All studies conformed to the
Helsinki declaration. Each patient was
randomised to receive either 10 mg or 40 mg
Is-5-Mn by random number selection within
sealed envelopes. From Table I it may be seen
that the two dosage groups were not signifi¬
cantly different except with regard to sex ratios.
STUDY PROCEDURE
Each patient fasted after a light breakfast on
the day of the study. Three lead (lead II) ECG
monitoring was begun by attachment to a
Hewlett Packard HP monitoring system
(Germany), and mean arterial blood pressure
(manual syphygmomanometer) was checked
every five minutes initially until all patients had
achieved haemodynamic stability for at least 20
minutes.
A 7-5 F introducer (Edwards, Critical Care
Division, Irvine, USA) was then placed in the
right femoral vein under local anaesthesia (10
ml of 2% lignocaine). The hepatic venous
pressure gradient (wedged hepatic venous
pressure minus free hepatic venous pressure)
was then estimated by inserting a Sidewinder II
catheter (Cordis, USA) into the main hepatic
vein under fluoroscopic screening. Inflating
and releasing the balloon enabled repeated
consistent measurements of wedge and free
hepatic pressure respectively to be made. The
Hewlett-Packard machine was zeroed for
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Table II Baseline haemodynamic characteristics. (Values, mean (SEM))
Is-5-Mn, Is-5-Mn,
Variable 10 nig (n = l2) 40 nig (n = 13) p value
Heart rate (bpm) 78-3 (3-5) 72-5 (3-0) p>0 1 (NS)
Mean arterial blood pressure 93-7 (4-0) 96-2 (2-2) P>0-5 (NS)
(mm Hg)
Wedged hepatic venous pressure 214 (2-0) 23-2 (16)* p>0• 317 (NS)
(mm Hg)
Free hepatic venous pressure 5-5 (1-2) 71 (1-2)+ p>0-317 (NS)
(mm Hg)
Hepatic venous pressure gradient 15 9 (1-8) 16 4 (0-7)* p>0-5 (NS)
(mm Hg)
Azygos vein blood flow (ml/min) 378 (91) 511 (103) p>0,317 (NS)
Liver blood flow (ml/min) 1227 (184)| 1313 (159)§ p>0-5 (NS)
*n- 12; tn=13; tn = 5; §n = 7.
pressure at the level of the right atrium at the
start of each procedure.
Liver blood flow was measured by the
constant infusion, indocyanine green dye
method. The Sidewinder II catheter was
then removed and an azygos catheter was
introduced into the azygos vein under fluoro¬
scopic screening. Estimation of the azygos
blood flow was made by the thermodilution
technique20 using 5% dextrose at 50 ml/min as
injectate. The position of the catheter was
noted for the next occasion of its use in that
patient to minimise the effect of change of
catheter position on flow.
Either a 10 mg or a 40 mg tablet of Is-5-Mn
was then administered orally. Heart rate, blood
pressure, and azygos vein flow recordings were
taken 30 minutes and 60 minutes after
administration of the drug. Sixty minutes after
administration of the tablet the azygos catheter
was removed and the Sidewinder catheter was
reinserted into the main right hepatic vein and
a further estimation ofwedged and free hepatic
venous pressure and liver blood flow was made
by the above methods.
CHRONIC ADMINISTRATION OF IS-5-MN
Each patient was given 100 tablets of their
randomised dose of Is-5-Mn (Boehringer-
Mannheim Ltd) and written instructions to
take one tablet at 9 am and one at 5 pm each
day - that is, allowing for a nitrate free interval.
Each patient was asked to return the box of
tablets at the end of the study (for a tablet
count). The last morning dose (on the day of
Tabic III Comparison of the effect of 10 mg and 40 mg Is-5-A1n on heart rate, mean
arterial blood pressure (MABP), and azygos vein blood (A,BF) flow in 25 patients with
cirrhosis. (Values mean (SEM))
After 1 After I After I
1st study 1st study month month month
1st study 1=30 1=60 1=0 1=30 t=60
Variable t=0 min min miii mill min miii
Dose 10 mg 10 mg 10 mg 10 mg 10 mg 10 mg
Is-5-Mn/no n= 12 n= 1 1 n= 12 n = 9 n = 9 n~9
Heart rate 78-3 79-0 80-5 75-8 77-3 77-4
(bpm) (3-5) (3-7) (4-5) (61) (6-5) (6-3)
MABP 93-7 85-3* 88-6* 89-6 87-1 88-2
(mm Hg) (4-0) (4-5) (4-5) (4-8) (4-4) (5-2)
AzBF 378-4 320-3* 324-4 512-2 517-2 664-0
(ml/min) (91-2) (91-2) (71-9) (130-0) (152-7) (142-4)
Dose 40 mg 40 mg 40 mg 40 mg 40 mg 40 mg
Is-5-Mn/no n= 13 n= 13 n= 13 n= 11 n= 11 n = 11
Heart rate 72-5 83-7* 82-7* 82-1* 87-7* 84-0*
(bpm) (3-0) (3-6) (3-6) (4-6) (5-0) (5-7)
MABP 96-2 87-8* 89-2* 94-4 89-6 90-3
(mm Hg) (2-2) (2-3) (2-0) (4-6) (3-6) (4-5)
AzBF 511 448-5 445-3 384-7 391-0 491-8
(ml/min) (102-6) (104-2) (103-0) (83-1) (100-2) (146-9)
*Denotes significant difference from 1st study t = 0 (baseline value) at least at 95% level.
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the second invasive procedure) was omitted.
The heart rate, blood pressure, hepatic venous
pressure gradient, estimated liver blood flow,
and azygos vein blood flow were measured
again after 28 days of Is-5-Mn treatment both
before and after rechallenge with their ran¬
domised nitrate dosage using the same
methodology as above. Patients were asked to
report headaches or any other side effect.
STATISTICAL ANA1 .YSIS
Results are expressed as mean (SEM) haemo-
dynamic values for each treatment group. Each
mean variable at one time point was compared
with the haemodynamic value at the time 0
(that is, baseline value) by a two tailed paired
Student's r test.
Correlation of changes in each haemody¬
namic variable with serum albumin, bilirubin,
and prothrombin ratio (PTR) was made using
the Spearman rank correlation test on Systat
Version 5.0 for Microsoft Windows.
Results
COMPLETION OF THE STUDY
Twelve patients were randomly allocated to
receive 10 mg and 13 to receive 40 mg of
Is-5-Mn. Four patients (two in each group)
failed to attend for the second invasive
procedure and in one patient the procedure
was abandoned for technical reasons.
BASELINE HAEMODYNAMIC CHARAC TERISTICS
No significant difference in baseline haemo¬
dynamic characteristics between the two treat¬
ment groups was seen (Table II).
HEAR T RATE RESPONSE TO IS-5-MN
No significant change in heart rate was seen
acutely or after four weeks of 10 mg Is-5-Mn
twice daily (Table III). In contrast, patients
given 40 mg Is-5-Mn showed a significant rise
in heart rate 30 and 60 minutes after drug
administration which was still present after a
month of therapy (Table III).
EFFECT OF IS-5-MN ON MEAN ARTERIAL BLOOD
PRESSURE
Acute administration of either 10 mg or 40 mg
Is-5-Mn produced a significant fall in blood
pressure after 30 and 60 minutes (Table III).
This fall in blood pressure was not sustained
up to or after rcchallenge with the nitrate at
one month (Table III).
EFFECT OF IS-5-MN ON THE HEPATIC VENOUS
PRESSURE GRADIENT
Wedged hepatic venous pressure fell signifi¬
cantly 60 minutes after 10 mg Is-5-Mn given
initially and after one month of nitrate use
(Fig 1). The pressure before challenge at one
month, however, was not significantly different
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Figure 1: The acute and




(A), free hepatic venous
pressure (FHVP') (B), and
hepatic venous pressure
gradient (HVPG) (C) in
patients with cirrhosis.
Mean values are given
and error bars represent
standard error of the mean
and p values illustrate the
result ofpaired t testing
between values at the time
points shown and the
baseline (1=0) values.
10 mg Is-5-Mn had no significant effect on free
hepatic venous pressure acutely or after
chronic nitrate use (Fig 1). The hepatic venous
pressure gradient showed sustained reduction
after acute and chronic nitrate use (Fig 1).
The wedged hepatic venous pressure fell
significantly acutely and after one month of
40 mg Is-5-Mn (Fig 2), an increasing effect
being seen with more exposure to the nitrate. A
dose of 40 mg Is-5-Mn had no statistically
significant action on the mean free hepatic
venous pressure (Fig 2). The hepatic venous
pressure gradient showed sustained reduction
after acute and chronic nitrate use (Fig 2), the
greatest effect being seen on rechallenge with
nitrate after a month of treatment.
EFFECT OF IS-5-MN ON AZYGOS VEIN BLOOD
FLOW
A dose of 10 mg Is-5-Mn produced a signifi¬
cant reduction of azygos flow within 30
minutes of administration but thereafter no
significant reduction was seen (Table III). Small
reductions of azygos flow were seen acutely
and chronically after 40 mg Is-5-Mn use but
these failed to reach statistical significance
(Table III). Most noticeable, however, was the
variability of response of azygos blood flow to
either dose of the nitrate as illustrated by the
large standard error values. This can be
Jones, Bangash, Walker, Simpson, 1'inlayson, Hayes
explained by division of all 25 patients (that is,
both dosage groups) into arbitrary groups at
baseline with low (less than 350 ml/min),
moderate (350-550 ml/min), and high azygos
flows (more than 550 ml/min). Although no
statistical analysis between the groups would be
valid, Figure 3 shows that those with low initial
values increase in response to nitrate and those
with high initial values reduce in response
to nitrate. Those with intermediate values
demonstrate little change in response to nitrate.
CORRELATION BETWEEN CHILD'S-PUGH
VARIABLES AND RESPONSE TO IS-5-MN
(SPEARMAN'S RANK CORREIATION TEST)
No significant correlation was found between
the change in heart rate, mean arterial blood
pressure, wedged hepatic venous pressure, free
hepatic venous pressure, hepatic venous
pressure gradient, and azygos blood flow with
serum bilirubin, albumin, and prothrombin
ratio in response to 10 mg Is-5-Mn at any time
point in the first study or at one month.
Similarly, no correlations were found with
the 40 mg group of Is-5-Mn except a reduction
of free hepatic pressure (in the first hour, first
study, r=-0'72) and reduction of azygos
blood flow (in the first hour, second study,
r = 0'750) were both significantly correlated
(p<0-05) with serum bilirubin. Also, the
reduction in wedged hepatic venous pressure
at the end of the second study hour (at one
month) was correlated with serum albumin
(r=0-65). Azygos blood flow reduction from
baseline to time zero on the first and second
study were both correlated with serum albu¬
min (r= -0-633 and --0-667 respectively).
Only the reduction in free hepatic venous pres¬
sure after the first hour in the first study corre¬
lated with the prothrombin ratio (r = 0-70) in
the 40 mg group.
EFFECT OF IS-5-MN ON ESTIMATED LIVER
BLOOD FLOW (ICG METHOD)
Figure 4 shows that only 40 mg Is-5-Mn pro¬
duces a significant fall in liver blood flow after
one hour (which coincides with a drop in the
mean arterial blood pressure). The liver blood
flow did not show a significant reduction with
chronic nitrate use.
SIDE EFFECTS
Three patients receiving 10 mg Is-5-Mn twice
daily reported headaches during the first 24
hours of therapy. One of these patients
described persistent headaches over the first
two weeks and withdrew from the study.
Five patients reported headaches after start¬
ing 40 mg Is-5-Mn which stopped within 24
hours. One of these five patients experienced
headaches for 10 days after beginning the
tablets, lasting 10-20 minutes after each tablet,
and withdrew from the study.
COMPLIANCE
Ten of the 10 mg group of patients (100% of
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Figure 2: The acute and chronic effect of 40 mg isosorbide-5-mononitrare on mean
wedged hepatic venous pressure (WHVP) (A), free hepatic venous pressure (FHVP) (13)
and heparic venous pressure gradient (HI 'P(i) (C) in patients zeith cirrhosis. Mean values
are illustrated, error bars represent standard error of the mean and p values illustrate the
result ofpaired t resting between values at the time points shozun and the baseline (t~0)
values.
those attending the follow up haemodynamic
study after one month) returned their unused
tablets. Nine patients (90%) had returned the
correct number of tablets and one patient had
returned one tablet too many. All claimed to
have taken their nitrate tablets diligently and
had outpatient appointment attendance rates
in excess of 85%.
Nine of the 40 mg group of patients (81-8%
of those attending the follow up haemo¬
dynamic study after one month) returned their
unused tablets. Eight patients (72-7%) had
returned the correct number of tablets and the
remaining patient had three tablets too many.
Again all patients claimed to have taken their
nitrate tablets and had outpatient appointment
attendance rates in excess of 90%.
Discussion
Is-5-Mn is a powerful venous and mild arterial
vasodilator.21 It has a prolonged half life (five
hours,22 little first pass metabolism,23 and dose
linear kinetics24 even in the presence of liver
disease.25 26
NO EVIDENCE FOR DOSE-DEPENDENCY OH
IS-5-MN IN REDUCTION OF HEPA TIC VENOUS
PRESSURE GRADIENT
Our study suggests that both 10 mg and 40 mg
of Is-5-Mn greatly reduce the hepatic venous
pressure gradient acutely and with chronic use.
This is of clinical relevance given the increas¬
ing interest in the use of nitrates to prevent
variceal bleeding in cirrhotic patients.
Only two previous groups have shown no
effect of nitrates on hepatic venous pressure
gradient.2 14 All others showed a reduction in
the hepatic venous pressure gradient which was
accompanied by a fall in the cardiac index and
mean arterial blood pressure (isosorbide dini-
trate,1 7 Is-5-Mn1 v"). In our study there was
no apparent advantage of one dose over the
other in achieving portal pressure reduction.
HOW IS THE REDUCTION IN HEPATIC VENOUS
PRESSURE GRADIENT ACHIEVED?
The reduction of hepatic venous pressure
gradient in previous studies and ours (by either
dose of Is-5-Mn) was achieved by a fall in the
wedged hepatic venous pressure rather than a
rise in the free hepatic venous pressure.
Reducing the wedged hepatic venous
pressure may be more important than reducing
the hepatic venous pressure gradient per se in
protection against variceal bleeds.27 28
EVIDENCE FOR DIFFERENT DOSES WORKING BY
DIFFERENT MECHANISMS
Many haemodynamic studies to date suggest
that different doses of nitrate may act by
different mechanisms15 2U and this may well be
the case in our study. Certainly, the 40 mg
dose seems to induce a greater haemodynamic
disturbance acutely - that is, increased heart
rate, reduced mean arterial blood pressure,
and liver blood flow - than the 10 mg dose.
Only the increase in the heart rate effect was
maintained after chronic use. Whether this
means greater efficacy of the higher dose in
prophylaxis of variceal bleeding remains to be
evaluated bv clinical studies.
HETEROGENEITY IN COI.IATHRAI. VESSEL
RESPONSIVENESS TO NITRATES
The efficacy of drugs in controlling an acute
variccal bleed or preventing recurrent haemor¬
rhage may be related to their ability to reduce
blood How through collateral vessels. Deter¬
mination of the effects of vasoactive agents on
both collateral blood flow and the hepatic
venous pressure gradient is therefore important
in evaluating their therapeutic potential.
Our results indicate that the effect of 10 mg
or 40 mg Is-5-Mn on azygos blood flow was
highly variable, including some individuals in
whom flow increased suggesting vasodilatation
of portasystemic collaterals. Those who had a
low azygos flow increased their flow in
response to nitrate and vice versa. Thus, the
degree of pre-existing porta-systemic shunting
seems important in the individuals' response to
nitrate.
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Figure 3: The acute and chronic effect of isosorbide-S-mononitrate administration (10 mg
and 40 nig groups combined) on azygos blood flout in patients with cirrhosis. Patients
are divided into 3 groups: (!) those with low initial azygos flows (<350 ml/nun); (2)
those with moderate azygos flows (350-550 mlJmin); (3) those with high azygos flows
(> 550 inl/min). Mean azygos flozes for each group are shown and the error bars represent
standard error of the mean.
ROLE OF SEVERITY OF LIVER DISEASE IN
PREDICTING AN INDIVIDUALS' RESPONSE TO
NITRATE
The severity of liver disease per se does not
seem to be an important variable in defining
the haemodynamic response to nitrates as so
few haemodynamic changes correlated with
serum bilirubin, albumin or prothrombin
ratio (which are the best available, though
imperfect, measures of severity). A few correla¬
tion tested positively but this would be
expected by chance alone given the large
number of correlations tested.
Other variables that have previously been
suggested to be responsible for different
Figure 4: The acute and
chronic effect of (A) 10 mg
or (13) 40 nig
isosorbide-5-mononirratc on
liver blood flow (ELBE)
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response to nitrates between individuals may
be the degree of autonomic impairment30 or
the baseline cardiac filling pressure.29
TOLERANCE TO NITRATES
Tolerance is well recognised in patients with
heart disease given nitrates for 18 hours or
longer.31 32 Our study and others3 10-1214 16
show a sustained fall in the hepatic venous
pressure gradient after chronic nitrate adminis¬
tration, which suggests full tolerance is not of
concern in patients with chronic liver disease.
To postulate why this may be the case we
need to first consider possible mechanisms of
tolerance.
Multiple subcellular mechanisms of nitrate
tolerance have been postulated, including con¬
version of the 'nitrate receptor' to the disulphide
form with lower affinity for nitrate,33 reduction
of sulphydryl groups necessary for the 'meta¬
bolic activation' of nitrates,34 reduction of vas¬
cular production of nitric oxide from nitrate,35
reduction in vascular metabolism to its dinitrate
metabolites,36 or molecular alteration of the
cellular soluble guanvlatc cyclase.3. These
mechanisms explain in vitro phenomena, but
are inadequate for the in vivo situation, for
example nanomolar concentrations of nitrates
cause tolerance in patients versus millimolar
concentrations in vitro on blood vessels.38
Recent evidence suggests, as expected, that
both subcellular and physiological mechanisms
are involved in nitrate tolerance in vivo.39
Chronic nitrate administration is accom¬
panied by a variety of compensatory physio¬
logical effects for example, raised plasma renin,
catecholamines, body weight and sodium
retention, and shifts in vascular volumes.40 12
These findings suggest that in vivo nitrate
tolerance might be brought about by physio¬
logical compensatory mechanisms.
Patients with cirrhosis have profound
physiological disturbance, however, including
high plasma catecholamines, sodium reten¬
tion, and shifts in vascular volumes,43 and
therefore may not be able to develop further
compensatory mechanisms of tolerance.
EFFECT OF NITRATES ON LIVER BLOOD FLOW
Calculations of hepatic resistance from previous
studies described above and our own study
show that either acute or chronic administration
of nitrates induce a significant reduction in
resistance rather than a reduction in liver blood
flow (which would be undesirable). This implies
either that portal flow is not reduced or that a
compensatory rise in hepatic arterial flow takes
place, that is, reciprocity. The difficulty in dis¬
tinguishing between these two inputs limits or
ability to interpret these data further.
COMPLIANCE AND SIDE EFFECTS
Our data suggest that the patients were taking
their nitrate tablets during this study; their
motivation to attend outpatient clinics was
high and the discrepancy in tablet counts
minimal. Side effects were modest.
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CONCLUDING REMARKS
An early clinical trial suggests a prophylactic
benefit of nitrates for variceal bleeding,44
although larger numbers of patients will be
needed in future studies. Our work suggests
that chronic administration of either 10 or
40 mg of Is-5-Mn, allowing for a nitrate free
interval each day is effective in achieving
hepatic venous pressure gradient reduction
but there is no non-invasive way of predict
collateral vessel response to nitrates.
Nitrates potentially have a number of
different mechanisms of hepatic venous
pressure reduction which may vary at different
doses. Fortunately, by mechanisms which
remain to be elucidated, patients with cirrhosis
do not develop full tolerance to nitrates.
This work has been presented in part at the British Society of
Gastroenterology Annual Meeting 15-17th September 1993
and thus appears in abstract form in Gut 1993; S20: T80.
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